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ABSTRACT 
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Toll-like receptors (TLRs) and the complement system play a crucial role in the innate immune 
response by mediating the initial recognition of, and prompt response to a variety of 
microorganisms. The concerted activation of TLRs and complement ensures efficient clearance 
of infection. Previous studies have documented synergism between TLRs and the receptor for 
the pro-inflammatory peptide C5a (C5aR/CD88), and regulation of TLR-induced pro-
inflammatory responses by C5aR, suggesting crosstalk between TLRs and C5aR. However, it is 
unclear whether and how TLRs modulate C5a-induced pro-inflammatory responses. This study 
tested the hypothesis that a genuine, bi-directional signalling crosstalk between TLRs and C5a 
receptors exists, involving not only modulation of TLR-mediated responses by C5a receptor 
activation, but also modulation by TLR activation of the extent and/or quality of cellular 
responses to C5a. The experiments described in this thesis confirmed this hypothesis by 
demonstrating a marked positive modulatory effect of TLR activation on cell sensitivity to C5a 
in vitro and ex vivo and identifying underlying mechanistic targets. Pre-exposure of peripheral 
blood mononuclear cells and whole blood to diverse TLR ligands or bacteria enhanced C5a-
induced pro-inflammatory responses. This effect was not observed in TLR4-signalling-deficient 
mice. TLR-induced hypersensitivity to C5a did not result from C5aR up-regulation or 
modulation of C5a-induced calcium mobilization. Rather, TLRs targeted the second C5a 
receptor, C5L2 (acting as a negative modulator of C5aR) by reducing C5L2 expression and 
activity. TLR-induced hypersensitivity to C5a was mimicked by blocking C5L2 and was not 
observed in C5L2KO mice. Furthermore, TLR activation inhibited C5L2 expression upon C5a 
stimulation. Expression of the key adaptor molecule β-arrestin 1, which mediates the 
inhibitory effects of C5L2 on C5aR, was also found to be negatively regulated by TLR activation. 
These findings identify a novel pathway of crosstalk within the innate immune system that 
amplifies innate host defence at the TLR-complement interface. Unravelling the mutually 
regulated activities of TLRs and complement may reveal new therapeutic avenues to control 
inflammation.
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1. Chapter 1: INTRODUCTION 
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1.1 The inflammatory response to infection 
The invasion of a normally sterile tissue by pathogenic microbes induces a prompt and robust 
response aimed at clearance of the infecting organisms. A wide range of cellular and soluble 
defence mechanisms are activated upon recognition of pathogens, with the common effect of 
inducing localised changes in the infected tissue [Medzhitov 2008]. These changes involve 
activation of the vascular endothelium, with consequent vasodilation, hyperaemia and 
increased vascular permeability. Their overall effect is to promote recruitment and 
extravasation both of migratory phagocytic cells and soluble mediators into the infected 
tissue, a process known as the inflammatory response. The inflammatory response is largely a 
consequence of the release of pro-inflammatory cytokines and chemokines such as tumour 
necrosis factor alpha (TNF-α), interleukin (IL)-1β, IL-6, IL-8, and monocyte chemoattractant 
protein 1 (MCP-1). 
Whilst this response is beneficial to the host, it is also potentially harmful, since the 
inflammatory response to infection may itself result in injury to tissues as a consequence of 
their infiltration by migratory phagocytic cells which release toxic reactive oxygen and nitrogen 
species. Hence, it is apparent that as well as being sufficiently robust, the response to infection 
must be proportionate; an excessive response may be as bad as an inadequate one. An 
example of this is the clinical syndrome of sepsis, in which an exaggerated, systemic 
inflammatory response to infection leads to the systemic release of massive quantities of pro-
inflammatory cytokines and chemokines, which induce inflammation in healthy tissues remote 
from the site of the infection, with serious consequences for the host [Takeuchi and Akira 
2010]. For this reason, the mechanisms that regulate the magnitude of inflammatory cytokine 
release in response to infection are of critical importance, and have been the focus of much 
attention during the last few decades, not only in the context of sepsis research, but also in 
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sterile inflammatory conditions such as trauma, major haemorrhage and burns, as well as the 
autoimmune diseases. 
The mechanisms that trigger and regulate the early pro-inflammatory cytokine response to 
infection are generally considered to fall within the purview of the innate immune system. An 
overview of the components of the innate immune system will be undertaken before a more 
detailed consideration of the specific components of innate immunity that are the primary 
focus of this study, namely, the Toll-like family of receptors and their ligands, and the 
complement component C5a and its receptors. 
1.2 The components of the innate immune system 
The innate immune system is comprised of a range of nonspecific and broadly specific defence 
mechanisms whose shared characteristic is that they do not require the clonal expansion of 
antigen-specific lymphocytes [Murphy 2012]. These include the epithelial barrier, soluble 
components (including the complement system) and pattern recognition receptors (PRRs) 
(summarised in Figure 1). 
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Figure 1. Pathogen recognition by components of the innate immune system. CRs, 
Complement Receptors; NLRs, Nucleotide Binding Domain Leucine-Rich Repeat 
Receptors; PRRs, Pattern Recognition Receptors;  RLRs, Retinoic Acid-Inducible Gene-I-
like Receptors; TLRs, Toll-like Receptors. Adapted from [Murphy 2012].
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1.2.1 The epithelial barrier 
The first defence against pathogens is a mechanical barrier: the epithelia that cover all of the 
body surfaces that come into regular contact with the external environment. Bulk flow of body 
fluids over these surfaces may provide an additional defence against their colonisation by 
pathogens, for example, the mucociliary escalator in the tracheobronchial tree. Alternatively, 
the maintenance of a chemical environment hostile to pathogens (by gastric acid, for example) 
may also serve to protect the endothelial barrier [Murphy 2012]. 
1.2.2 Soluble components 
The epithelial barrier is reinforced by a number of secreted antimicrobial proteins, including 
antimicrobial enzymes, peptides and chemokines, as well as soluble pattern-recognition 
receptors that activate other components of the innate immune system. 
1.2.2.1 Antimicrobial enzymes 
Lysozyme, described by Fleming in 1922 [Fleming 1922], is a glycosidase that cleaves bacterial 
cell wall peptidoglycans. It is secreted in tears, saliva and by specialised accessory epithelial 
cells in the gut such as Paneth cells, and is an important defence against Gram-positive 
organisms [Harder 2007]. Another example is secretory phospholipase A2, a basic enzyme that 
is able to penetrate bacterial cell walls and hydrolyse membrane phospholipids [Boyanovsky 
and Webb 2009]. 
1.2.2.2 Antimicrobial Peptides 
Antimicrobial peptides are conserved, phylogenetically primitive defence mechanisms that 
have been extensively studied in insects. Human antimicrobial peptides include defensins, 
histatins and cathelicidins, and are widely expressed in cells such as epithelia that are 
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commonly exposed to microbes [Wiesner and Vilcinskas 2010]. Defensins are ubiquitous small 
cationic peptides able to disrupt bacterial and fungal cell membranes as well as the envelope 
proteins of certain viruses [Lehrer and Lu 2012]. Histatins are predominantly secreted by 
salivary epithelia, and are important in protecting the oral mucosa against commensal yeasts 
such as Candida albicans [Peters 2010]. Cathelicidins are produced constitutively by 
phagocytic cells and inducibly by keratinocytes and gut and lung epithelial cells in response to 
infection; they are known to play an important role in wound healing [Steinstraesser 2011]. 
1.2.2.3 Antimicrobial chemokines 
Chemokines are a crucial component of the innate immune response to infection, as their 
principal role in immune defence is the recruitment of phagocytic cells to sites of infection. 
However, a number of chemokines are also reported to exert a direct antimicrobial effect. 
CCL-28 has been reported to show broad microbicidal activity and to play an important role in 
mucosal defence [Hieshima 2003]. The neutrophil chemokines CXCL-7 [Durr and Peschel 
2002], CXCL-9, CXCL-10 and CXCL-11 [Cole 2001], the platelet-derived chemokines CXCL-4, 
CATP-3 and CCL-5 [Tang 2002] have also been reported to have direct antimicrobial activity.  
1.2.2.4 Soluble pattern recognition receptors 
The distinctive characteristic of the receptors of the adaptive immune system is high specificity 
for a particular non-self antigen, through receptor affinity maturation achieved by VDJ gene 
segment rearrangement during leucocyte maturation and selection [Murphy 2012]. In 
contrast, pattern recognition receptors (PRRs) of the innate immune system are “ready-
made”, germ line-encoded, and thus display broad specificity for classes of conserved 
microbial component molecules not found in the host [Janeway and Medzhitov 2002]. These 
are also known as pathogen- or microbe-associated molecular patterns (PAMPs or MAMPs). 
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Endogenous molecules such as DNA, whose presence in the extracellular milieu is indicative of 
host injury, are known as damage-associated molecular patterns or DAMPs, and may also be 
ligands for the PRRs of the innate immune system. PRRs are expressed either on or inside cells, 
or as soluble molecules and in certain cases, as both. The cellular PRRs will be considered in 
more detail below; the soluble PRRs include collectins, ficolins and pentraxins. 
 a. Collectins  
Collectins are calcium-dependent members of the lectin family of proteins, and are found both 
as membrane-bound receptors such as dectin-1 and as soluble proteins. Soluble collectins 
include mannan-binding lectin (MBL), surfactant proteins A and D, conglutinin, and hepatic 
and placental collectins. Soluble collectins are secreted by myeloid cells as well as epithelia, 
and typically bind to carbohydrate residues on the surface of microbes, where they induce cell 
lysis by disrupting the integrity of the membrane and cause agglutination and opsonisation of 
pathogens. MBL also has a vital role in the innate immune response as the initiator of the 
lectin pathway of complement activation; bound MBL interacts with MBL-associated serum 
proteases (MASPs), resulting in cleavage and activation of C4 and C2 [Gupta and Surolia 2007] 
– discussed in more detail in section 1.2.3 below. 
b. Ficolins 
Ficolins are structurally related to MBL and can also cause complement activation via the 
lectin pathway as well as opsonising pathogens for phagocytosis. They differ in their specificity 
for different carbohydrate moieties [Endo 2007]. 
c. Pentraxins 
Pentraxins include C-reactive protein, serum amyloid P component (short pentraxins) and 
pentraxin 3 and its family members (long pentraxins). Short pentraxins are synthesized in the 
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liver and secreted into the blood in response to inflammatory stimuli, while long pentraxins 
are secreted by myeloid cells and epithelia. Their typical ligands vary widely, but include a 
range of molecules associated with pathogens or damage to host tissues. They can activate 
complement via the classical pathway and also mediate opsonophagocytosis via Fc receptors. 
They have been likened to the innate immune system’s analogue for antibodies [Bottazzi 
2010]. 
1.2.3 The complement system 
Another major component of the innate immune system is the complement system, which 
comprises a series of more than 35 proteins and glycoproteins found in plasma and other 
bodily fluids, and on cell surfaces [Carroll and Sim 2011].  
1.2.3.1 History  
The complement system was first recognised late in the 19th century when the leading 
microbiologists Bordet, Ehrlich and Nuttall discovered a bactericidal function of blood on 
anthrax bacilli [Bordet 1895 and 1898]. In 1888 Nuttall demonstrated that fresh plasma 
possessed a bactericidal activity that was abolished when heated to 56°C [Nuttall 1888]. 
Bordet later showed that the bactericidal activity of heat-treated immune serum could be 
restored with fresh non-immune serum, which alone had no activity. On the basis of these 
observations, Ehrlich and Morgenroth [Ehrlich and Morgenroth 1899] proposed that there 
were two soluble bactericidal components in blood: heat-stable ‘amboreceptors’ (later 
identified as antibodies) that were found in immune serum and a heat-labile component found 
in non-immune serum which ‘complemented’ the microbicidal properties of the 
amboreceptors. 
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In the 1920’s and 30’s substantial progress was made with the identification of 4 complement 
components and the recognition that a lytic mechanism was responsible for their activation 
[Whitehead 1925, Gordon 1926, Gordon and Wormall 1929]. By 1941 four protein 
components had been identified and at least partly purified [Pillemer and Ecker 1941]. In 1958 
Louis Pillemer reported the discovery of a second, antibody-independent pathway of 
complement activation, which he named the properdin pathway (and which we know now as 
the Alternative Pathway) [Wedgewood and Pillemer 1958]; sadly the scientific community of 
the day was not ready for Pillemer’s breakthrough, and the professional ridicule that he 
endured as a consequence of his discovery contributed to his suicide in 1957.  
Developments that occurred during the 1960’s included a detailed investigation of ‘immune 
adherence’, the phenomenon by which complement-coated particles adhere to red blood cells 
(part of the process of opsonisation), standardisation of complement function assays by 
measuring the capacity to lyse red blood cells, and the separation of 9 distinct complement 
proteins from guinea-pig serum [Nelson and Nelson 1959 and Nelson 1966]. In the 1970’s and 
1980’s, protein components were identified and sequenced, and cDNA and genomic DNA 
clones were also obtained and sequenced [reviewed in Müller-Eberhard 1975, Müller-
Eberhard 1988 and Campbell 1988]. Moreover, cell-surface complement receptors were 
identified and characterised, as were both cell-surface and soluble complement regulatory 
proteins [reviewed in Wilson 1987 and Hourcade 1989]. Another substantial development of 
the 1980’s was the beginning of an appreciation of the role that complement activation plays 
in driving the adaptive immune response, as a result of ligation of complement receptors on B-
lymphocytes and dendritic cells (DC) [Pepys 1974, reviewed in Fearon 1998]. A third activation 
pathway, the lectin Pathway, was discovered by the Yamashina group in 1987 [Ikeda 1987]. 
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In the last 20 years, complement research has explored the role of the complement cascade in 
the clearance of damaged-self material [Walport 2001a and b], the function of complement 
regulatory proteins and the part played by their dysregulation in chronic inflammatory 
diseases such as age-related macular degeneration [reviewed in Rodriguez de Cordoba and de 
Jorge 2008]. The discovery of new proteases (mannan-associated serum proteases or MASPS) 
[Schwaeble 2002] and new recognition molecules (ficolins and collectin-11) [Matsushita 2009 
and Hansen 2010] has led to a new appreciation of the complexity of the lectin pathway. X-ray 
crystallography and nuclear magnetic resonance studies have revealed the three-dimensional 
structures of many complement proteins [Arlaud 2007 and Gros 2008], and the development 
of agents aimed at therapeutic manipulation of complement activation [Qu 2011] has 
culminated in the clinical use of the anti-C5a monoclonal antibody eculizumab. 
1.2.3.2 Pathways of complement activation 
Soluble complement proteins circulate in plasma and other bodily fluids as inactive precursors. 
Specialised sensor molecules detect non-self signals such as characteristic patterns of 
microbial carbohydrates and respond by inducing conformational changes in their structure 
that trigger an auto-amplifying catalytic cascade which results in rapid generation of activated 
complement products. These activated complement products have a wide range of pro-
inflammatory and immunomodulatory effects, including direct lysis and opsonisation of 
pathogens as well as inducing chemotaxis, granule enzyme release and the generation of 
reactive oxygen and nitrogen species by phagocytic cells. They may also activate the 
coagulation cascade and have profound effects on vascular smooth muscle tone. Complement 
activation can occur by any or all of four pathways: the classical, alternative, lectin and 
extrinsic protease pathways (summarised in Figure 2). The classical, alternative and lectin 
pathways converge in the activation of C3, the most abundant complement protein, which has 
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a number of effects: first, it acts as an auto-amplification mechanism, catalysing the activation 
of more C3; second, it generates opsonic protein fragments that coat non-self surfaces and 
label them for phagocytosis by migratory leucocytes; third, it results in the generation of 
chemotactic anaphylatoxins that recruit migratory phagocytes to the site of inflammation; and 
lastly it results in the assembly of a C5 convertase complex that triggers activation of the 
terminal pathway, resulting in the assembly of the lytic membrane attack complex (MAC) and 
the release of the most potent anaphylatoxin, C5a [Carroll and Sim 2011]. In the extrinsic 
protease pathway, C5 may be directly activated by serine proteases of the coagulation cascade 
and by a cellular protease expressed by differentiated phagocytes [Huber-Lang 2006, Amara 
2008]. 
Each of these pathways is initiated by different recognition proteins; for the classical pathway, 
this is the C1q multimer and for the lectin pathway, MBL or other structurally similar 
molecules. The alternative pathway is more complex, since the existence of a specific sensor 
molecule is somewhat controversial; also there is a constant low-level ‘tick-over’ activation of 
the pathway due to spontaneous hydrolysis of C3. The catalytic activity of this spontaneously-
generated C3(H20) is strongly inhibited by complement regulatory proteins on host tissues, 
and it is the absence of these inhibitors on exogenous surfaces (such as pathogens or synthetic 
materials) that is critical for amplifying complement activation via the alternative pathway 
[Carroll and Sim 2011, Ehrnthaller 2011].  
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Figure 2. Overview of complement activation pathways. MASP, mannan-
associated serine protease; MBL, mannan-binding lectin. Adapted from [Amara
2008], [Carroll and Sim 2011] and [Huber-Lang 2002].
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The different activation pathways have a number of components that are functionally, and to 
some extent structurally analogous. The sensor components of the classical and lectin 
pathways are the C1 complex and MBL (L-ficolins or collectin-11), respectively; these 
molecules are structurally related and play a similar role in both pathways, namely that of 
target recognition and activation of the C3 convertase complex. The large opsonin/convertase 
proteins C3b (alternative) and C4b (classical/lectin) are structurally similar, and serve to 
anchor catalytically active convertases to non-self surfaces, as well as linking complement-
coated pathogens to cell-surface complement receptors. Component C2a of the 
classical/lectin pathways and factor Bb of the alternative pathway are also structurally similar 
and functionally analogous, mediating the C3 convertase activity of the active complex. 
 a. The classical pathway 
The classical pathway sensor is the C1 complex, which is composed of a C1q hexamer and two 
molecules of each of two serine proteases C1r and C1s. As befits its role, soluble C1 is found 
abundantly in blood, with a mean plasma concentration of 115 µg/ml [Tan 2010]. Each C1q 
monomer is comprised of a three intertwined chains (A, B and C chains) with a collagen-like 
region and a globular head. Disulphide bridges stabilise adjacent C1q monomers, giving the 
hexamer the overall appearance of a bunch of tulips. The catalytic elements, the two C1s/C1r 
dimers, bind in a Ca2+-dependent manner to the ‘stems’ (Figure 3) [Pflieger 2010]. 
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Figure 3. Structural organisation of the C1 complex. (A) Structure of the
C1q hexamer and its association with C1r/C1s tetramer. (B) Representation
of the association between the A (blue), B (green) and C (light blue) chains.
Inset in B highlights the positions of lysine residues in the A (position 59), B
(position 61 and 65) and C (position 58) chains likely to be involved in the
binding site of the C1r/C1s tetramer. CLR, collagen-like region. Adapted
from [Pflieger 2010].
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The classical pathway is activated by C1 binding to a target molecule. The Fc region of antigen-
bound IgM and IgG is the primary target of C1.It is recognised however that C1q can also bind 
to a wide range of non-immunoglobulin activators including endogenous DAMPs and acute 
phase reactants such as free nucleic acids or C-reactive protein, microbial antigens such as 
Group B streptococcal capsular proteins and synthetic materials such as carbon nanotubules 
[reviewed in Kang 2009]. Binding of the globular heads of C1q induces a conformational 
change in the C1q hexamer that results in cleavage and activation of the C1r subunits, which in 
turn cleave the C1s molecules to form an active serine protease [Dodds 1978]. The activated 
C1r/s tetramer cleaves C4 and C2 to generate the classical/lectin pathway C3 convertase, 
C4b2a, with release of the anaphylatoxin C4a. C4b2a activates C3, yielding the small peptide 
anaphylatoxin C3a and a large opsonic and catalytic fragment C3b. C3b can either bind 
covalently to the target surface or to C4b in the C4b2a complex. The former results in 
activation of the alternative pathway via the formation of C3b-factor B complex (the 
alternative pathway C3 convertase), and the latter in formation of the C5 convertase C4b3b2a, 
which initiates the terminal pathway [Ehrnthaller 2011, Carroll and Sim 2011]. 
The classical pathway is regulated by the C1 inhibitor (C1-INH). C1-INH binds the C1 complex 
and initiates the dissociation of the fragments C1r and s, resulting in an irreversible 
inactivation of the serine protease. 
b. The alternative pathway 
The alternative pathway can be activated directly by contact with many types of complex 
carbohydrate structures present on the surfaces of pathogens [Ehrnthaller 2011]. As 
mentioned above, however, an important characteristic of the alternative pathway is its ‘tick 
over’ generation of C3b and thus large-scale complement activation via the alternative 
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pathway may be more a consequence of the absence of complement inhibitors on the surface 
of pathogens or synthetic materials, than of the presence of a specific trigger.  
C3 is a member of the C3/α2-macroglobulin protein family, which are large proteins of 1400-
1800 amino acids in length; complement components C4 and C5 are structurally similar 
members of this family and share about 30% sequence homology with C3. C3 and C4 are 
characterised by a reactive thioester moiety necessary for covalent attachment to molecular 
or cellular targets, and undergo profound conformational changes upon activation [Blandin 
and Levashina 2004]. The crystal structure of unactivated human C3 was determined in 2005 
[Jansen 2005] (Figure 4) and comprises a β-chain consisting of residues 1-645 and an α-chain 
consisting of residues 650-1641. Together these chains form 13 domains [Fredslund 2006]: 
eight homologous macroglobulin domains which comprise the core of the molecule and the 
linker, anaphylatoxin, CUB (C1r/s, Uegf, Bmp1), thioester and C345c domains [Gros 2008]. 
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Figure 4. Complement component C3. (A) Ribbon diagram of C3. Thioester
group (red spheres), anchor region (grey) and α chain N-terminus (black) are
shown. Domains are colour-coded: Macroglobulin (MG) domains 1-8 (1,
blue; 2, orange; 3, magenta; 4, gray; 5, green; 6, pink; 7, cyan and 8, yellow),
anaphylatoxin (ANA, red), C1r/s, Uegf, Bmp1 (CUB, dark blue), thioster (TED,
green), linker (LNK, gold), and C345C (russet) domains. (B) Domain sequence
and arrangements in C3. Colour scheme matches that in (A). Sequential
removal of peptide segments is shown, representing proteolytic activation
and inactivation. Black lines represent disulphide bridges. [Adapted from
Janssen 2005].
 
The alternative pathway of complement activation is summarised in Figure 5. Spontaneous 
slow hydrolysis of C3 (half-life ~ 230 h) generates a fluid-phase C3b-like molecule C3(H20), 
which is capable of associating with complement factor B, and is in turn cleaved by the soluble 
factor D, yielding a soluble complex C3(H20)Bb which has C3 convertase activity [Pangburn 
1992]. Further molecules of C3 are activated by clipping off the anaphylatoxin domain  
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Figure 5. Overview of the alternative pathway. Spontaneous hydrolysis of C3 yields 
C3(H2O) which binds factor B. Bound Factor B is activated by Factor D to yield a C3 
convertase C3(H2O)Bb. This activates C3 by cleaving off the anaphylatoxin domain to 
release the anaphylatoxin C3a and C3b which rapidly binds to pathogen surfaces. 
Properdin stabilises C3b and facilitates the recruitment of the pro-enzyme factor B; 
recruitment of factor B is inhibited by factor H. Binding of a second molecule of C3b 
yields the alternative pathway C3 convertase (C3bBbC3b). Alternatively, bound C3b 
may associate with  C4b2a (the classical pathway  C3 convertase) to yield the C5 
convertase (C4b3b2a). This activates C5 and initiates the terminal pathway. C3b is 
sequentially degraded by the soluble protease Factor I. Adapted from [Carroll and 
Sim 2011] and [Ehrnthaller 2011]. 
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between Arg726 and Ser727, resulting in a conformational change that exposes the highly 
reactive thioester group, which rapidly (half-life < 100 µs) bonds covalently to any accessible 
nucleophile molecules (such as sugar residues on microbial surfaces). Surface-bound C3b 
forms the base for the alternative pathway C3 convertase: the plasma globulin protein 
properdin binds to C3b and facilitates the recruitment of the pro-enzyme factor B as well as 
greatly increasing the half-life of the intrinsically unstable C3bB complex. The bound factor B is 
then activated by the soluble protease factor D to yield factor Bb. Binding of another molecule 
of C3b yields the alternative pathway C3 convertase C3bBbC3b, which contributes to a positive 
feedback loop, activating more molecules of C3. Bound C3b may alternatively associate with 
C4b and C2a, yielding the C5 convertase C4b3b2a, which activates the terminal complement 
pathway by cleaving C5 to C5a and C5b. C3 may also be activated by the classical pathway 
convertase (C4b2a) or by MASPs of the lectin pathway [Gros 2008].   
Regulation of the alternative pathway is achieved by a number of soluble and membrane-
bound complement regulatory proteins, as well as by the intrinsic instability of C3bBb, which 
decays spontaneously with a half-life of 60 seconds [Kerr 1980]. Complement regulatory 
proteins inactivate C3bBb in two ways: by enhancing the spontaneous decay of C3bBb (decay-
accelerating activity), and/or by enhancing the proteolytic cleavage of C3b into iC3b by the 
soluble protease factor I (cofactor activity) (Figure 5).   
Factor I breaks down surface-bound C3b, yielding the fragments iC3b, C3c and C3dg. 
Membrane-bound regulators such as decay-accelerating factor (DAF, CD55) and membrane 
cofactor protein (MCP, CD46), and complement receptor 1 (CR1, CD35) are cofactors for factor 
I as well as having decay-accelerator activity.  
The soluble complement regulatory factor H (FH) is a 155-kDa elongated glycoprotein 
consisting of 20 complement control protein (CCP) domains, each comprising 60 amino acids 
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[Sim and Di Scipio 1982]. Binding sites for C3b are found at CCP1-4, 12-14 and 19-20. FH is 
found in plasma at concentrations between 150-750 µg/ml [Tan 2010]. FH binding to C3b 
prevents formation of C3bB and so inhibits assembly of the convertase complex; it also 
possesses decay-accelerating activity and cofactor activity, enhancing the proteolytic 
breakdown of C3b. FH is reported to bind preferentially to C3b on endogenous cell surfaces 
due to the presence of negatively charged residues such as scialic acids that are not found on 
pathogens. FH can also bind to negatively charged residues on endogenous molecules such as 
heparin. Certain pathogenic bacteria, such as Neisseria meningitidis also express negatively 
charged residues on their cell surfaces which are capable of binding FH. Since FH is a 
complement inhibitor, this represents microbial ‘hijacking’ of a host defence strategy and 
helps the bacteria to evade complement-mediated lysis and phagocytosis [Meri and Pangburn 
1990]. 
c. The lectin pathway 
The lectin pathway is in many respects similar to the classical. The lectin pathway analogues of 
the C1 complex are MBL, L-ficolin and collectin 11 [Hansen 2010]; the MASPs are structurally 
similar and functionally analogous to the C1r/s tetramer and similarly catalyse the breakdown 
of soluble C4 and C2 to the classical pathway C3 convertase C4b2a. 
MBL, L-ficolin and collectin 11 are somewhat less abundant in plasma than is C1q, with a 
plasma concentration ranging from less than 1 µg/ml to about 25 µg/ml [Hansen 2010]. MBL 
and collectin-11 are members of the collectin family [Holmskov 2003], which are proteins 
composed of collagen-like and carbohydrate recognition domains (CRD). Ficolins are 
structurally and functionally related, but their CRD is a fibrinogen-like domain.  
MBL consists of 18 identical 32 kDa subunits typically arranged as a hexamer of trimers (Figure 
6A), although tetramers or dimers may also form [Jensenius 2009]. Each monomer is 
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comprised of an N-terminal region, a collagen-like domain, an α-helical coiled-coil ’neck’ 
region and a CRD [Drickamer 1986] (Figure 6B). The N-terminal domain contains 21 amino 
acids with cysteines in positions 6, 13 and 18. Cys6 is critical for the formation of a disulphide 
bridge that links monomers within the trimer; Cys13 and Cys18 are involved in disulphide 
bridges that stabilise the overall hexamer. The collagen-like region is comprised of 12 repeats 
of a Gly-X-Y motif where Y is typically proline or hydroxyproline. The monomer spirals in a left-
handed helix, each of which is coiled with two others in a right-handed helix to form the 
trimer. The trimers are stabilised by interactions between the NH group of the glycines and CO 
groups of the prolines. This ‘stem’ region forms the binding site for the MASPs. Each monomer 
terminates in a globular carbohydrate recognition domain. The close approximation of 6 
groups of 3 CRDs is indispensable for the high affinity of the molecule for microbial sugar 
residues [Jensenius 2009]. 
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Figure 6. Structure of human mannan-binding lectin (MBL). (A) Schematic
of human MBL structure showing the conformation of hexamer of trimers.
(B) Diagram of MBL trimer showing N-terminal region (amino acids 1-21),
collagen-like domain (amino acids 22-81), neck region (α-helix coiled-coil,
amino acids 82-111) and carbohydrate recognition domain (amino acids
112-230). Adapted from [Holmskov 2003] [Sheriff 1994] and [Drickamer
1988].
 
MBL binds terminal mannose, glucosamine and fucose sugars on the surface of bacteria and 
fungi, resulting in the activation of MASPs which catalyse the activation of C4 and C2 to 
generate the classical/lectin pathway C3 convertase C4b2a. C3 activation results in an auto-
amplification loop as described above. As well as its role in triggering complement activation, 
MBL and the other detector molecules of the lectin pathway have been shown to function as 
opsonins, able to bind to certain microbes in serum-free conditions and mediate enhanced 
uptake by phagocytic cells without requiring complement activation [Kuhlmann 1989]. 
However, this plays a proportionally lesser role in opsonisation of pathogens, since relatively 
few molecules of C1q, MBL or ficolin are found on the foreign surface, whereas brisk 
complement activation will rapidly cover a foreign particle in C3b. 
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d. The extrinsic protease pathway 
The three canonical pathways of complement activation described above converge at the level 
of C3 activation. The classical pathway C3 convertase C4b2a is reported to have C5 catalytic 
activity, but has very low catalytic efficiency [Rawal and Pangburn 2003] and thus C3 activation 
is the primary mechanism for generation of an efficient C5 convertase and subsequent 
initiation of the terminal pathway. Thus, in the total absence of C3, activation of the terminal 
pathway would be predicted to be at the least greatly inhibited. Ward and co-workers used a 
murine model of immune complex-mediated lung injury to demonstrate that complement-
dependent lung injury occurred at an equivalent intensity in spite of the genetic deletion of 
C3, suggesting the presence of an alternative C5 convertase in C3-deficient mice [Huber-Lang 
2006]. The observation that C5a levels in bronchoalveolar lavage fluid and pulmonary injury 
scores in C3-deficient but not wild-type mice were greatly reduced by inhibitors of the 
coagulation cascade indicated that the extrinsic C5 convertase might be a serine protease of 
the coagulation cascade.  
Thrombin (factor IIa) is a serine protease that catalyses the conversion of fibrinogen to fibrin, 
the final common pathway of the coagulation cascade. Ward and colleagues found that in the 
mouse model of complement-mediated lung injury, thrombin activity in the C3-deficient mice 
was up-regulated compared with that of wild-type mice, and that purified human thrombin 
was capable of activating purified or recombinant human C5 in a dose-dependent manner. 
Hence it appears that thrombin is capable of activating C5 independently of other components 
of the coagulation cascade. The investigators also found evidence that factors Xa, and XIa and 
plasmin (but not factor VII or tissue factor) were able to directly activate both C3 and C5 
[Amara 2008]. The physiological significance of this pathway (in the presence of functional C3) 
is not established, but conditions such as sepsis which cause massive complement activation 
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are typically accompanied by dysregulated activation of the coagulation cascade (for example 
in disseminated intravascular coagulation), and thus it is plausible that thrombin might 
contribute to pathological systemic complement activation in sepsis. It has also been shown 
that terminally differentiated phagocytic cells are able to activate C5 directly, presumably 
through the action of a membrane-bound or secreted serine protease [Huber–Lang 2002]. 
e. The terminal pathway 
The pathways of complement activation converge with the activation of C5. C5 is a large (196 
kDa) protein that is structurally similar to C3 and C4. It is composed of 8 macroglobulin 
domains, a CUB (C1r/s, Uegf, Bmp1) domain, the C5d domain (analogous to the thioester 
domain in C3 and C4) and an extended linker region between macroglobulin domains 1-2 and 
4-6 [Fredslund 2008]. Activation of C5 results from cleavage at Arg751-Leu752, which releases 
the potent chemotactic and vasoactive peptide C5a, (discussed in more detail below) and the 
larger fragment C5b which forms the basis of non-enzymatic assembly of the membrane 
attack complex. The C5b fragment sequentially combines with C6 and C7 and integrates into 
the phospholipid membrane [Podack 1980]. The addition of one C8 molecule creates the 
complex of C5b678, which forms a small transmembrane pore which is enlarged by the 
polymerisation of between 10 and 18 molecules of C9, creating a hole of about 100 Å in 
diameter [Podack 1984]. With loss of the membrane barrier function, unrestricted movement 
of water and small molecules along their concentration gradients may result in lysis of the 
target cell. 
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 1.2.3.3 Effects of complement activation 
a. Opsonisation of pathogens  
All of the three canonical pathways result in the activation and degradation of C3b. C3b 
degradation products are potent opsonins that greatly facilitate the clearance of pathogens. 
Surface-bound C3b is a ligand for complement receptor 1 (CR1), which is strongly expressed on 
red blood cells [Fearon 1981]. Thus, complement-coated particles are transported to the 
spleen bound to red blood cells. As the particle circulates, its affinity for CR1 decreases as C3b 
is degraded to iC3b by Factor I; CR1 has cofactor activity for Factor I. iC3b, on the other hand, 
has a high affinity for CR3 and CR4, which are expressed by phagocytic cells. When the red 
blood cell passes through the spleen, where there are abundant macrophages, the opsonised 
particle - now mainly coated with iC3b - is transferred to resident macrophages, which ingest 
and destroy it [Carroll and Sim 2011]. Bound iC3b is itself gradually degraded to the smaller 
fragment C3dg, which is a ligand for CR2. CR2 is not found on phagocytic cells, but is a 
component of the co-stimulatory B-cell receptor complex. It is predominantly through CR2 
that the complement system acts as an adjuvant to the B cell response, promoting 
proliferation of antigen-specific B-cell clones that have bound a specific antigen via their 
immunoglobulin-like B-cell receptor [Carroll 2000]. 
b. Cell lysis 
Although apparently dramatic in its effects, the capacity to form MAC seems to be largely 
dispensable in host defence; the only adverse effect of deficiency of C5-9 appears to be an 
increased susceptibility to meningococcal infections [Nagata 1989]. Extracellular lysis of these 
organisms appears to contribute substantially to clearance of infections, since they are 
capable of intracellular survival [Walport 2001a]. Paradoxically, deficiency of terminal pathway 
components may actually convey a survival advantage in Neisserial infections, as witnessed by 
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the high prevalence of inherited C6 deficiency in areas in which they are endemic. It has been 
suggested that C6 deficiency is protective against Neisserial endotoxaemia in infantile 
gastroenteritis [Orren 1987].  
c. Formation of the anaphylatoxins C3a, C4a and C5a 
The small peptide fragments C3a, C4a and C5a play a vital role in the host response to 
infection. They are chemotactic for neutrophils, potentiate phagocytosis and the generation of 
reactive oxygen species in phagocytic cells, induce complex effects on vascular smooth muscle 
tone, cause degranulation of mast cells and have a varying capacity to induce inflammatory 
cytokine release [Guo and Ward 2005]. C5a, the primary focus of this study, is discussed in 
more detail in section 1.3 below. 
d. Adverse effects of complement activation 
The complement system plays an important role in host defence and homeostasis, but like 
many other components of host immunity, it appears to be a two-edged sword; as well as 
having a vital role in the clearance of pathogens, inappropriate or dysregulated complement 
activation may result in ‘friendly fire’ injury to endogenous cells and tissues. Complement 
activation contributes to the initiation and maintenance of chronic sterile inflammatory 
conditions such as rheumatoid arthritis [Ballanti 2011], atypical haemolytic uraemic syndrome 
[Norris and Remuzzi 2009], age-related macular degeneration [Khandhadia 2012], systemic 
lupus erythematosus and many others [reviewed in Chen 2010].  
The potent anaphylatoxin C5a in particular is strongly implicated in the pathophysiology of 
sepsis. It is thought to contribute to the development of septic cardiomyopathy (a form of 
sepsis-induced cardiac failure that contributes to septic shock). It has been implicated in the 
pathological apoptosis of adrenal medullary cells during sepsis, with a resulting deficiency of 
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the adrenergic amine hormones that are critical for maintaining vascular tone and blood 
pressure. Excessive intravascular C5a generation in models of sepsis also contributes to 
neutrophil dysfunction, resulting in failure of neutrophil chemotaxis and impaired microbial 
killing; this is probably a key factor in the immunosuppression and susceptibility to ‘second-hit’ 
infections by opportunistic pathogens that is commonly seen in sepsis patients who survive 
the initial inflammatory insult [reviewed in Ward 2010a and b]. However, C5a is also a potent 
inducer of inflammatory cytokine and chemokine release from leucocytes and vascular 
endothelial cells. The contribution of C5a to the ‘cytokine storm’ that triggers systemic 
inflammation and widespread tissue injury and multi-organ failure is perhaps its most 
significant contribution to the pathophysiology of sepsis [Ward and Gao 2009]; this is the 
particular focus of this study.  
1.3 The anaphylatoxin C5a and its receptors 
The discovery of C5a began with the observation that incubation of an antigen with its 
corresponding antiserum resulted in the production of a heat-stable substance that was 
chemotactic for neutrophils [Boyden 1962]. Although itself heat-stable at 56˚, this substance 
was not produced if the serum was heat-treated (to 56˚ for 30min) prior to incubation, 
suggesting the existence of a heat-labile chemotaxin-generating factor, probably an enzyme, in 
serum containing antibody-antigen complexes. The observation by Müller-Eberhard that 
perivascular neutrophil infiltration in experimental immune complex-induced vasculitis was 
abolished by complement depletion raised the possibility that the chemotaxin was a 
complement protein [Ward 1965]. Mayer demonstrated in 1968 that sheep erythrocytes pre-
treated with guinea-pig IgG and exposed to the first four complement components were 
capable of cleaving C5 with the production of a high MW complex of C5, 6 and 7 and release of 
a peptide fragment with a molecular mass of ~ 15000 Da [Shin 1965]. This peptide fragment 
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was chemotactic for neutrophils, and induced smooth muscle contraction in isolated guinea-
pig ileum strips; it was also shown to induce degranulation of basophils and mast cells 
[Johnson 1975]. Subsequent studies have demonstrated a wide range of effects of C5a, 
including induction of oxidative burst and generation of reactive oxygen species in phagocytic 
cells, expression of activation markers and increased leucocyte adhesion and diapedesis, 
regulation of tissue regeneration and fibrosis and neurodevelopment, and induction of pro-
inflammatory cytokines and chemokines release by leucocytes [Strey 2003 and Guo and Ward 
2005], the latter being the primary focus of this study (discussed in more detail below). 
Figure 7. Structure of human C5a. Amino acid sequence (A) and secondary and
tertiary structure of human C5a (B). Four α-helices are shown in grey and inter-α
helical loops 1-4 are shown in red (D1, amino acids 12-20), green (D2, amino acids
28-33), and blue (D3, amino acids 38-46). Disulphide bridges are shown in yellow.
Adapted from [Guo and Ward 2005].
TLQKKIEEIA AKYKHSVVKK CCYDGACVNN DETCEQRAAR 
ISLGPRCIKA FTECCVVASQ LRANISHKDM  QLGR
A
B
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1.3.1 Structure  
The amino acid sequence of C5a was determined between 1976 and 1978 by Fernandez and 
Hugli [Fernandez and Hugli 1976 and 1978] and is shown in Figure 7. It is a 74-amino acid 
peptide, arranged in an antiparallel four-helix bundle stabilised by three disulphide bridges 
between Cys21-Cys47, Cys22-Cys54 and Cys34-Cys55 [Zuiderweg 1989, Zuiderweg and Fesik 1989, 
and Zhang 1997]. The helix bundle is highly cationic and confers high affinity for the negatively 
charged cell surface. The N-terminal segment (residues 1-69) is responsible for receptor 
binding, while the C-terminal pentapeptide (residues 69-74) form a bulky ‘tail’, which is 
responsible for receptor activation. In the absence of the C-terminal pentapeptide, the N-
terminal helix (residues 4-12) will bind to the receptor but without agonist activity. 
Neutralizing antibodies to C5a have implicated residues Lys20-Arg37 as critical for the 
molecule’s affinity for its main receptor, C5aR, while its potency is determined by the 
composition of the terminal pentapeptide (especially Arg74), and by the composition of loop 1 
(especially the lysines at positions 12, 14, 19, and 20) and loop 3. 
The predicted mass of the 74-amino acid peptide is 10.4 kDa. Approximately 25% of the 
observed mass (~12.9 kDa) of the native peptide is contributed by a carbohydrate moiety of 
~2.5 kDa attached to Asn64, the composition of which shows some variability. The 
carbohydrate side chain appears to contribute to the chemotactic activity of the native 
peptide, since the absence of glycosylation results in a reduction of C5a-induced chemotaxis in 
human neutrophils [Perez 1981]. Interestingly, the chemotactic effect of C5a for human 
neutrophils is augmented by an anionic polypeptide factor present in human serum, proposed 
to bind to a sialic acid residue in C5a’s carbohydrate side chain [Perez 1986]. This ‘co-
chemotaxin’ was identified as vitamin D-binding protein [Kew and Webster 1987], and was 
shown to enhance neutrophil chemotaxis to both C5a and its degradation product, C5adesArg 
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[Binder 1999]. This finding may have implications (largely uncommented-on) for the 
interpretation of subsequent C5a research, since most studies of the activity of C5a have been 
conducted using recombinant C5a expressed in bacteria, which typically results in a 
polypeptide that altogether lacks the carbohydrate side-chain.  
1.3.2 Clearance  
In vivo, C5a is an ephemeral peptide, due to the rapid kinetics both of its enzymatic 
deactivation and receptor-mediated uptake by leucocytes. Ubiquitous serum and cell 
membrane-bound carboxypeptidases rapidly (within seconds) convert it to the more stable 
C5adesArg by clipping off the N-terminal arginine, which is reported to decrease its biological 
activity ~10-100 fold [Bokisch and Muller-Eberhard 1970]. It is likely that this also occurs in in 
vitro models of C5a stimulation of myeloid cells, which express both membrane-bound and 
secreted carboxypeptidases [Krause 1998].  
As well as being enzymatically deactivated, C5a and C5adesArg are rapidly cleared from 
plasma by receptor-mediated uptake. I125-labelled C5a administered by intravascular injection 
to rabbits was found to have a plasma half-life of 2 min, and C5adesArg only slightly longer 
[Webster 1982]. Radiolabelled C5a and C5adesArg rapidly redistributed from the plasma to 
highly vascular organs, where they accumulated. This presumably reflected massive neutrophil 
activation and extravasation. Consistent with this, it was found that a neutropenia followed 
intravascular C5a activation, and numerous in vivo models have found neutrophil infiltration of 
the lungs and other highly vascular tissues to be a rapid consequence of intravascular 
complement activation [reviewed in Ward 2010a].  
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1.3.3 Biological activity 
C5a is chemotactic for migratory phagocytic cells, and induces contraction of smooth muscle 
and degranulation of mast cells. It induces oxidative burst in neutrophils and macrophages and 
potentiates oxidative burst in response to other stimuli. It is a weak inducer of inflammatory 
cytokines in its own right, but interacts synergistically with other inflammatory stimuli to 
regulate release of inflammatory mediators, and thus is a vital component of the cytokine 
response to infection and sterile inflammatory stimuli (discussed in more detail below). As well 
as being a potent mediator of innate immune responses, it also has a role in the regulation of 
the adaptive immune system, promoting survival and proliferation of both CD4+ and CD8+ T 
cells [Fang 2007 and Lalli 2008]. It has also been shown to have roles outside the immediate 
scope of the immune system, mediating bone remodelling and directional migration of neural 
tissue cells, and it has also been proposed to mediate in utero implantation and placentation 
[Salmon 2011]. 
It has been observed that C5a and C5adesArg appear to elicit qualitatively different effects in a 
manner that is difficult to explain simply on the basis of the reduced potency of the stable 
metabolite. For instance, basophils stimulated with C5a release both pro-inflammatory 
cytokines and lipid mediators of inflammation, whereas stimulation with equipotent 
concentrations of C5adesArg results in cytokine release alone [Eglite 2000]. These findings are 
suggestive of the action of more than one receptor for the anaphylatoxins C5a and C5adesArg. 
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1.3.4 Receptors for C5a1 
1.3.4.1 C5aR (CD88) 
The existence of a specific cell-surface receptor for C5a was demonstrated by Chenoweth in 
1978 [Chenoweth and Hugli 1978] using I125-labelled C5a competition binding studies in 
human neutrophils. The gene for the receptor was cloned and sequenced in 1991 [Boulay 
1991], [Gerard and Gerard 1991] and encodes a 42-kDa protein consisting of 350 amino acids, 
with a carbohydrate moiety attached at Asn5. Additional post-translational modifications 
include sulphations at Tyr11 and Tyr14. The gene is localised to chromosome 19q13.33 and 
consists of two exons, the first of which contains the start codon and the 5’ UTR, and the 
second contains the entire translated sequence, stop codon and 3’ UTR. This gene structure is 
characteristic of the family of 7 transmembrane region G protein-coupled receptors (GPCRs), 
which contains both of the C5a receptors as well as other chemokine receptors. The gene is 
known to have two non-synonymous single nucleotide polymorphisms resulting in Asp2Asn 
and Asn278Lys substitutions; neither is known to be associated with disease [Birney 2006]. 
a. Structure 
The C5aR protein has an overall structure typical of G protein-coupled receptors (see Figure 8). 
C5aR ligation involves two distinct events: the aspartate-rich acidic N-terminus of the receptor 
interacts with the basic core of C5a, and the C-terminus of C5a interacts with a pocket formed 
by hydrophobic residues in the transmembrane domains and charged residues at the base of 
the extracellular loops [Monk 2007]. The first event is responsible for ligand binding (affinity) 
and the second for receptor activation (agonist activity). The ligand-binding domain of C5aR  
                                                          
1
 Here and subsequently in this thesis, the term C5a receptor is used generically to refer to either or 
both of the receptors for C5a. C5aR is used to indicate CD88 or C5a Receptor 1, and C5L2 to indicate 
gpr77 or C5a Receptor 2. 
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Figure 8. Structure of human C5aR. Structure of human C5aR (CD88)
showing possible interaction sites with C5a. Transmembrane regions of
C5aR are shown as mauve cylinders. Possible interaction sites with C5a in
the second extracellular loop and N-terminus are shown in red. Inter-α
helices of C5a are shown in red (D1), green (D2) and blue(D3). From [Guo
and Ward 2005].
 
has been identified in a number of ways: antibodies raised against the N-terminal peptide 
sequence exhibit C5aR antagonist activity [Morgan 1993], and deletion of the N-terminus 
prevents ligand binding [Mery and Boulay 1993]. A C3aR-C5aR chimera, having the N-terminal 
region of C3aR also fails to bind C5a, but all three retain the ability to respond to peptide 
analogues of the C-terminal region of C5a [Crass 1999]. Mutational analysis of C5aR using a 
yeast selection system suggested that Arg175, Glu199, Arg 206 and Asp282 are critical residues in 
the juxta-membrane region of the extracellular loops for the activation site. 
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b. Tissue distribution  
Initially shown to be expressed on myeloid leucocytes (which show the strongest expression), 
C5aR is known to be widely expressed as a cell-surface receptor on a range of cell types 
including lymphocytes (B and T-cells), endothelial cells and a range of cells in the central 
nervous system, skin, heart, connective tissue, kidney, liver and lung [reviewed in Monk 2007]. 
Its tissue expression is up-regulated in non-myeloid cells by inflammatory stimuli such as 
bacterial lipopolysaccharide (LPS), IL-6 and TNF-α, and in models of sepsis [Hunt 2005, 
Riedemann 2003 and Stahel 2000], but downregulated in myeloid cells (especially neutrophils) 
in response to sepsis [Huber-Lang 2005]. Stimulation of neutrophils with C5a leads to rapid 
receptor internalisation followed by slower recycling to the cell surface, possibly with re-
release of functional C5a back into the extracellular medium [Scola 2009]. 
c. Ligand specificity 
Radiolabelled C5a competition binding studies showed that C5aR binds C5a avidly, and 
C5adesArg with 20 to 200x less affinity. Reported IC50 values of C5a for C5aR are in the range 
of 2-20 nM and of C5adesArg for C5aR 400-700 nM [Cain and Monk 2002, Kalant 2003, 
Okinaga 2003]. It has also been shown that C5aR is capable of binding a homodimer of the 
ribosomal protein S19, resulting in activation of downstream signal transduction pathways 
[Nishiura 2010]. 
d. Signal transduction 
GPCRs like C5aR are the largest protein receptor superfamily in the body. GPCRs transduce 
extracellular signals through a cascade of protein phosphorylation events and second 
messenger intermediates (Figure 9). GPCRs undergo a conformational change upon ligand 
binding that promotes activation (phosphorylation) of the heterotrimeric GTPase (G protein).  
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Figure 9. Model of G protein-coupled receptor signal transduction. (A) 
Heterotrimeric G protein bound to the intracellular loops of a G protein-coupled 
receptor (GPCR) in its ‘resting’ state.   (B) Ligand binding induces a conformational 
change in the GPCR, causing dissociation of G protein monomers and subsequent 
activation of signal transduction cascades. (C) Phosphorylation of intracellular loops of 
the GPCR by G receptor kinases (GRK) prevents re-association of G proteins and 
promotes (D) association of β-arrestins with the phosphorylated receptor. (E) β-
arrestin promotes clathrin-mediated internalisation of the receptor-ligand complex, 
leading to (F) β-arrestin-dependent recruitment of  signal transduction intermediates 
(such as non-receptor tyrosine kinase Src and the rho-family GTPases Ras and Raf), 
resulting in G protein-independent signal transduction. [Adapted from Luttrell 1997, 
Lefkowitz 2004 and Shukla 2011].
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Activation of the G protein results in its dissociation into α and βγ subunits, which initiate G 
protein-dependent signalling [Audet and Bouvier 2012]. After dissociation of the G-protein 
subunits, G-receptor kinases (GRKs) phosphorylate serine/threonine residues primarily in the 
C-terminal intracellular ‘tail’ of the receptor. Receptor phosphorylation promotes binding of 
the multifunctional adaptor proteins, β-arrestins, which sterically hinder further G-protein 
coupling with the activated receptor and lead to clathrin-mediated internalisation of the 
receptor [Lefkowitz 1998].  
The role of β-arrestins is wider than just termination of GPCR signalling: as well as mediating 
clathrin-dependent receptor internalisation, β-arrestins may recruit a range of other signalling 
intermediates to the activated receptor and serve as a scaffold for a signalling complex that 
engages G protein-independent signalling pathways. Importantly in the context of this study, 
β-arrestins have been shown to be able to scaffold upstream components of many of the 
signalling pathways critical for inflammatory responses (such as cytokine production). In 
particular, β-arrestin 1 has been shown to recruit non-receptor tyrosine kinases of the Src 
family which form a catalytic complex with small rho-family GTPases and are known to 
activate the mitogen-activated protein kinases (MAPKs) p38 (MAPK14), extracellular signal-
related kinase 1/2 (ERK1/2, MAPK3/1) and c-Jun N-terminal kinase 1/2 (JNK1/2, MAPK8/9) as 
well as phosphoinositol-3-kinase (PI3K) and Akt [Luttrell 1997, McDonald 2000, Povsic 2003, 
Gong 2008].  
Furthermore, it appears that GPCR signalling is more complex than a ‘two-state model’ in 
which the G protein is switched ‘on’ by ligand binding or ‘off’ by GRK phosphorylation. First, 
GPCRs may adopt multiple ‘active states’, engaging different pathways with different G-
protein subunits, one or other of which may be favoured according to different circumstances. 
For example, the β2-adrenergic receptor may sequentially engage Gαs and Gαi subunits as well 
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as signalling via β-arrestin 2, depending on the degree of phosphorylation of its intracellular 
loops [Lefkowitz 1998]. Second, GPCRs may form homo- or heterodimers, which appear to 
exhibit distinct behaviour in regards of internalisation/deactivation and signalling; C5aR has 
been reported to homodimerise [Floyd 2003] and heterodimerise with the chemokine 
receptor CCR5 [Huttenrauch 2005]. Third, receptor clustering in membrane microdomains 
such as lipid rafts may affect G-protein coupling and trafficking [DeFea 2008]. 
C5aR G protein-dependent signal transduction proceeds through Gαi2 [Sheth 1991, Skokowa 
2005], a pertussis toxin - sensitive G protein. Gα16 coupling has been shown in cultured cell 
lines but its occurrence in primary cells is controversial [Monk and Partridge 1993]. The Gβγ 
protein subunits have also been shown to be critical for C5aR signalling [Hwang 2004 and 
2005]. Consistent with this, it has been reported that the Gβγ subunits (rather than Gα 
subunits) are principally involved in activation of MAP kinase cascades in other GPCRs 
[Lefkowitz 1998]. C5aR is known to bind to β-arrestins 1 and 2 [Braun 2003] and an effect of β-
arrestin 1 binding on signal transduction has been documented [Bamberg 2010]. 
C5aR ligation may elicit a number of different cellular responses, including the cytoskeletal 
rearrangements involved in chemotaxis, induction of oxidative burst metabolism and the 
release of pro-inflammatory cytokines (the particular focus of this study). C5aR signal 
transduction (Figure 10) has been studied predominantly in the context of chemotaxis and the 
induction of oxidative burst in professional phagocytic cells, and consequently the pathways 
involved specifically in the induction of cytokine synthesis have not been completely 
documented. However, many of the signal transduction pathways reported to mediate 
chemotaxis and oxidative burst are also known to be involved in the induction of cytokine 
secretion. This is discussed further in Section 1.5 and Figure 18 (below). 
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Figure 10. Overview of C5a receptor signal transduction. C5aR interacts with 
protein kinases, GTP-binding proteins, non-receptor tyrosine kinases and other 
signalling enzymes, which in turn activate downstream signal transduction 
intermediates, leading to: actin remodelling and cytoskeletal rearrangement, 
activation of transcription factors leading to changes in gene expression, and 
initiation of oxidative burst metabolism leading to generation of reactive oxygen 
species. DAG, diacyl glycerol; ERK, extracellular signal-related kinase; PAKs, p21-
activated kinases; JNK, c-Jun N-terminal kinase; NADPH, nicotinamide adenine 
dinucleotide phoshate; NF-κB, nuclear factor κB. Adapted from [Monk 2007].
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1.3.4.2 C5L2 (gpr77) 
a. Structure  
The existence of a second receptor for C5a was first reported by the Takahashi group in 2000 
[Ohno 2000]. The group amplified a 700-bp fragment of DNA from a cDNA library isolated 
from human immature dendritic cells using degenerate primers based on known conserved 
regions in the second and seventh transmembrane regions of non-chemokine 
chemoattractant receptors (including IL-8R, C5aR, C3aR and f-met-leu-phe receptor {fMLPR}). 
An expression plasmid was constructed and stably transfected into HEK-293 cells. Sequence 
homology with human C5aR (38%), C3aR (33%) and fMLPR (29%) suggested that the new 
receptor might be a GPCR. Analysis of the amino acid sequence suggested that the protein 
possessed a serpentine structure with several common characteristics of the GPCRs including 
several Ser/Thr residues that provide the phosphorylation site for binding of β-arrestins to 
C5aR in the intracellular C-terminus. 
b. Tissue distribution and subcellular localisation  
Expression of mRNA for C5L2 is reported in a wide range of human tissues; its expression 
parallels that of C5aR mRNA, but is generally of lesser abundance. Early reports [Okinaga 
2003] suggested that C5L2 might be expressed in greater abundance than C5aR in certain 
tissues (especially skeletal and cardiac muscle), whereas Gerard et al found C5L2 consistently 
less abundant than C5aR [Bamberg 2010]; this might reflect intersubject variability in the 
relative expression levels of the mRNA for the two receptors. Expression of C5L2 at the protein 
level has been reported in a range of leucocyte subtypes including monocytes, macrophages 
and neutrophils, as well as in astrocytes, glial cells, fibroblasts and adipocytes [reviewed in 
Monk 2007].  
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The subcellular localisation of C5L2 is still a subject of some controversy. Many of the early 
data concerning the subcellular localisation of C5L2 pertain to transfection systems in cultured 
cell lines and may not reflect the cellular localisation of the receptor in cells that naturally 
express it. A number of techniques have been used to assess the presence of C5L2 either at 
the cell-surface or in intracellular compartments, with apparently conflicting results.  
The Takahashi group [Ohno 2000] detected cell-surface expression of C5L2 on immature but 
not mature human monocyte-derived dendritic cells by flow cytometry. Gerard et al. reported 
that cell surface expression of C5L2 was detectable by flow cytometry on human neutrophils 
and monocytes [Okinaga 2003]. Köhl and co-workers found strong surface expression of C5L2 
on purified human monocytes and the mast cell line HMC-1, but none on human neutrophils 
[Otto 2004]. In this study, the investigators found that mean fluorescent intensity of C5L2 
staining on monocytes varied by a factor of 3 between four donors, raising the possibility that 
cell-surface expression of C5L2 may vary substantially between different donors of the same 
species. Ward et al. used Western blot of a whole-cell lysate and flow cytometry to 
demonstrate C5L2 expression in human and rat neutrophils [Huber-Lang 2005]. The Ward 
group also used confocal microscopy to investigate the sub-cellular localisation of C5L2 in rat 
neutrophils [Gao 2005], which showed a uniform peripheral staining for both C5L2 and C5aR, 
indicating a cell-surface expression pattern for both receptors. However, neutrophils isolated 
from blood samples taken 24 h after caecal ligation and puncture (CLP) showed a cortical 
redistribution of C5aR (suggesting receptor internalisation) but unchanged peripheral C5L2 
distribution.  
Monk and colleagues used I125-labelled C5a to assess cell-surface expression of C5L2 on human 
neutrophils [Scola 2009]. Briefly, neutrophils were loaded with I125-labelled C5a in the 
presence and absence of a specific C5aR antagonist. C5a uptake in the presence of an excess 
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of C5aR antagonist was attributed to C5a binding to C5L2, and the difference between this and 
C5a uptake in the absence of C5aR antagonist attributed to C5a binding to C5aR. The 
investigators found that C5L2 expression on neutrophils was weak compared with that of C5aR 
(4,617 ±1,373 C5L2 molecules per cell compared with 97,306 ± 42,658 of C5aR, mean ±SD). 
These findings were consistent with their observation that C5L2 expression in stably 
transfected RBL cells was predominantly intracellular, with >60% of the receptor localised 
within the cell, compared with <20% of C5aR. Notably, the ratio of cell-surface C5L2 to C5aR 
expression exhibited significant variation between the 4 donors tested (range 2.4% to 29.7%, 
median 4.5%). These findings were in contrast with those of the Ward group [Gao 2005], who 
had reported predominantly cell-surface expression in rat neutrophils.  
Gerard and co-workers’ findings [Bamberg 2010] were in agreement with those previously 
reported by Scola [Scola 2009] and discussed above. They reported that pre-incubation of 
human neutrophils with the mouse anti-human C5L2 monoclonal antibody (mAb) clone 1D9, 
previously shown to block C5L2, had no effect on I125C5a binding, suggesting little or no 
surface expression of C5L2. Flow cytometry analysis of human neutrophils using another C5L2-
specific mAb (clone 4C8) showed no increase in fluorescence over isotype control in intact 
neutrophils, but a substantial increase when cells were permeabilised with saponin before 
incubation with the primary antibody, both of which findings suggested an intracellular 
localisation for C5L2, at least in human neutrophils. Confocal microscopy supported this 
observation; C5aR showed a distinct peripheral staining pattern consistent with cell-surface 
expression in resting cells, with rapid redistribution to the cytoplasm following stimulation 
with C5a. C5L2, however, showed a diffuse cortical staining pattern in resting cells 
characteristic of intracellular localisation of the receptor. 
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The apparent inconsistency between the findings of Köhl et al [Otto 2004], who failed to 
demonstrate cell-surface C5L2 expression on human neutrophils, with the later studies may 
perhaps be explained on the basis of a predominantly intracellular location for C5L2 in human 
neutrophils, and the reported wide intersubject variation in cell-surface expression. 
Furthermore, while the Köhl group report that C5L2 labelling with the primary antiserum 
occurred at zero degrees, several of the other studies report incubating with antibody at room 
temperature, in which conditions antibody might be internalised and bind to intracellular 
receptors. It is more difficult to reconcile the findings of Ward et al [Gao 2005] in rat 
neutrophils with those of Monk and Gerard in human neutrophils [Scola 2009 and Bamberg 
2010]. It is possible that C5L2 has a different subcellular localisation in rat compared with 
human neutrophils. 
In summary, C5L2 has been shown to be expressed as a cell-surface protein in monocytes and 
macrophages as well as astrocytes and glial cells. It has been reported to be predominantly 
expressed at the cell surface in rat neutrophils, and predominantly intracellular in human 
neutrophils. In cells which exhibit surface expression, its abundance may vary significantly 
from one donor to another. 
c. Ligand specificity  
The status of the putative chemokine receptor C5L2 as a receptor for C5a was demonstrated 
by Cain and Monk [Cain and Monk 2002] who showed specific binding of C5a, C5adesArg, C4a 
and C3a to C5L2 using radiolabelled C5a competition assays. The affinity of C5L2 for C5a was 
similar to that reported for C5aR (Kd=9.5 nM for C5L2 compared with 7.7nM for C5aR) but the 
affinity of C5L2 for C5adesArg was approximately ten-fold higher than the affinity of C5aR 
(Kd=36.5 nM compared with 412 nM). Furthermore, the on-off rates of the two receptors are 
very different. Using a model of L1.2 lymphoblasts transfected with either C5aR or C5L2, 
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Gerard and co-workers demonstrated that C5a binding to C5aR reaches equilibrium within 
minutes whereas binding to C5L2 had not reached equilibrium by 2 hours. Similarly, the off-
rate of C5L2 was estimated to be eight times slower [Okinaga 2003]. 
A detailed and comprehensive study published by the Monk group in 2007 [Scola 2007] 
addressed the issue of the molecular basis for the apparent preference of C5L2 for binding 
C5adesArg rather than C5a. As previously discussed, the C5aR’s primary binding site for C5aR 
is a series of acidic and Tyr residues at the N-terminus of the peptide; a secondary binding site 
in the hydrophobic pocket formed by the transmembrane helices mediates agonist activity. 
However, a panel of C5a agonists that selectively bind to the hydrophobic pocket had 
relatively little effect on C5a or C5adesArg binding to C5L2, suggesting that this site was less 
important for C5L2 binding of its ligands. Hence it appears that acidic and tyrosine residues at 
the N-terminus are critical for C5a binding to C5aR, and for C5adesArg binding to C5L2, but 
that C5a binds to different residues on C5L2. The authors also identified sulphation of N-
terminal tyrosine residues as critical for C5aR binding to either ligand, whereas inhibition of 
tyrosine sulphation had only a small effect on C5a binding to C5L2 and none on C5desArg 
binding.  
Importantly, the authors also noted that rat and mouse C5aR and C5L2 (which are commonly-
used experimental models) do not exhibit similar affinities for the two ligands to the human 
receptors. Mouse and especially rat C5L2 have a lower affinity for murine C5a and much 
higher affinity for C5adesArg, such that at concentrations of C5a observed in vivo, C5L2 is 
essentially a receptor for C5adesArg, with very little capacity to bind C5a [Scola 2007]. Hence a 
degree of caution is needed when generalising findings from these models to humans. 
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d. Signal transduction and function 
Thirteen years after its initial description, the function of C5L2 is still a matter of controversy. 
Upon its discovery in 2000, the Gerard group noted that the receptor lacked the PKC 
phosphorylation site possessed by C5aR and C3aR on the third intracellular loop, which is 
important for intracellular signal transduction [Ohno 2000]. Furthermore, the third 
intracellular loop of most GPCRs contains a conserved Asp-Arg-X motif that is critical for G-
protein binding. C5aR has Asp-Arg-Phe and C3aR has Asp-Arg-Cys, but C5L2 has Asp-Leu-Cys, 
suggesting that it is unlikely to couple to G-proteins. Consistent with this, Cain and Monk 
found that C5L2 couples only very weakly to classical GPCR signal transduction pathways [Cain 
and Monk 2002]. Supra-physiological stimulating concentrations of C5a, C5adesArg, C4a or 
C3a failed to induce Ca2+ mobilisation or granule enzyme release in RBL cells transfected with 
C5L2. The authors also found no evidence of ligand-mediated receptor internalisation, a 
typical consequence of GPCR activation and signalling, and so concluded that the likely 
function of C5L2 was as a scavenger receptor, acting as a ‘sink’ for activated complement 
fragments. Interestingly, however, priming C5L2-transfected RBL cells with C5a or C5adesArg 
before activation with IgE immune complexes (known to induce activation of nuclear factor-
kappa B (NF-κB) and inflammatory cytokine release via the Fcε Receptor1/Tyrosine Kinase 
pathway) did result in ~30% increase in granule enzyme release, in a pertussis toxin-
dependent manner, which suggested a Gi-mediated effect of C5L2 on Fc receptor signal 
transduction [Ten 1999]. This raised the possibility that, regardless of its putative role in C5a 
signal transduction, C5L2 might exert a regulatory effect on the signal transduction of other 
receptors.  
A further study by the Gerard group in 2003 produced results both concordant and contrasting 
with those of Cain and Monk [Okinaga 2003]. Consistently with previous findings, the authors 
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were unable to demonstrate C5a-induced Ca2+ flux in cell lines transfected with C5L2, even 
when Gα16 was co-transfected. A weak C5a-induced Ca
2+ mobilisation was achieved by 
inducing Leu132Arg mutation at the critical G-protein-binding site in intracellular loop 3 (thus 
restoring the Asp-Arg-X motif critical for G-protein binding), which was enhanced by co-
transfection with Gα16. However, the relative weakness of the signal compared with that seen 
in a C5aR+ Gα16 co-transfectant model suggests that the AspLeuTyr mutation in C5L2 is not the 
only factor in uncoupling C5L2 from G protein signalling.  
It is notable that the Ca2+ flux induced by this mutation was sustained rather than transient, 
which the authors interpreted as reflecting a lack of ligand-induced receptor deactivation. 
Ligand-induced deactivation of GPCRs is typically a consequence of C-terminal Ser/Thre 
phosphorylation by GRKs. Consistent with this, whereas C5aR was rapidly and strongly 
phosphorylated in response to C5a stimulation, C5L2 showed much lesser degree of, and 
slower phosphorylation. The authors also failed to observe C5a-induced ERK1/2 
phosphorylation in C5L2-transfected L1.2 lymphoblasts. If the findings from this experimental 
model may be generalised, it would suggest that if C5L2 were able to modulate responses of 
cells to C5a it is more likely to reflect an effect on the kinetics of the C5a-C5aR interaction than 
signal transduction through C5L2 itself, which would be consistent with a role as a decoy 
receptor. 
The Gerard group presented the first data generated using a C5L2-deficient C57/BL6 mouse 
model in 2005 [Gerard 2005], data which were consistent with the general hypothesis that the 
primary function of C5L2 was to attenuate C5aR-mediated pro-inflammatory responses by 
scavenging ligand. In a model of immune complex-mediated pulmonary injury (which is 
characterised by pulmonary complement activation), C5L2-deficient mice exhibited greater 
neutrophil infiltration and more severe histological pulmonary inflammation than wild type 
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mice. Lung tissue homogenates showed higher levels of the pro-inflammatory cytokines IL-6 
and TNF-α, and isolated bone marrow cells from C5L2-deficient mice showed enhanced 
chemotaxis in response to C5a. These data indicating a more ‘pro-inflammatory’ phenotype in 
C5L2-deficient mice would suggest that C5L2 was exerting an inhibitory effect on C5a-
mediated inflammatory responses in the wild-type animals. 
An intriguing study conducted by Feinstein and co-workers in 2005 co-incidentally identified 
the presence of C5L2 in rat astrocytes [Gavrilyuk 2005]. Immunohistochemical staining of rat 
brain tissue for C5L2 showed that it was expressed throughout the rat brain in neurones and 
astroglia. Using generation of reactive nitrogen species (levels of nitric oxide synthase (NOS) 
and nitrites) as a marker for LPS-induced inflammation, the investigators showed an anti-
inflammatory effect of C5L2: preincubation of cultured rat astrocytes with an antisense 
oligonucleotide to rat C5L2 resulted in a 2.5-fold increase in LPS-induced NOS mRNA and 
nitrite levels. Transfection of C6 glioma cells with C5L2 resulted in a significant reduction 
(>70%) of NF-κB activation in response to LPS treatment compared with cells not expressing 
C5L2. Interestingly, this effect was observed in the absence of exogenously administered C5a, 
raising the possibility that constitutive activation of C5L2 might have a modulatory effect on 
TLR-mediated inflammatory responses; this possibility is discussed in more detail in sections 
1.5 and 3.8 (below).  
The Klos group demonstrated that C5L2 is constitutively expressed by the epithelial HeLa cell 
line [Johswich 2006]. C5aR however was neither constitutively nor inducibly expressed in 
these cells. The myeloblastic cell lines U937 and HL-60 were found to express C5L2 
constitutively, and inducibly upon stimulation with IFNγ and dibutyryl cAMP, but not TNF-α. 
However, no C5a-induced Ca2+ mobilisation could be shown in these cell lines. Thus the 
investigators concluded that the likely role of C5L2 is as non-signalling receptor or ‘sink’ for 
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C5a/C5adesArg, in which context it might inhibit C5a-induced inflammatory responses 
mediated by C5aR. They did not, however, exclude the possibility of Ca2+-independent 
signalling via C5L2, nor did they address the question of why an epithelial cell might express a 
decoy receptor for C5a when it does not express the ‘live’ receptor, C5aR. 
Up to this point, functional studies had consistently found that blockade or deficiency of C5L2 
resulted in a stronger response to C5a or other inflammatory stimuli, suggesting an inhibitory 
effect of C5L2 on pro-inflammatory responses to C5a (and possibly other stimuli). However, 
data from independently-generated C5L2-deficient C57/BL6 and BALB/c mouse models were 
presented by Yeh and colleagues in 2007 [Chen 2007], suggesting a different and more 
complex function for C5L2 than that previously proposed. In a detailed and comprehensive 
study, the investigators presented findings that appeared to demonstrate a role for C5L2 in 
potentiating both C5a and C3a-mediated inflammatory responses. Neutrophils from wild-type 
mice showed similar sensitivity to C5a to those from C5L2-deficient animals, as measured by 
expression of activation markers and IL-6 release. However, C5a-induced MAPK signalling in 
cells from C5L2-deficient mice was found to be inhibited compared with wild-type cells. A 
corresponding effect on C5a-mediated chemotaxis was also reported in that recruitment to 
and activation of neutrophils in thioglycollate- and C5a-inoculated dorsal air pouches were 
reduced in C5L2-deficient mice compared with wild-type littermates. C5L2 deficiency was also 
associated with reduced airway hyper-responsiveness and lung inflammation in an OVA-
induced asthma model. These findings suggested that in this experimental model, C5L2 was 
either potentiating signal transduction through C5aR or directly transducing C5a signals itself 
since its deficiency resulted in greatly attenuated MAPK phosphorylation; neither effect was 
consistent with its previously-proposed role as a decoy receptor for C5a. 
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An investigation published by the Ward group in 2008, conducted using the Gerard group’s 
C5L2-deficient mice, produced the first conclusive evidence of C5L2 signal transduction 
independently of C5aR [Rittirsch 2008]. The investigators found that in vitro C5a stimulation of 
murine macrophages induced the release of high mobility group box protein 1 (HMGB1), a 
chromatin-binding protein that is mobilised from the nucleus and secreted in response to 
inflammatory stimuli, and functions both as a marker and late mediator of inflammation in 
sepsis [Wang 2008]. Sepsis also induced significant plasma levels of HMGB1. In both the in 
vitro and sepsis models HMGB1 secretion was unaffected by either blockade or deficiency of 
C5aR, but was abolished either by C5L2 deficiency or by treatment with a C5a antagonist, 
suggesting that HMGB1 secretion was dependent on the interaction of C5a with C5L2, rather 
than C5aR. The C5a-mediated release of HMGB1 in vitro could be blocked by inhibitors of 
specific MAPK pathways (ERK1/2 and JNK1/2 but not p38), indicating that C5L2 is in fact 
capable of coupling to the MAPK signal transduction pathways without any requirement for 
C5aR. The findings of this study are discussed in more detail in section 1.5 (below). 
Since C5L2 has been shown to be incapable of signalling through G proteins in numerous 
model systems, it is possible that the effects described above are mediated by a G protein-
independent signal transduction mechanism. Zaman and co-workers [Van Lith 2009] 
developed a β-galactosidase complementation assay that demonstrated C5a- and C5adesArg-
induced co-localisation of C5L2 with β-arrestin 2 in a CHO transfectant system. Gerard et al. 
[Bamberg 2010] reproduced these findings in human neutrophils, demonstrating by confocal 
microscopy and co-immunoprecipitation that stimulation of neutrophils with C5a induces co-
localisation of C5L2 with β-arrestin 1. The investigators also showed that C5aR at the cell 
surface is rapidly internalised to cytoplasmic vesicles upon C5a stimulation, where it associates 
with C5L2, raising the possibility of a C5aR ligation-dependent formation of a C5aR/C5L2/β-
arrestin signalling complex. This would suggest that C5L2 ligation of C5a is a secondary event, 
49 
 
following C5aR ligation and internalisation, which would be consistent with the group’s finding 
of a predominantly intracellular location for C5L2 in human neutrophils. Also consistent with 
this hypothesis, the investigators were able to block association of C5L2 with β-arrestin 1 by 
pre-incubating cells with an anti-C5aR antibody prior to C5a stimulation. Antibody blockade of 
C5L2 resulted in a dramatic enhancement of neutrophil chemotaxis but had no effect on Ca2+ 
signalling, consistent with employment of a G protein-independent signalling pathway. It did, 
however, enhance ERK1/2 phosphorylation.  
These findings led the investigators to propose a model in which C5L2, through its association 
with β-arrestin 1, exerted a negative regulatory effect on C5aR-mediated ERK1/2 
phosphorylation and chemotaxis. Since C5L2 had been shown to be predominantly 
intracellular, and since blockade of C5aR prevented co-localisation of C5a and C5L2, the 
authors proposed that C5L2 activation was a secondary event, strictly dependent upon C5aR 
ligation and internalisation. However, whilst explaining their own findings in human 
neutrophils, this hypothesis is not consistent with the earlier evidence provided by the Ward 
group that C5L2 is capable of inducing HMGB1 release by C5aR-deficient murine macrophages.  
Köhl and co-workers [Zhang 2010] identified a role for C5L2 in the regulation of adaptive 
immunity in a mouse model of allergic asthma. C5a is reported to have biphasic effects in the 
context of allergy [Köhl 2006], while it is a key mediator of inflammation in the context of 
acute exacerbations of asthma, it has been reported to have a negative regulatory role during 
allergen sensitisation by moderating DC-mediated activation of naïve T cells. Zhang et al. 
found that in an ovalbumin-induced asthma model, C5L2-deficient BALB/c mice exhibited 
decreased airway hyper-responsiveness, histological airway inflammation and leucocyte 
infiltration as well as reduced serum levels of IgE compared with wild-type littermates. C5L2-
deficient pulmonary cells harvested by bronchoalveolar lavage and then cultured overnight 
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secreted lower levels of the TH2-promoting cytokines IL-4, IL-5, IL-13 and IL-10. Similar results 
were obtained using a house dust mite-induced model of asthma; in this model, cultured cells 
retrieved by bronchial lavage of C5L2-deficient mice secreted also much higher levels of IL-17 
than wild-type mice. These findings suggested that C5L2 was responsible for the release of 
cytokines that promoted an allergenic TH2 polarisation of CD4
+ T cells, and that its absence 
resulted in a cytokine milieu favouring TH17 polarisation. 
An alternative role for C5L2 as a receptor for the inactive stable metabolite of C3a, 
C3adesArg77, was proposed by the Monk and Cianflone groups in 2002 [Kalant 2002]. 
C3adesArg had previously been shown to be identical with acylation-stimulating protein, a 
regulator of lipid metabolism in adipocytes and other connective tissue cells [Baldo 1993]. 
C3adesArg has very low affinity for C3aR, and has not been shown to induce any 
immunological effects in haematopoietic cells that express C3aR. Kalant et al. found that both 
human adipocytes and fibroblasts express mRNA for C5L2, and that C5L2 bound both 
C3adesArg and C4adesArg. This study prompted a rapidly growing body of research into the 
potential function of C5L2 as a regulator of lipid metabolism, with possible roles in the 
pathogenesis of obesity and atherosclerosis. Whilst this is a fascinating field of investigation, a 
detailed discussion of this part that C5L2 may play in lipid metabolism lies beyond the scope of 
this thesis. 
In summary, the issues of C5L2’s function and signal transduction mechanism remain a subject 
of controversy. Most studies have shown that it fails to induce significant Ca2+ mobilisation in 
response to C5a stimulation, which suggests that C5L2 is unable to couple efficiently to G 
proteins, as expected on the basis of the Asp-Leu-Cys mutation in the third intracellular loop. 
However, this does not exclude the possibility that it may participate in a G protein-
independent signal transduction mechanism, and indeed there is evidence that in human 
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neutrophils, it may at least modulate C5aR-mediated ERK1/2 signalling through its interaction 
with β-arrestin 1 [van Lith 2009, Bamberg 2010], while in murine macrophages it appears able 
to induce MAPK phosphorylation and HMGB1 release in response to C5a without the need for 
any interaction with C5aR [Rittirsch 2008], suggesting that it may be capable of signalling in its 
own right.  
C5L2’s status as a decoy receptor is uncertain, since studies in primary cells have questioned 
its cell-surface expression [Otto 2004, Bamberg 2010] and functional data have suggested that 
it may not antagonise the effects of C5aR [Rittirsch 2008]. Finally, the question of its ultimate 
function is unresolved: it is unclear whether or not it exerts a pro- or an anti-inflammatory 
effect, or whether it inhibits or potentiates C5aR-mediated inflammatory responses, since it is 
reported to have different effects on different inflammatory mediators in different cell types 
(and even in the same cell types but between different species). 
1.4 Pathogen recognition by the cells of the innate immune 
system 
The leucocytes of the innate immune system include neutrophils, (polymorphonuclear 
leucocytes, PMN), monocytes and macrophages, dendritic cells (DC) and natural killer cells 
(NK). PMN, monocytes/macrophages and DCs have a range of important homeostatic 
functions in addition to their role in pathogen recognition and the response to infection: they 
participate in the clearance of dead cells, promote tissue repair in response to sterile injury 
and are involved in lipid scavenging. DCs, in addition, regulate T cell tolerance to self-antigens 
and maintain the numbers and functional competence of lymphocytes [Sancho and Reis e 
Sousa 2012]. However, the major function of all these cells is chemotaxis to the site of 
infection and phagocytosis of pathogens, both in order to clear infecting organisms and to 
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present processed antigen to the B- and T-cells of the adaptive immune system [Murphy 
2012]. They also play a key role in orchestrating the exaggerated secretion of pro-
inflammatory chemokines and cytokines that is implicated in pathological inflammatory 
responses, as in the case of sepsis. The primary function of NK cells is the destruction of virus-
infected and tumour cells [Murphy 2012]. 
Pathogen recognition by innate immune cells is accomplished mainly through several families 
of PRRs (Figure 1). These include cytoplasmic and cell membrane-associated PRRs.  
1.4.1 Cytoplasmic PRRs  
The cytoplasmic PRRs are located intracellularly and are typically not associated with 
membranous organelles. Their primary function is the detection of components of intracellular 
pathogens. They include retinoic acid-inducible gene-I-like receptors (RLRs), nucleotide binding 
domain leucine-rich repeat receptors (NLRs) and membrane-associated receptors of the 
collectin and scavenger receptor (SR) families as well as some members of the Toll-like 
Receptor (TLR) family. 
1.4.1.1 Retinoic acid-inducible gene-I-like receptors (RLRs) 
RLRs play an important role in the recognition of intracellular viral RNA, in response to which 
they promote the secretion of pro-inflammatory cytokines and type I interferons. Key RLRs 
include RIG-I, MDA5, and LGP2, which contain a helicase domain capable of unwinding double-
stranded RNA (dsRNA). Ligation leads to assembly of a signalling complex that localises to the 
mitochondria and induces activation and translocation of NF-κB and Interferon Response 
Factors (IRFs) 3 and 7 (Kato 2011).  
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1.4.1.2 Nucleotide binding domain leucine-rich repeat receptors (NLRs) 
NLR proteins belong to the Signal Transduction ATPases with Numerous Domains (STAND) sub 
clade of the AAAATPase superfamily. They are characterized by a centrally-located nucleotide-
binding domain, a variable number of highly polymorphic C-terminal leucine-rich repeats 
(LRRs), and diverse N-termini [Bonardi 2012]. Human NLRs include the Class II Transactivator 
(CTA), a regulator of MHCII expression; NAIP, which triggers activation of the caspase-
containing inflammasome protein complex in response to bacterial flagellin; nucleotide 
oligomerisation domain 1 (Nod 1, NLRC1) and Nod2 (NLRC2), which recognize bacterial 
proteoglycans and result in activation of NF-κB; and members of the NLRP (NALP) family, 
which are reported to exhibit negative regulatory functions on inflammatory responses 
[Robertson 2012 and Lamkanfi and Kanneganti 2011]. 
 
1.4.2 Cell Membrane-associated PRRs  
These PRRs, which are expressed not only by innate immunocompetent cells but also by a 
wide range of cell types and tissues, include the collectins, scavenger receptors and the Toll-
like receptor families.  
1.4.2.1 Cell membrane-associated collectins 
C-type lectin receptors (CLRs) are members of a superfamily of more than 1,000 proteins 
classified into 17 sub-groups on the basis of receptor structure [Sancho and Reis e Sousa 
2012]. Their ligands include protein, carbohydrate and lipid components of pathogens and 
‘damaged self’ molecules, and they trigger a range of responses including endocytosis, 
phagocytosis and secretion of pro- and anti-inflammatory cytokines. Ca2+-dependent Group II 
CLRs such as DC-SIGN and Dectin-2 bind mannose and fucose residues from a range of viral, 
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bacterial, mycobacterial and protozoan pathogens. Some (Ca2+-independent) Group V CLRs 
such as DCAL-1 bind endogenous ligands expressed on CD4+ T cells and are involved in 
regulating the adaptive immune response. Others, such as DNGR-1 are involved in 
phagocytosis and clearance of necrotic host T cells. Others, including Dectin 1, are critical for 
the recognition and phagocytosis of mycobacterial and fungal pathogens, recognising 
microbial β-glucan motifs. Group VI CLRs include the macrophage mannose receptor, which 
mediates recognition and phagocytosis of a range of viral, bacterial, fungal and protozoan 
pathogens by binding to mannose residues [Sancho and Reis e Sousa 2012]. 
1.4.2.2 Scavenger receptors 
SRs are expressed predominantly on macrophages and monocytes. They were first defined 
functionally, on the basis of their ability to bind and internalise modified low-density 
lipoproteins [Goldstein 1979]. They have been strongly implicated in the process of vascular 
inflammation that leads to the formation of atherosclerotic plaques, and it is in this context 
that they have been most extensively studied [Kzhyshkowska 2012], but they have also been 
shown to be involved in recognition of microbial ligands. SRs are divided into 8 classes (SR-A to 
-H) on the basis of the structure of their extracellular domains. Members of the SR-A class such 
as macrophage receptor with a collagenous structure (MARCO) have been shown to bind cell-
wall components from both Gram-positive (e.g. Lipoteichoic acid, LTA) and Gram-negative 
(e.g. LPS) bacteria. Other SRs known to bind microbial ligands include CD36 (which recognises 
diacyl lipopeptides), oxidized low-density lipoprotein receptor 1 and scavenger receptor 
expressed by endothelial cell-I (which recognise outer membrane protein A of Klebsiella 
pneumoniae) [reviewed in Plüddermann 2006]. 
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1.4.2.3 Toll-like receptors  
Genetic research into the embryogenesis of the fruit fly Drosophila Melanogaster conducted 
during the 1980’s, identified a protein, Toll, which was critical for induction of dorsal-ventral 
polarity in the Drosophila embryo [Anderson and Nϋsslein-Volhard 1984 and Anderson 1985]. 
Toll was demonstrated to be activated by Spätzle, the end product of a proteolytic cascade, 
and to signal via a serine kinase (Pelle) to activate a member of the NF-κB family, Dorsal. A 
possible immunological function for this pathway was suggested in 1991 by Gay and Keith 
[Gay and Keith 1991], who observed that the signalling domain of the mammalian IL-1 
receptor was homologous to the cytoplasmic domain of Drosophila Toll. IL-1 is part of the 
acute phase response to infection characterized by fever and the secretion of defense proteins 
into the circulation. This discovery suggested that this cytoplasmic domain, now known as the 
Toll-interleukin receptor homology (TIR) domain, was involved in signaling processes not only 
in the restricted context of insect development but also in the generation of initial responses 
to infection by mammalian/human immune system cells. The full significance of this discovery 
was demonstrated in 1996 when Le Maitre et al, noting earlier observations that the promoter 
regions of a number of Drosophila antimicrobial genes also contain NF-κB binding sites, 
showed that Toll was necessary for the Drosophila antifungal response, which involved 
production of the antimicrobial peptide drosomycin [Lemaitre 1996]. 
The first mammalian Toll-like receptor, later identified as TLR1, was cloned in 1991 [Nomura 
1994] and mapped to human chromosome 4 [Taguchi 1996]. A human homologue of 
drosophila Toll, later identified as TLR4, was expressed in a monocytic cell line by Janeway in 
1997, who also demonstrated that a constitutively active form of the receptor induced the 
expression of inflammatory cytokines and co-stimulatory molecules, clearly indicating a role in 
the immune response [Medzhitov 1997].  
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At this point, the investigation intersected with another long-running enquiry, namely the 
search for the identity of the receptor for bacterial endotoxin (lipopolysaccharide). When 
Beutler et al demonstrated by positional cloning analysis of the LPS-insensitive mouse strain 
C3H/HeJ that a point mutation in the TIR domain of TLR4 was responsible for the defect in LPS 
signal transduction [Poltorak 1998], and that another LPS-resistant mouse strain 
(C56BL/10ScCr) lacked the entire tlr4 gene, it became clear that the gene previously identified 
as lps (coding for a putative LPS receptor) was in fact the tlr4 gene [reviewed in Beutler and 
Rietschel 2003]. These findings were swiftly corroborated by Malo and colleagues [Qureshi 
1999], using a similar genetic approach, and by the Akira group [Hoshino 1999] who 
recapitulated the LPS-resistant phenotype by targeted mutation of the tlr4 gene. Identification 
of 9 other human TLRs and a still-growing array of the cognate ligands for the encoded 
receptors has followed in the subsequent years, bringing the total to 11, although tlr11 has not 
been found to be expressed in humans [Chaudhury 1998, Rock 1998, Takeuchi 1999, Hemmi 
2000, Hemmi 2002 and Zhang 2004]. 
a. Subcellular localisation and ligand specificity  
TLR 1, 2, 4, 5, and 6 are predominantly expressed at the cell surface, whereas TLR 3, 7, 8 and 9 
are predominantly associated with intracellular vesicles [Watts 2008 and Paludan 2011]. TLR7 
and TLR9 are exclusively present in the endoplasmic reticulum of resting cells, but rapidly 
traffic to endolysosomes after ligand stimulation [Kim 2008]. This translocation is regulated by 
the chaperone proteins UNC93b1 and PRAT4a [Tabeta 2006]; PRAT4a is also responsible for 
the trafficking of TLR4 to the plasma membrane while gp96 - a member of the heat-shock 
protein family - appears to be a general chaperone for TLRs [Yang 2007]. Cell-surface TLRs are 
endocytosed following ligand binding; the endocytosed TLRs may be recruited to, and signal 
from, phagosomes containing endocytosed bacteria. The small GTPase Rab11a appears to 
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regulate this recruitment in the case of TLR4 endosomes [Husebye 2010]. The subcellular 
localisation of TLRs broadly reflects their ligand specificity: the intracellular TLRs are 
predominantly receptors for components of intracellular pathogens such as viruses and 
protozoa, while the extracellular TLRs recognise a diverse array of ligands found in the 
extracellular milieu (summarised in Table 1).  
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Table 1. TLR Recognition of microbial components 
HCMV, human cytomegalovirus; HSV1, herpes simplex virus 1; MMTV, mouse mammary 
tumour virus; ND, not determined; RSV, respiratory syncytial virus. Adapted from [Akira 2006] 
and [Lin 2011]. 
 
Microbial component Species TLR usage 
Bacteria   
Lipopolysaccharide Gram-negative Bacteria TLR4 
Diacyl Lipopeptides Mycoplasma TLR6/TLR2 
Triacyl Lipopeptides Bacteria  
and Mycobacteria 
TLR1/TLR2 
Lipoteichoic Acid Gram-positive Bacteria TLR6/TLR2 
Proteoglycans Gram-positive Bacteria TLR2 
Porins Neisseria spp TLR2 
Lipoarabinomannan Mycobacteria TLR2 
Flagellin Flagellated Bacteria TLR5 
CpG-DNA Bacteria  
and Mycobacteria 
TLR9 
ND Uropathogenic Bacteria TLR11 (mouse) 
Fungi   
Zymosan Saccharomyces cerevisiae TLR6/TLR2 
Phospholipomannan Candida albicans TLR2 
Mannan Candida albicans TLR4 
Glucuronoxylomannan Cryptococcus neoformans TLR2 and TLR4 
Parasites   
tGPI-mutin Trypanosoma TLR2 
Glycosylinositolphospholipids Trypanosoma TLR4 
Hemozoin Plasmodium TLR9 
Profilin-like molecule Toxoplasma Gondii TLR11 (mouse) 
Viruses   
DNA Viruses TLR9 
dsRNA Viruses TLR3 
ssRNA RNA viruses TLR7 and TLR8 
Envelope proteins RSV, MMTV TLR4 
Haemagglutinin Protein Measles virus TLR2 
Envelope glycoproteins  HCMV, HSV1 TLR2 
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Bacteria are grouped according to the staining properties and thus the composition of their 
cell walls. A major component of the cell wall of Gram-positive bacteria is a thick layer of 
peptidoglycan (PG) composed of alternating residues of N-acetylglucosamine and N-
acetylmuraminic acid, which is anchored to the underlying cell membrane by lipoteichoic acid 
(LTA) (Figure 11A). Both PG and LTA are recognised by TLR2. Gram-negative bacteria have a 
relatively thin PG layer, but are surrounded by an additional outer membrane composed 
largely of lipopolysaccharide (LPS) (Figure 11B). LPS is the prototypical TLR4 ligand, and is a 
potent inducer of immune responses. Mycobacterial cell walls also have a relatively thin PG 
layer that is reinforced by a thick, mycolate-rich hydrophobic layer (Figure 11C).Mycobacterial 
cell wall components are ligands of TLR2. DNA from all classes of prokaryotic organisms is a 
ligand for TLR9.  
The structure of a typical fungal cell wall is shown in Figure 11D. A number of fungal 
polysaccharides have been identified as TLR ligands. TLR4 was shown to recognise mannans 
[Shoham 2001] and glucuronoxylmannan [Netea 2004]. Zymosan, a cell wall component of 
Saccharomyces cerevisiae has been shown to bind to TLR2 [Sato 2003]. Fungal DNA is also a 
ligand for TLR9 [Akira 2006]. 
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Figure 11. Structure of typical microbial cell walls. Simplified structure 
of typical  (A) Gram-positive, (B) Gram-negative bacterial, (C)
mycobacterial and (D) fungal cell walls. Inset in (B) shows structure of 
Lipid A from E. coli K12 strain. LAM, lipoarabinomannan; LPS, 
lipopolysaccharide; LTA, lipoteichoic acid; NAG, N-acetyl glucosamine; 
NAM, N-acetyl muraminic acid; TA, teichoic acid. Adapted from 
[Abdallah 2007, Murphy 2012 and Netea 2008]. 
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TLRs are also involved in the recognition of viruses, both at the cell surface and in endosomal 
compartments. TLR2 and TLR4 have been shown to play a role in the sensing of viral envelope 
proteins. TLR2 has been shown to recognise human cytomegalovirus (HCMV) [Compton 2003], 
herpes simplex 1 virus (HSV1) [Kurt-Jones 2004] and vaccinia virus [Zhu 2007] and TLR4 to 
detect respiratory syncytial virus fusion protein [Kurt-Jones 2000] and mouse mammary 
tumour virus [Rassa 2002]; the viral ligand has not been identified in all cases.  
Viral nucleic acids are detected by the intracellular TLRs 3, 7, 8 and 9. Double-stranded RNA 
(dsRNA) is recognised by TLR3 [Alexopoulou 2001) and the synthetic dsRNA analogue poly I:C 
is commonly used as a TLR3 ligand. TLR7 and 8 sense viral genomic single stranded RNA 
(ssRNA [Diebold 2004 and Heil 2004] and play a key role in innate immune responses against 
ssRNA viruses such as influenza virus [Diebold 2004 and Lee 2007]. TLR9 recognises 
unmethylated CpG motif-containing single strand DNA (ssDNA) oligodeoxynucleotides [Latz 
2007] and detects genomic DNA of DNA viruses such as human herpes viruses [Lund 2004, Heil 
2004 and Krug 2004]. 
Protozoan proteins may also be recognised by TLRs. Profilins are cytoskeletal proteins involved 
in actin polymerisation, which play a key role in the motility and thus the capacity to invade 
host T cells of parasites such as Plasmodium, Toxoplasma, Cryptosporidium and Cyclosporum 
species [Kucera 2012]. Toxoplasma and Plasmodium profilins have been shown to be ligands 
for mouse TLR11 [Rosenberg 2005 and Kursula 2008], while protozoan DNA is a ligand for 
TLR9. Host or microbial molecules capable of binding DNA may facilitate its transfer to the 
endosomes and thus enhance TLR9 activation. The malarial parasite Plasmodium falciparum 
digests host haemoglobin into a hydrophobic polymer known as hemozoin that was found to 
induce inflammatory responses in a TLR9-dependent manner [Coban 2005]. However, purified 
hemozoin is itself immunologically inert and its mode of action appears to be by the 
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presentation of protozoan DNA to TLR9 [Parroche 2007]. The endogenous nuclear protein high 
mobility group box protein 1 (HMGB1) may play a similar role [Ivanov 2007]. 
Endogenous molecules may also be TLR ligands; ‘damaged self’ or ‘altered self’ molecules 
(sometimes referred to as Danger-Associated Molecular Patterns or DAMPs) may be released 
as a result of sterile cellular injury or stress and are important mediators of inflammation, 
especially in the autoimmune diseases [Lin 2011]. Endogenous molecules that are reported to 
be TLR ligands are summarised in Table 2. However, the identification of endogenous 
molecules as TLR ligands is fraught with difficulties relating to the contamination of 
preparations of endogenous molecules by microbial TLR ligands, especially LPS [Marincek 
2008]. 
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Table 2. Proposed endogenous TLR ligands 
TLR Proposed Endogenous Ligand 
TLR2 Heat Shock Proteins 
 HMGB1 
 Biglycan 
  
TLR3 mRNA 
  
TLR4 HMGB1 
 Heat Shock Proteins 
 Fibronectin Extra Domain A 
 Minimally Modified Low-Density Lipoproteins 
 Hyaluronan Fragments 
 Heparan Sulphate 
 Fibrinogen 
 Lung Surfactant Protein A 
  
TLR7 ssRNA 
  
TLR9 Hypomethylated CpG-DNA 
 HMBG1 
 
 
HMGB1, High Mobility Group Box Protein 1; ssRNA, single-stranded RNA. Adapted from [Rifkin 
2005]. 
b. Tissue distribution  
As befits their primary role in early pathogen recognition, TLRs are predominantly expressed 
on phagocytic cells of the myeloid lineage. However, they are also found in non-myeloid 
leucocytes and in a range of other cells and tissues [Sandor and Buc 2005].  
Professional phagocytes express the widest range of TLRs: PMN, monocytes and macrophages 
express all TLRs except TLR3 [Muzio 2000 and Hornung 2002]. DCs show a variable pattern of 
TLR expression; myeloid DCs express all TLRs except TLR7 and TLR9, which are expressed 
almost exclusively in plasmacytoid DCs. Additionally, the TLR expression pattern of DCs may 
depend to some extent on their stage of maturation: Visintin and colleagues reported that 
immature DCs express TLR1, 2, 4 and 5 but that expression tends to decrease upon DC 
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maturation [Visintin 2001]. By contrast, TLR3 mRNA is expressed by mature DCs only [Muzio 
2000]. Eosinophils express TLR1, 2, 4, 6, 7 and 9 [Nagase 2003], Basophils express TLR2 and 
TLR4, and Mast Cells express TLR2 and TLR6 [Sabroe 2002]. NK cells, which are important in 
the early response to viral infections, have been shown to express mRNA for TLRs 1-8, with 
highest expression of TLR2 and 3. Accordingly, NK cells have been shown to be capable of 
being directly activated by ligands for TLR2, 3, 5 and 9 [reviewed in Yang 2011] 
TLRs are also expressed by non-myeloid lymphocytes: B cells can be functionally divided into 
‘innate-like’ B cells - found predominantly in the marginal zones of lymph nodes - which 
mediate a rapid, T cell-independent IgA and IgM response to infections; and adaptive or 
follicular B cells localised to germinal centres - which mediate slower, T-cell dependent and 
predominantly IgG responses. Innate-like B cells express high levels of TLRs 1, 2, 4, 6, 7 and 9, 
and both proliferate and secrete high levels of antibody in response to stimulation with their 
ligands [reviewed in Rawlings 2012]. 
A range of T lymphocyte populations have also been shown to express TLRs either 
constitutively or inducibly, and to respond to stimulation with their ligands [reviewed in 
Kabelitz 2007]. CD25highCD4+ regulatory T cells (Tregs) but not CD25-CD4+ naïve T cells were 
found to express TLR2 and TLR8 mRNA and protein [Peng 2005]. Purified tonsillar T cells were 
found to express mRNA for TLRs 1, 2, 3, 5, 9 and 10, with distinct differences in expression 
reported between CD4+ and CD8+ subsets [Mansson 2006]. Unconventional T cells that have 
the alternative γδ T-cell receptor (TCR) are reported to express TLRs 1,2,3,5 and 6 [Wesch 
2006 and Bress 2006]. TLR expression has also been reported to be inducible on stimulation of 
a number of T cell subsets either solely by TLR ligands [Iwasaki and Medzhitov 2004], 
[Napolitani 2005, Pasare and Medzhitov 2003 and Pasare and Medzhitov 2004] or upon 
costimulation of the TCR [Komai-Koma 2004 and Liu 2006]. 
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TLRs are also expressed in a variety of non-haematopoietic tissues. They are widely expressed 
in epithelial tissues including the skin, respiratory, intestinal and genitourinary tracts. 
Keratinocytes express TLR1-5 constitutively and mRNA for TLR2 and TLR4 has been detected in 
nasal mucosa and salivary glands. TLR2 is expressed throughout the respiratory epithelium, 
and TLR4 in alveolar epithelial cells. Epithelial cells of the lower digestive tract are in constant 
contact with microbes but only microbial invasion of the basolateral epithelial compartment 
induces an inflammatory response; consistent with this, expression of TLR2 and TLR4 on the 
apical surface of colonic epithelia is very low, but higher on the basolateral surface, which also 
expresses TLR5. The female genital tract epithelium has been shown to express mRNA for TLRs 
1, 2, 3, 5 and 6 [Sandor and Buc 2005 and Kuroishi 2007]. 
Vascular endothelial cells appear to express TLRs 2, 4 and 5 [Sandor and Buc 2005 and Ward 
2009]. Expression is not uniform, and TLR2 in particular appears to be inducible in regions of 
the vasculature that are exposed to turbulent flow (such as bifurcation of large vessels). 
Intriguingly, these are the regions of the vascular tree that are most prone to the development 
of atherosclerosis, which is also associated with upregulation of TLR2 expression in endothelial 
cells [Dunzendorfer 2004]. Thus, a role for vascular endothelial TLR2 is likely in the 
pathogenesis of atherosclerosis. 
c. Accessory molecules and co-receptors 
TLR recognition of their ligands often requires the action of a co-receptor or accessory 
molecule [reviewed in Lee 2012]. A summary of the known TLR accessory molecules is shown 
in Table 3. Of particular note are the TLR4 accessory molecules: lipopolysaccharide-binding 
Protein (LBP), CD14 and MD2. The hydrophobic LPS molecule tends to form micelles when in 
aqueous solutions (such as in blood plasma); these micelles are poorly recognised by TLR4. LBP 
is a 481-amino-acid acute phase response serum protein that binds LPS with high affinity and 
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causes the disaggregation of micelles of LPS, thus facilitating its transfer to CD14. CD14 is a 
375-amino-acid glycoprotein composed of leucine-reach repeats (LRRs). It is present as a 
soluble form in the blood and other biological fluids or as a glycosylphophinositol-anchored 
membrane protein mainly on myeloid cells [Ferrero 1990, Dziarski 1998, Labéta 2000]. Its role 
is not limited to the recognition of LPS as it interacts with multiple ligands for both cell-surface 
and endosomal TLRs [Hailman 1994, Dziarski 1998, Baumann, 2010, Lee 2006, Nakata 2006, 
Georgel 2007 and Kurt-Jones 2000] and enhances their ability to activate TLRs by delivering 
the microbial component to the corresponding TLR [Frey 1992, Labéta 2000, and Gay and 
Gangloff 2007]. MD-2, also known as LY96, is a 160-amino-acid soluble glycoprotein that 
associates with the extracellular domain of TLR4 and is necessary for TLR4 expression at the 
cell surface, as well as the initial interaction of TLR4 with LPS [Shimazu 1999 and Nagai 2002]. 
Park et al. identified the crystal structure of the TLR4-MD-2-LPS complex [Park 2009], 
demonstrating that the LPS molecule buries five of its six lipid chains into a hydrophobic 
pocket on MD-2. Two MD-2-LPS complexes are necessary to bridge two TLR4 molecules and 
induce TLR4 homodimerisation, a critical event in TLR4 activation. 
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Table 3. TLR co-receptors and accessory molecules. 
 
FSL1, S-(2,3-bispalmitoyloxypropyl)-CGDPKHSPKSF; GPI, glycosylinositolphosphate; HMGB1, 
High Mobility Group Box 1 Protein; LBP, lipopolysaccharide-binding protein; LPS, 
lipopolysaccharide; LTA, Lipoteichoic acid; ODNs, oligodeoxynucleotides; oxLDL, oxidised low 
density lipoprotein; Pam3CSK4, Tripalmitoyl-cysteinyl-seryl-(lysyl)3-lysine; poly I:C, polyinosinic-
polycytydylic acid; TRIL, TLR4 interactor with leucine-rich repeats. Adapted from [Lee 2012]. 
 
d. Structure 
TLRs are single-pass transmembrane proteins comprised of an extracellular ligand-binding 
domain, a single transmembrane helix, and an intracellular signalling domain [Gay and 
Gangloff 2007]. The extracellular domains bind either directly to ligands or to ligand-
coreceptor complexes, initiating ligand-mediated multimerisation of the receptor. The 
intracellular domains have substantial sequence homology with the IL-1 receptor and are 
together known as Toll/IL-1R homology (TIR) domains (Figure 12A) [Gay and Keith 1991]. TLR 
signalling adaptor proteins also contain TIR domains. These adaptor proteins are recruited to 
the TIR domains of TLRs by heterotypic TIR-TIR interactions as a consequence of ligand binding  
Name Localisation Interacting TLR Ligand 
LBP Secreted None demonstrated LPS 
MD2 Plasma membrane, extracellular 
fluid 
TLR4 LPS 
CD36 Plasma membrane, Golgi TLR2, TLR4, TLR6 FSL1, LTA, oxLDL, 
amyloid-β fibrils 
CD14 Secreted, Plasma membrane 
(GPI-linked), Endolysosomes 
TLR2, TLR3, TLR4, 
TLR7, TLR8, TLR9 
LPS, peptidoglycan, 
Pam3CSK4, polyI:C, 
CpG DNA 
TRIL Plasma membrane, early 
endosomes 
TLR3, TLR4 LPS 
Progranulin Secreted, endolysosomes TLR9 CpG-A, CpG-B, CpG-
C and inhibitory 
ODNs 
HMBG1 Nucleus, cytoplasm, can be 
secreted following TLR ligation 
TLR9, possibly TLR3 
and TLR7 
CpG-A ODNs, CpG-B 
ODNs, DNA, RNA 
LL37 Early endosomes Possibly TLR7 and 
TLR9 
Mammalian DNA, 
mammalian RNA 
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Figure 12. TLR structure. (A) Schematic representation of TLR structure,
showing the leucine-rich repeat (LRR) extracellular domain, transmembrane
domain (TM) and intracellular Toll/IL-1R homology (TIR) domain. (B) Folding
domains of TLR 1,2,4 and 6, showing the functional significance of structural
boundaries. Adapted from [Kang 2011].
 
and receptor oligomerisation [Kang and Lee 2011]. Aggregation of TLRs and adaptor proteins 
activates signal transduction cascades that ultimately lead to activation of transcription factors 
such as NF-κB and IRFs, and the synthesis and secretion of mediators of inflammation. 
The extracellular domains of TLRs belong to the LRR family of proteins, which contains nearly 
20,000 members [Interpro 2012] and are involved in a diverse array of functions, mostly 
involving protein-protein interactions. LRR family members have a structure characterised by 
repeating LRR modules, each of which contains a 20 - 30-amino acid sequence that includes 
69 
 
the motif LxxLxLxxN. The side chains of the conserved leucines point inwards into the protein 
core and are involved in forming the hydrophobic core. The conserved asparagine residues are 
important in maintaining the overall shape of the protein, because they form a continuous 
hydrogen-bond network with backbone carbonyl oxygens of neighbouring LRR modules. The 
variable ‘x’ residues are exposed to the solvent, and may play important roles in interactions 
with the ligand. As a result, the roles of the different residues in the LRR motifs are distinct: 
the variable residues are important for ligand binding and protein-protein interactions, while 
the leucines and asparagines confer stability. All LRR family proteins have a characteristic 
horseshoe-like solenoid structure; the concave part of the structure is comprised of a central 
β-sheet built of parallel strands provided by the LxxLxLxxN motifs, whereas the amino acid 
residues outside this motif form either parallel helices or loops and constitute the convex part 
of the structure [Kang and Lee 2011]. 
The TLR extracellular domains belong to the ‘typical’ subfamily of LRR proteins, but they are 
unusual family members in a number of respects [Jin and Lee 2008a and b]. Most members of 
this family are involved exclusively in protein-protein interactions, and their ligand binding 
sites are located in the concave portion of the protein; the ligands of most TLRs are not 
proteins, and their binding sites are typically located on the convex curve of the protein. The 
typical LRR subfamily has 24 amino acids in its LRR with a conserved pattern of 
xLxxLxxLxLxxNxLxxLPxxxFx; however, the number of amino acids in the LRR modules of TLRs is 
very variable, ranging from 19 to 33. Additionally, the convex curve of the TLR extracellular 
domain contains atypical structures such as α-helices and irregular loops, which makes the 
convex surfaces of TLRs unusually ‘bumpy’ and thus suited to interactions with non-protein 
ligands [Kang and Lee 2011]. 
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While the central β-sheet of most LRR proteins has a uniform radius and tilt, the central β-
sheets of some of the TLRs show structural transitions that divide the proteins into three 
domains: N-terminal, central and C-terminal. These structural discontinuities seem to be the 
result of irregular LRR sequences in the central domain; the proteins lack the usual sequence 
of asparagine networks that stabilises the overall horseshoe-like shape, allowing structural 
distortions. These distortions appear to have functional significance: the ligand-binding 
pockets of TLR1, 2 and 6 coincide with the transition between the C-terminal and central 
domains, while one of the MD-2 binding sites of TLR4 is located close to the boundary 
between the N-terminal and central domain (Figure 12B) [Jin 2007, Kang 2009 and Kim 2007]. 
Crystal structures of TLR2- and 4-ligand complexes are shown in Figures 13 and 14. 
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Figure 13. TLR2 Ligand Binding. Models of extracellular domains (ECD) of (A)
TLR1(green)/2(blue) and (B) TLR2/6(gold) heterodimers showing binding of
Pam3CSK4 (TLR1/2) and Pam2CSK4 (TLR2/6). (C and D) Detail of proposed
interaction between receptor hydrophobic pockets and fatty acid tails of
Pam3CSK4 (C) and Pam2CSK4 (D). In (D) phenylalanine residues in positions 343
and 365 of the TLR6 ECD (orange) block the lipid-binding pocket present in
TLR1. From [Kang 2011].
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Figure 14. TLR4 ligand binding. Ribbon diagram (A) and crystal structure (B) of
the TLR4-MD2-LPS complex. In (A) The N-Terminal, Central and C-Terminal
domains of TLR4 (grey) are divided by broken lines. The A and B patches of the
dimerisation interface with MD-2 (blue) are marked by broken red and orange
surfaces, respectively. (C) Detail of the dimerisation interface between TLR4
and MD-2 showing the binding site of the R2 lipid chain of LPS (red). Other
parts of Lipid A and core carbohydrates are shown in pink and orange,
respectively. Hydrophobic residues forming the LPS binding site are shown in
light green (TLR4) and light blue (MD2) and hydrophilic residues are shown in
dark green (LPS) and dark blue (MD2). (CO), backbone carbonyl oxygen; (NH)
backbone amide nitrogen. From [Kang 2011].
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TLR3 belongs to the single-domain fold subfamily because its LRR domain has uniform β-
sheets with a continuous asparagine network [Choe 2005]. The crystal structures of TLRs 5, 7, 
8, 9 and 10 have not yet been reported, but sequence analysis suggests that the first four 
belong to the single-domain subfamily, whereas TLR10 is likely to belong to the three-domain 
subfamily [Matsushima 2005 and 2007]. Functional analysis of the TLRs agrees with this 
classification: the three-domain TLRs utilise hydrophobic internal pockets as their binding sites 
for hydrophobic ligands such as LPS, whereas the single-domain TLRs interact with hydrophilic 
ligands such as nucleic acids, via surface-exposed residues. The crystal structure of the TLR3-
dsRNA complex is shown in Figure 15. 
Figure 15. TLR3 ligand binding. Crystal structure of the TLR3-dsRNA complex.
TLR3 C-terminal and N-terminal sites are indicated. From [Kang 2011].
This image has been removed by the author for 
copyright reasons.
 
 
e. Activation 
Ligand-induced multimerisation is a key event in TLR activation. TLR2 forms heterodimers with 
TLR1 and TLR6; TLR4 typically homodimerises but may also heterodimerise with TLR5 [Mizel 
2003] and with TLR6 in a CD36-dependent manner [Stewart 2010]; the other TLRs form 
homodimers [Kawai and Akira 2010]. The presence of a cross-linking ligand seems necessary to 
the formation of TLR4 homodimers [Kim 2007], whereas TLR1/2 and TLR2/6 may dimerise in 
the absence of ligand [Triantafilou 2006]. Although receptor cross-linking is a necessary step in 
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TLR activation, it is not sufficient: many TLR-specific antibodies cross-link TLRs without any 
evidence of an agonist effect [Shimazu 1999 and Matsumoto 2002]. It is thought that ligand-
induced dimerization also results in a conformational change of the TLR extracellular domain, 
which in turn promotes the rearrangement of the transmembrane helices and permits the 
formation of a stable receptor-receptor signalling complex [Gay and Gangloff 2007]. 
f. Signal Transduction 
After ligand binding, TLRs activate signalling pathways that provide specific immunological 
responses tailored to the nature of the microbial or endogenous ligand. The specific response 
initiated by a particular TLR depends upon the recruitment of a single or specific combination 
of TIR-domain containing adaptor proteins [Kawai and Akira 2011].  
The TIR domain is between 135 and 160 amino acids in length, and is composed of a central 
five-stranded parallel β-sheet which is surrounded by 5 α-helices [Xu 2000]. Each TIR domain 
contains three conserved regions named Boxes 1, 2 and 3. The Box 1 sequence is common to 
all TLRs. Box 2 contains a large conserved surface present in all TLRs and the adaptor protein 
myeloid differentiation gene product 88 (MyD88), known as the BB loop. A point proline-
histidine mutation of the TLR4 BB loop is responsible for the absence of TLR4 signalling in the 
C3H/HeJ mouse [Poltorak 1998]. It appears that the BB loop is of critical importance for the 
homodimerisation of TLRs [Nyman 2008], while an interaction between the BB loop of TLR1 
and a death domain (DD) loop (located on the opposite side to the BB loop) of TLR2 is 
predicted [Gautam 2006]. 
The formation of a stable TIR-TIR platform by ligand-induced TLR dimerisation promotes 
homotypic protein-protein interaction with other TIR domain-containing adaptor proteins, 
resulting in the assembly of a functional signalling complex, which initiates a chain of 
phosphorylation and ubiquitination events culminating in the activation of NF-κB and other 
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transcription factors leading to the expression of a diverse array of genes related to the 
inflammatory response, particularly the expression of pro- or anti-inflammatory cytokines 
[O’Neill and Bowie 2007]. To date, five TIR domain-containing adaptor proteins have been 
identified [Gay 2011]: MyD88; MyD88 adaptor-like (MAL; also known as TIR domain-containing 
adaptor protein or TIRAP); TIR domain-containing inducing interferon β (TRIF; also known as 
TIR-containing adaptor molecule 1 or TICAM-1); TRIF-related adaptor molecule (TRAM or 
TICAM-2); and sterile-alpha and HEAT-Armadillo motifs-containing protein (SARM). TLR 
ligation may lead to activation of a MyD88-dependent signalling pathway, used by all TLRs 
(except TLR3) that predominantly results in the secretion of inflammatory cytokines, and a 
MyD88-independent pathway (used by TLR3 and TLR4) which proceeds via the adaptor TRIF 
and results in Type I interferon secretion [Kawai and Akira 2010]. 
The MyD88-dependent pathway 
The critical role of MyD88 in TLR signalling has been demonstrated by a number of studies of 
MyD88-/- mice in the context of a number of disease models; these animals are resistant to 
endotoxic shock but highly susceptible to infections by a range of different pathogens 
[Takeuchi 2000, Adachi 2001, Scanga 2002, Edelson 2002, Henneke 2002 and Muraille 2003]. It 
is now known that all TLRs except TLR3 signal through MyD88 [Kawai and Akira 2011].  
MyD88 contains a death domain (DD) at its N-terminus and a TIR domain at the C-terminus. 
The DD of MyD88 interacts with the BB loop of the TLR cytoplasmic domain [Gautam 2006] 
and forms a stable signalling complex. MyD88 recruitment to the TIR domain of the TLR4 
homodimer is dependent on MAL/TIRAP; MAL possesses a binding site for 
phosphatidylinositol-4,5-bisphosphate (PIP2), a major component of the plasma membrane 
and the interaction of MAL with PIP2 facilitates the recruitment of MyD88 to the receptor 
complex. The other MyD88-dependent TLRs do not use MAL for recruiting MyD88, although it 
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has a role in recruiting other signalling intermediates to the TLR2 signalling complexes [Kagan 
and Medzhitov 2006 and Brikos and O’Neill 2008]. The DDs of MyD88 are also involved in the 
interaction with interleukin receptor-associated kinase (IRAK) 4; binding of MyD88 to the TIR 
domains of the TLR dimer induces a conformational change that releases the MyD88 DD from 
a repressed state and enables it to interact stably with IRAK4. The net result is the sequential 
recruitment to the TIR domains of the ligand-stabilised TLR dimer of a helical structure 
comprised of a first layer of 2 MyD88 monomers, then a second layer of four more MyD88 
monomers, followed by a third layer of four IRAK4 monomers and a fourth layer of four IRAK2 
monomers; this signalling complex is known as the Myddosome (Figure 16) [Lin 2010]. 
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Figure 16. Helical assembly of the Myddosome. TLR ligation leads to receptor 
dimerisation and the recruitment, via homotypic TIR-TIR interactions, of six 
MyD88 monomers. Sequential recruitment of four IRAK-4 and two IRAK-1 
monomers results in assembly of the stable signalling complex. DD, death 
domain; MyD88, myeloid differentiation gene product 88; TIR, Toll/IL-1 
receptor homology domain [Adapted from Kang 2011].
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IRAK1 is next recruited to the Myddosome and activated; its activation results in dissociation 
from the Myddosome and association with TNF-α-receptor-associated factor 6 (TRAF6) [Kawai 
and Akira 2010]. TRAF6 is an E3 ligase that catalyses the polyubiquitination of Lys63 (K63) of 
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IRAK1 in conjunction with the dimeric E2 ubiquitin conjugating enzymes Ubc13 and Uev1A. 
Activated TRAF6 associates with four downstream proteins via its K63-linked polyubiquitin 
chains: TGF-β-activated kinase1 (TAK1) and the TAK1-binding proteins 1-3 (TAB1-3) to form an 
active catalytic unit [Chen 2005]. TAK1 is then responsible for phosphorylating the inhibitor of 
NF-κB (IκB) kinase (IKK) complex. IKK is also ubiquitinated by the Uev1/Ubc13/TRAF6 complex 
[Doyle and O’Neill 2006]. The IKK complex consists of three subunits, IKKα, β and γ [Brikos and 
O’Neill 2008]; IKKγ (also called NF-κB essential modulator, NEMO) is a scaffold protein that 
holds the other subunits in proximity to IκB, whereas the α and β subunits are responsible for 
catalytic activity, phosphorylating IκB proteins. The function of IκB is the repression of NF-κB; 
quiescent NF-κB in the cytoplasm is associated with IκB. Phosphorylation of IκB by IKKα and β 
results in dissociation of IκB from NF-κB, which then translocates to the nucleus. The activated 
transcription factor plays a critical role in the induction of many inflammatory responses, 
including transcription of inflammatory cytokines [Kawai and Akira 2010 and Doyle and O’Neill 
2006].The signal transduction pathway is summarised in Figure 17.  
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Figure 17. Overview of TLR signal transduction pathways. Key TLR signal transduction 
intermediates. IKK, inhibitor of NF-κB kinase; IRAK, interleukin receptor-associated 
kinase; IRF3/5/7, interferon response factor 3/5/7; MAL, Myeloid adaptor-like (also 
known as TIRAP); MyD88, myeloid differentiation gene product 88; NF-κB, nuclear factor 
kappa B; RIP1, receptor-interacting protein-1; SHP-1, protein tyrosine phosphatase, non-
receptor type 6; TAB2/3, TGF-β-activated kinase binding protein 2/3; TAK, TGF-β-
activated kinase ; TANK, TRAF family member-associated NF-κB activator ; TBK, TANK-
binding kinase;  TRADD, TNF receptor-associating via death domain; TRAF6, TNF 
receptor–associated factor 6; TRIF, TIR domain-containing inducing interferon beta (also 
known as TICAM-1). Adapted from [Kawai and Akira 2010].
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TLR7 and TLR9 in plasmacytoid DCs also signal via MyD88, and may result either in activation 
of NF-κB, leading to secretion of the pro-inflammatory cytokines IL-6 and IL-12p40 [Takaoka 
2005] or of the transcription factor interferon response factor 7 (IRF7), leading to the secretion 
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of type I interferons. In this context, IRF7, which is constitutively expressed by plasmacytoid 
DCs, binds MyD88 and forms a signalling complex with IRAK4, TRAF6, IRAK1 and IKKα [Kawai 
and Akira 2008]. IRF7 is phosphorylated by IRAK1 and IKKα, dissociates from the signalling 
complex and translocates to the nucleus, where it binds to IFN-stimulated response element 
motifs and promotes the expression of type-1 interferons. Additional components that control 
the production of type-1 interferons in plasmacytoid DCs have also been identified, and 
illustrate the way in which the response to a given TLR ligand may be ‘fine-tuned’ in different 
cell types or in the presence of alternative stimuli: OPNi, a precursor of osteopontin, is a TLR9-
inducible protein that is sequestered in the cytoplasm of plasmacytoid DCs and becomes a 
component of the MyD88-IRF7 complex [Shinohara 2006]; pharmacological inhibition of 
phosphoinositol-3-kinase (PI3K) and its downstream intermediates mTOR and p70S6K results 
in disruption of the interaction between TLR9 and MyD88 [Kagan and Medzhitov 2006], 
causing a reduction in nuclear translocation of IRF7 [Cao 2008].  
It is thought that polarisation of the TLR7 and 9 response either towards IRF7 activation and 
interferon production or towards NF-κB activation and pro-inflammatory cytokine secretion is 
determined by the subcellular trafficking of the receptor. NF-κB activation predominates as a 
result of TLR7 and 9 ligation in early endosomes, whereas IRF7 activation is the result of 
subsequent trafficking of the TLRs to lysosome-related organelles under the control of the 
chaperone protein AP2 [Sasai 2010]. 
Given the critical role played by MyD88 in LPS-induced NF-κB activation, it would be expected 
that NF-κB activation would be abolished in MyD88-deficient mice. The observation that 
animals lacking MyD88 were still capable of mounting a response to LPS, albeit at a lower 
amplitude and after a delay, suggested that a delayed MyD88-independent TLR4 signalling 
apparatus might also exist [Yamamoto 2002]. 
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The MyD88-independent pathway 
The MyD88-independent pathway employs an alternative adaptor protein, TIR domain-
containing adaptor inducing interferon β (TRIF) in a pathway that culminates not only in 
activation of NF-κB, but also the interferon β promoter. This pathway is initiated from an 
endosomal compartment, either via TLR3 (which is constitutively located in endosomes) or via 
TLR4, which is internalised to endosomes following ligand binding [Kagan 2008]. The role of 
TRIF was revealed by the fact that overexpression of TRIF resulted in constitutive activation of 
NF-κB and the IFN-β promoter, whereas TRIF-/- animals showed a decreased response to TLR4 
activation but an unchanged response to TLR2, TLR7 and TLR9. TRIF/MyD88 double knockout 
animals were unable to activate NF-κB at all [Brikos and O’Neill 2008]. This pathway has been 
shown to be utilised by TLR4 in conjunction with the MyD88 pathway (as described above), 
but exclusively by TLR3.  
TRIF is recruited to the TLR following ligand binding. TRIF in turn recruits TRAF6, TAK1 and the 
adaptor (RIP1) through a distinct RIP homotypic interaction motif. RIP1 binds the adaptor TNF 
receptor-associating via death domain (TRADD) and undergoes K63-linked polyubiquitination 
by Pellino-1, a member of the Pellino family of RING-like domain-containing E3 ubiquitin 
ligases. The complex of TRIF with TRAF6, TRADD, Pellino1 and RIP1 activates TAK1, which in 
turn activates the NF-κB pathways. 
As well as leading to NF-κB activation, the TRIF pathway leads to IRF3 activation. TRIF recruits 
a signalling complex involving the IKK-like kinase TRAF-family-member associated NF-κB 
activator (TANK)-binding kinase 1 (TBK1), the IKK homologue IKKε and IRF3 or IRF7. The 
formation of this complex leads to phosphorylation of IRF3 or IRF7 by TBK1 or IKKε, which bind 
to interferon sequence response elements and initiate transcription of IL-6, IL-12, TNF-α and 
interferon β [Kagan 2008]. 
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g. Modulation of TLR signalling 
As noted above, excessive cytokine responses to infection are implicated in a number of 
disease states. Thus, negative regulation of TLR activation pathways is of critical importance. 
Negative regulators of TLR activation have been identified at multiple levels, including soluble 
decoy receptors, inhibitors of adaptors or related proteins, ubiquitin ligases, deubiquitinases, 
transcriptional regulators and regulators of RNA stability [Kawai and Akira 2010]. They exist in 
a soluble form, either intracellularly or secreted into plasma or other bodily fluids. A 
consideration of some of the key inhibitors of TLR activation follows below (summarised in 
Table 4). 
Soluble TLRs 
A naturally-occurring soluble form of TLR2 (sTLR2) was first detected and characterised in our 
laboratory [LeBouder 2003, LeBouder 2006 and Raby 2009]. sTLR2 comprises the ECD of 
membrane-bound TLR2 (mTLR2) and is generated by post-translational modifications of 
mTLR2 rather than splice variants or mutations of the TLR2 gene. It is found in human plasma, 
breast milk, saliva, amniotic fluid [Kuroishi 2007 and Dulay 2009] and mouse peritoneal lavage 
fluid [Raby 2009]. It is secreted by monocytes in response to TLR2 ligation, most likely by 
proteolytic cleavage of endocytosed mTLR2 [LeBouder 2003]. It has been shown to negatively 
regulate mTLR2-mediated inflammation both by sequestering ligand (decoy receptor) and by 
disrupting the interaction between the co-receptor CD14 and the membrane-bound TLR [Raby 
2009]. In human plasma, it appears to be a marker for systemic inflammation and has been 
found to predict disease progression in HIV/AIDS and mortality in congestive heart failure after 
myocardial infarction [Heggelund 2004 and Ueland 2006]. sTLR2 in breast milk may also have a 
role in promoting neonatal immunity [Henrick 2012].  
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A human soluble TLR3 has been generated by cloning the cDNA of the TLR3 ECD and 
transfection of HEK 293 cells [Sun 2006] although natural expression of the protein has yet to 
be demonstrated. A splice variant capable of producing a soluble product of the mouse tlr4 
gene was reported [Iwami 2000] and the existence of human soluble TLR4 has been 
demonstrated in saliva [Zunt 2009]. A naturally-occurring soluble form of TLR5 is found in fish 
[Tsujita 2006]. A naturally-occurring soluble form of human TLR9 has also been reported 
[Chockalingham 2011]. All of these gene products appear to be capable of negatively 
modulating inflammatory responses mediated by the relevant TLR. 
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Table 4. Negative regulators of TLR activation 
 
IRAK, interleukin receptor-associated kinase1; JNK, c-jun N-terminal Kinase; MyD88, myeloid 
differentiation gene product 8; ND, not determined; NF-κB, nuclear factor kappa B; NOD2, nucleotide 
oligomerisation domain-containing protein 2; p38, p38 mitogen activated protein kinase; PI3K, 
phosphoinostol-3-kinase; RIP, receptor-interacting protein; SARM, Sterile-alpha and HEAT-Armadillo 
motifs-containing protein; SIGIRR, single immunoglobulin IL-1R-related molecule; SOCS1, suppressor of 
cytokine signalling 1; TANK, TRAF family member-associated NF-κB activator; TOLLIP, toll-interacting 
protein; TRAF6, TNF receptor-associated factor 6; TRAILR, TNF-related apoptosis-inducing ligand; 
TRIAD3A, Triad-domain containing protein 3A;. s, indicates soluble form of protein. Adapted from [Liew 
2005].   
 
 
Regulator Expression and Induction TLR Possible 
mechanism 
A20 LPS-induced expression in macrophages TLR2, 3, 
4, 9 
De-ubiquitylates TRAF6 
Atg16L1 Constitutively in macrophages TLR4 Inhibits TRIF activation 
IRAK-M LPS-induced expression in monocytes TLR4, 9 Inhibits phosphorylation 
of IRAK1 
NOD2 ND TLR2 Suppresses NF-κB 
PI3K Constitutively expressed by most cells TLR2, 4, 
9 
Inhibits p38, JNK and 
NFκB function 
RIP3 Constitutively expressed by most cells TLR3, 4 Inhibits TRIF activation 
SARM Constitutively expressed by most cells TLR3, 4 Inhibits TRIF activation 
SHP-1 Macrophages TLR4 Suppresses IRAK1 
SIGIRR Mainly expressed by epithelial cells and 
immature DCs but downregulated by 
activation 
TLR4, 9 Interacts with TRAF6 
and IRAK 
SOCS1 LPS- and CpG-induced expression in 
macrophages 
TLR4, 9 Suppresses IRAK 
ST2L LPS-induced expression in macrophages TLR2, 4, 
9 
Sequesters MyD88 and 
MAL 
sTLR2 Constitutively expressed in breast milk, saliva, 
plasma and amniotic fluid 
TLR2 Decoy receptor,  
Blocks interaction with 
CD14 
sTLR3 ND TLR3 Decoy receptor 
sTLR4 Saliva TLR4 Blocks interaction with 
MD2 
sTLR5 ND in human cells TLR5 Decoy receptor 
sTLR9 Constitutively expressed in HEK 293 cells TLR9 Decoy receptor 
sMyD88 LPS-induced expression, mainly in the spleen TLR4 MyD88 antagonist 
TANK Constitutively expressed by most cells   
TOLLIP Constitutively expressed by most cells TLR2, 4 Phosphorylates IRAK1 
TRAILR Constitutively expressed by most cells TLR2, 3, 
4 
Stabilises IκBα 
TRIAD3A Constitutively expressed by most cells  TLR4, 9 Ubiquitylates TLRs 
Zinc-finger 
RNases 
Constitutively expressed by most cells All Degrade cytokine mRNA 
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Soluble MyD88 
Soluble MyD88 (sMyD88) is a naturally-occurring splice variant of MyD88 that contains its DD 
but lacks the binding domain for IRAK4. It is thought that sMyD88 promotes the formation of 
sMyD88-MyD88 complexes, effectively sequestering MyD88 and preventing it interacting with 
IRAK4 and initiating downstream signalling [Liew 2005]. 
IRAK-M 
IRAK1, IRAK2 and IRAK4 are components of the MyD88-dependent pathway; IRAK-M, which is 
expressed only in monocytes and macrophages, is an inactive kinase due to a point mutation 
in its catalytic site. However, this mutation appears to have resulted in a change of function 
rather than a loss-of-function since IRAK-M-/- mice responded to an LPS or CpG DNA challenge 
with increased secretion of pro-inflammatory cytokines, suggesting an inhibitory function. Its 
exact mechanism of action is unclear [Wesche 1999 and Kobayashi 2002] 
SOCS-1 
The suppressor of cytokine signalling-1 (SOCS-1) plays a key role in the inhibition of pro-
inflammatory cytokine secretion, as witnessed by the fact that SOCS-1-/- mice die within three 
weeks of birth because of multiorgan inflammation mediated by hypersensitivity to IFN-γ 
[Alexander 1999]. SOCS1-/-mice are hypersensitive to LPS and other TLR ligands, responding 
with increased levels of the pro-inflammatory cytokines TNF-α, IL-6, IL-12 and IFNγ. SOCS-1 
has been shown to inhibit responses to a range of inflammatory signals by increasing the 
degradation of the NF-κB p65 subunit [Ryo 2003 and Gingras 2004]. 
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RIP-3 
Receptor-interacting protein-3 (RIP-3) is an inactive member of the RIP-1 family, which inhibits 
TLR signalling either by sequestering TRIF and preventing RIP-1 binding, or by phosphorylating 
RIP-1 and preventing NF-κB activation [Meylan 2004]. 
TANK 
TRAF family member-associated NF-κB activator (TANK) binds both TBK1 and IRF3. TANK-/- 
macrophages and B cells show exaggerated NF-κB activation and IL-6 production in response 
to TLR ligands compared with wild-type cells, and also showed enhanced TRAF6 
ubiquitination, indicating that TANK may be an inhibitor of TRAF6 ubiquitination in both 
macrophages and B cells [Kawagoe 2009]. These animals spontaneously develop autoimmune 
glomerulonephritis that resolves with antibiotic treatment. The wild-type phenotype is 
rescued by deletion of IL-6 or MyD88. 
TOLLIP 
The Toll-interacting protein (TOLLIP) appears to have a complex regulatory role in TLR 
signalling. Didierlaurent and colleagues [Didierlaurent 2006] found no effect of TOLLIP 
knockout on the ex vivo response of DCs and lymphocytes to TLR3, 4, 5, and 9 agonists, but 
that TOLLIP-deficient mice challenged in vivo with a low dose of LPS responded with lower 
levels of IL-6 and TNF-α than wild-type, suggesting a positive regulatory role for TOLLIP. The 
effects of a lethal dose of LPS were unchanged as a result of TOLLIP knockout; these conflicting 
results are difficult to interpret. However, Shah et al. [Shah 2012] using targeted siRNA 
knockdown of TOLLIP found it to serve an inhibitory role in human monocytes, suppressing 
secretion of the pro-inflammatory cytokines IL-6 and TNF-α and enhancing secretion of the 
anti-inflammatory cytokine IL-10 in response to stimulation with TLR2 and TLR4 ligands. These 
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discrepancies suggest that the role of TOLLIP may be complex and vary between different 
species and cell types. 
SARM 
Sterile-alpha and HEAT-Armadillo motifs-containing protein (SARM) is the most recently-
identified of the TIR-domain-containing TLR adaptor proteins. Unlike the other adaptors, it 
functions as a TLR-induced inhibitor of NF-κB and IRF activation. Its expression is up-regulated 
by TLR ligation, and small interfering RNA (siRNA) knockdown of SARM leads to enhanced 
cytokine production on stimulation via TLR3 or TLR4 [Carty 2006]. Thus, it is likely to function 
as an endogenous inhibitor of TLR-induced pro-inflammatory responses, probably by 
interfering with TRIF activation [Brikos and O’Neill 2008]. 
SIGIRR 
The single immunoglobulin IL-1R-related molecule (SIGIRR) is a plasma membrane-bound TIR-
domain-containing protein which has been shown to inhibit IL-1R and TLR signalling. SIGIRR-/- 
mice show enhanced inflammatory responses to LPS and CpG DNA, indicating that SIGIRR 
affects both TLR4 and TLR9 signalling. SIGIRR has been shown to interact with TLR4, TLR5 and 
TLR9 as well as the signalling intermediate TRAF6. Thus, it is thought that SIGIRR inhibits TLR 
signalling by interfering with the recruitment of TIR-domain-containing adaptors to the TLR 
[Wald 2003]. 
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ST-2 
Suppressor of tumorigenicity-2 (ST-2) is another TIR-domain-containing receptor. It has been 
found to interact with MyD88 but not TRIF; accordingly, macrophages from ST-2-/- mice were 
found to respond with higher levels of inflammatory cytokines to stimulation with LPS, 
lipopetides and CpG DNA, but not poly I:C, suggesting a role as an inhibitor of the MyD88-
dependent pathway [Brint 2004].  
TRAF1 and TRAF4 
Unlike TRAF6, TRAF1 and TRAF4 have inhibitory roles in TLR signalling [Brikos and O’Neill 
2008]. TRAF1 has been shown to bind to TRIF, and TRAF4 to both TRIF and TRAF6, resulting in 
their inactivation and inhibition of downstream signalling via both MyD88-dependent and -
independent pathways. TRAF4 has been shown to inhibit NF-κB activation by TLRs 2, 3, 4, and 
9 as well as TLR3- and TLR4-induced IFN-β promoter activation.  
TRAILR 
TNF-related apoptosis-inducing ligand (TRAIL) receptor (TRAILR) is a member of the TNF-
receptor superfamily. TRAILR-deficient mouse macrophages produce increased levels of pro-
inflammatory cytokines in response to TLR2, TLR3 or TLR4 activation. TRAILR seems to inhibit 
TLR signalling by stabilising IκB and thus reducing nuclear translocation of NF-κB [Diehl 2004 
and Liew 2005] 
Atg16L1 
Atg16L1 is a mediator of autophagy, mutations of which have been linked to ulcerative colitis. 
Atg16L1-deficient mice macrophages show a TRIF-dependent enhancement of caspase 1 
activation and production of IL-1β and IL-18 in response to LPS. They also exhibit a colitic 
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phenotype, with increased susceptibility to disease in models of ulcerative colitis. This 
suggests that Atg16L1 may be a negative regulator of TRIF in intestinal macrophages [Cadwell 
2008]. 
Zinc-finger RNases 
Zc3h12a is a TLR-inducible regulatory protein that contains a CCCH-type zinc finger domain 
and an RNase domain. It targets the 3’ untranslated regions (UTR) of IL-6 mRNA for 
degradation. Zc3h12a-deficient macrophages produce prodigious amounts of IL-6 and IL-
12p40, but normal amounts of TNF-α in response to TLR ligands, and Zc3h12a-deficient mice 
show enhanced autoantibody production [Matsuhita 2009]. Tristetraprolin (Xfp36), another 
zinc finger-containing protein, binds absorbance-unit rich elements (AUREs) in the 3’ UTR of 
TNF-α mRNA and targets them for degradation. Xfp36 prevents the development of 
autoimmune rheumatoid arthritis in a mouse model [Carrick 2004]. 
A20 
A20 is a TLR-inducible protein that has two enzymatic activities, acting both as an E3 ubiquitin 
ligase and a deubiquitinase. In vitro analysis has shown that A20 restricts NF-κB activation by 
modulating RIP1 and TRAF6. A20–deficient mice die prematurely from spontaneous multi-
organ inflammation and cachexia, indicating that A20 has anti-inflammatory effects in vivo, 
perhaps by inducing tolerance to commensal bacteria, since the administration of antibiotics 
prevents cachexia, and A20/MyD88 double-/- animals do not exhibit the inflammatory 
phenotype [Turer 2008]. 
SHP-1 
Mice bearing mutations in the tyrosine phosphatase Src homology-2 containing tyrosine 
phosphatase-1 (SHP-1) develop inflammatory lesions associated with aberrant macrophage 
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activation in response to TLR stimulation. MyD88 deficiency suppresses this inflammation, 
suggesting that SHP-1 negatively regulates the MyD88-dependent pathway; it has also been 
reported to suppress the functions of IRAK1 and IRAK2 [Croker 2008 and An 2008].  
1.5 The TLR-C5a receptor interaction 
The signal transduction pathways involved in the release of pro-inflammatory cytokines and 
chemokines in response to TLR and C5a receptor activation are complex and subject to a 
considerable degree of overlap (Figure 18). Furthermore, it is likely that in vivo the two 
systems are typically activated simultaneously, since during infection or sterile injury to tissues 
stimuli that activate TLRs are also likely to activate complement. Thus it is perhaps not 
surprising that there should be a functional interaction between the two receptor systems, 
and indeed a substantial body of literature demonstrates this to be the case. 
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Figure 18. Overlapping signalling pathways involved  in TLR- and C5aR-induced 
cytokine secretion. Complex and overlapping signal transduction pathways lead to 
cytokine secretion in response to TLR and C5aR activation, via activation of NF-κB 
and mitogen-activated protein kinase cascades. ATF-1, activating transcription factor 
1; CREB, cyclic AMP responsive element binding protein; ELK-1, ETS-like tyrosine 
kinase-1; ERK1/2, extracellular signal related kinase 1/2; MEK1/2, MAPK/ERK kinase
1/2; JNK1/2, c-Jun N-terminal kinase 1/2; MK, MAPK-activated protein kinase; MKKs, 
MAPK kinase; PAKs, p21-activated kinases; PKC, protein kinase C; IκB, inhibitor of NF-
κB;  IKKαβγ, IκB kinase, subunits αβγ; PI3K, phosphoinositol-3-kinse; TAK-1, TNF 
receptor-associated kinase-1. Adapted from [Monk 2007, Flannery and Bowie 2010, 
and Kawai and Akira 2010]. 
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1.5.1 Early studies demonstrating synergistic enhancement of pro-
inflammatory cytokine release 
A functional interaction between TLRs and C5a receptors was first explicitly demonstrated by 
Gelfand and co-workers [Okusawa 1987], who found that peripheral blood mononuclear cells 
(PBMC) exposed to C5a in combination with LPS released more IL-1 than the sum of that 
released by either stimulus alone (indicating a synergistic interaction between the two 
stimuli). A certain amount of controversy dogged this and other early studies, since C5a alone 
is a weak inducer of inflammatory cytokine release, and the detection methods for secreted 
cytokines were based on biological activity assays and so were less sensitive than modern 
antibody-based methods; many investigators concluded that while C5a alone could induce 
transcription of pro-inflammatory cytokines, a second signal (typically LPS) was necessary for 
inducing protein synthesis [Cavaillon 1990 and Schindler 1990]. However, it subsequently 
became clear that exposure of isolated leucocytes or whole blood to C5a induced an 
inflammatory response (including the transcription and secretion of IL-1, IL-6 and IL-8) that 
could be greatly potentiated by concurrent administration of LPS [Schindler 1990, Montz 1991, 
Czermak 1999 and Mack 2001] or other non-microbial TLR ligands [Kuhns 2007]. 
The synergistic effect of the TLR-C5a receptor interaction on the induction of cytokine release 
was not restricted to blood cells. Synergistic enhancement of inflammatory cytokine release by 
the combination of LPS and C5a has been reported in alveolar epithelial cells [Riedemann 
2002a] and hepatic Kuppfer cells [Mack 2001]. The Ward group [Czermak 1999] also found 
that co-stimulation of rat neutrophils with LPS and C5a in vivo resulted in enhanced C5a-
induced chemotaxis ex vivo, indicating that other functions of C5a as well as pro-inflammatory 
cytokine release were capable of being enhanced by co-incident TLR activation. 
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Thus, early reports indicated that concurrent activation of TLRs and C5a receptors resulted, in 
a number of different human and murine cell types, in enhanced inflammatory responses 
compared with those elicited by stimulating either receptor individually.  
1.5.2 Findings from murine models of sepsis 
Infection causes both complement activation (and thus generation of C5a) and the release of 
multiple TLR ligands. Hence, much information about the C5a-TLR interaction has been yielded 
by studies using animal models of infection, especially murine models employing targeted 
genetic deletions. Whilst a range of murine models has been used by investigators, it is 
generally accepted that the caecal ligation and puncture (CLP) model most closely represents 
the kind of infective challenge involved in sepsis in humans [Ward 2010a and b].  
A number of studies published by the Ward group between 2001 and 2012 using the murine 
CLP model have firmly implicated C5a and its receptors in the pathophysiology of sepsis. In 
particular, these studies have identified the TLR-C5a receptor interaction as playing a critical 
role in the dysregulated inflammatory response that characterises sepsis. C5a was found to 
potentiate the inflammatory cytokine response to CLP sepsis, since the administration of a 
neutralising antibody to C5a had the effect of reducing the CLP-induced plasma levels of 
inflammatory mediators (IL-6 and TNF-α) as well as improving bacterial clearance, reducing 
histological evidence of multi-organ failure and improving survival [Huber-Lang 2001a and b, 
Riedemann 2002b].  
The CLP model had a complex effect on C5aR expression: neutrophil C5aR expression was 
rapidly down-regulated by CLP sepsis; this down-regulation was strongly associated with 
increased septic lethality. The investigators found a corresponding deficit in ex vivo C5a-
induced chemotaxis and oxidative burst metabolism in neutrophils from animals with CLP 
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sepsis [Huber-Lang 2001a, Huber-Lang 2002 and Guo 2003]; prevention of this deficit probably 
accounted for the enhancement in bacterial clearance seen in CLP animals treated with anti-
C5a. On the other hand, CLP sepsis was found to up-regulate expression of C5aR in the vital 
organs (heart, lung, liver, and kidneys). This increased C5aR expression in non-haematopoietic 
tissues was also associated with histological evidence of multi-organ failure and with lethality, 
and was dependent on plasma IL-6 [Riedemann 2002b, Riedemann 2003]. The TLR-C5a 
receptor interaction was explicitly implicated in this picture by the finding that in vitro, C5a 
appeared to synergistically enhance LPS-induced release IL-6 by neutrophils. The contribution 
of neutrophils to the composition of the plasma cytokine milieu has elsewhere been reported 
to be relatively small compared with that of monocytes [Sabroe 2002 and Møller 2005], but 
neutrophil IL-6 appeared to play an important role in this model: the investigators found that 
neutrophil depletion before induction of CLP led to a similar decrease in plasma IL-6 to that 
observed in animals treated with anti-C5a. This suggested that the neutrophil TLR-C5a 
receptor interaction was critically involved in the elevated plasma IL-6 levels that had 
previously been shown to induce tissue C5aR up-regulation, which itself seemed to be at least 
partly responsible for organ failure and septic lethality.  
The investigators proposed a mechanism that might account for the relationship between 
tissue C5aR expression and mortality [Laudes 2002]. A murine model of endotoxaemia showed 
that in vivo exposure to LPS induced the expression of C5aR in microvascular endothelial cells, 
raising the possibility that endothelial cells might be implicated in the harmful effects of C5a 
during CLP sepsis. An in vitro stimulation model revealed that consecutive TLR activation and 
C5a stimulation significantly enhanced the release of the neutrophil chemoattractants 
macrophage inflammatory protein-2 (MIP-2) (CXCL2) and MCP-1 (CCL2) compared with that 
induced by LPS alone (C5a alone did not induce chemokine release). Since neutrophil 
infiltration of vital organs during sepsis is known to have a critical role in inflammatory tissue 
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injury and organ failure, these findings suggested that the link between the previously 
observed increased tissue expression of C5aR and lethality in the CLP model was TLR /C5aR 
synergy in the release of neutrophil chemoattractants by vascular endothelia [Laudes 2002]. 
This study identified two key elements of the TLR-C5a interaction that are of particular 
relevance to the pathophysiology of murine sepsis. The first was the direct enhancing effect of 
the TLR-C5a receptor synergy in inducing cytokine release (neutrophil IL-6 and endothelial 
chemokines). The second was an indirect enhancing effect of TLR activation in CLP sepsis 
(mediated by IL-6 released from neutrophils) upon C5a-induced release of neutrophil 
chemokines through the upregulation of C5aR expression in vascular endothelia. 
The effects of the TLR-C5a receptor interaction were observed to vary between different cell 
types. Rat alveolar epithelial cells responded to co-stimulation with LPS+C5a with a synergistic 
enhancement in the release of IL-1β, cytokine-induced neutrophil chemoattractant-1 (CINC-1), 
macrophage migration inhibitory protein-2 (MMIP-2) and TNF-α [Riedemann 2002a]. 
However, rat neutrophil MMIP-2 release was found to be attenuated by stimulation with 
LPS+C5a compared with that induced by either ligand alone [Riedemann 2004]. Similarly, 
mouse neutrophil TNF-α release was reported to be attenuated by LPS+C5a compared with 
LPS alone, whereas in alveolar macrophages LPS+C5a induced synergistic enhancement of 
TNF-α release. Murine alveolar macrophages and neutrophils exhibited a capacity for 
synergistic enhancement of CINC-1 and macrophage inflammatory protein (MIP, CXCL2), 
whereas PBMC did not [Guo 2006]. Thus it appeared that the effect of the TLR-C5a receptor 
interaction might be more complex than to globally enhance the release of pro-inflammatory 
cytokines, since its effects on TNF-α and other inflammatory mediators were positive in some 
cell types, but negative in others. 
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The signal transduction pathways involved in TLR ligand- and C5a-induced cytokine release 
were also investigated [Guo 2006]. Concurrent stimulation of murine neutrophils and alveolar 
macrophages with LPS and C5a induced a synergistic enhancement of MIP-2 release by 
neutrophils and alveolar macrophages. Perhaps unsurprisingly, NF-κB inhibition abolished 
secretion of MIP-2 in response to any stimulus. Inhibition of MAP Kinase JNK1/2 had no effect 
on MIP-2 secretion in either neutrophils or macrophages, whereas inhibition of p38 MAPK 
attenuated macrophage MIP-2 secretion and abolished neutrophil MIP-2 secretion. 
Interestingly, the investigators found that while TLR4 activation alone induced cytokine 
release, it did not induce significant phosphorylation of either ERK1/2 or p38 MAPK. On the 
other hand, in both alveolar macrophages and neutrophils, C5a induced rapid ERK1/2 and p38 
phosphorylation, an effect that was enhanced by the addition of LPS. Thus, while TLR 
activation alone did not induce significant phosphorylation of ERK1/2 and p38, it did appear to 
up-regulate C5a-induced phosphorylation. This suggested that while the MAPK pathways were 
not critically involved in LPS-induced MIP-2 release, they did play a role in mediating the TLR-
C5a receptor synergistic enhancement of MIP-2 release.  
A later study by the Ward group also implicated the PI3K/Akt pathway in the regulation of 
cytokine release in response to C5a receptor and TLR activation [Riedemann 2004]. 
Macrophage migration inhibitory factor (MIF) is an immunomodulatory and pro-inflammatory 
cytokine released by macrophages, eosinophils, T cells and epithelia in response to TLR4 
activation (amongst other stimuli). It is known to activate T cells and induce secretion of pro-
inflammatory cytokines from macrophages, and is implicated in pro-inflammatory cytokine 
release and lethality in murine models of endotoxaemia as well as human sepsis [Bozza 1999, 
Gando 2001]. The investigators found that in murine CLP sepsis, neutrophils were the main 
source of plasma MIF, and that plasma MIF levels were reduced in response to either 
neutrophil depletion or C5aR mAb blockade, suggesting that neutrophil C5aR ligation was 
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critical to sepsis-induced MIF secretion. In vitro, the combination of LPS and C5a induced an 
increased level of MIF secretion from neutrophils compared with that induced by either 
stimulus alone. PI3K phosphorylation was observed in response to C5a stimulation, and 
enhanced by the concurrent administration of LPS with C5a but was not induced by LPS alone 
(although LPS alone did induce MIF secretion). All MIF release was abolished by addition of a 
PI3K inhibitor, indicating that PI3K signalling was necessary for MIF release induced by LPS 
alone, even though PI3K phosphorylation was not observed in response to LPS stimulation 
alone.  
A further investigation by the Ward group into the effects of PI3K inhibition on CLP septic 
lethality [Wrann 2007] expanded and developed these findings. Mice that were treated with 
an inhibitor of PI3K before induction of CLP sepsis exhibited higher plasma levels of TNF-α, IL-
1β, IL-6 and IL-10, as well as higher mortality than animals with intact PI3K signalling. In 
contrast with the group’s previous reports, these findings indicated a protective, anti-
inflammatory effect of PI3K in the setting of experimental sepsis. The use of PI3K inhibition in 
vitro revealed an intriguing effect of PI3K on the release of IL-1β and IL-8 by isolated 
neutrophils. In this model, the levels of cytokines released in response to stimulation with 
LPS+C5a were not substantially higher than those seen in response to LPS or C5a alone. 
However, when cells were stimulated with LPS+C5a (but not LPS or C5a alone) in the presence 
of a PI3K inhibitor, a marked enhancement of cytokine release was observed. These findings, 
while difficult to explain fully, suggest that in murine neutrophils, the capacity of C5a to 
synergise with LPS in the induction of IL-1β and IL-8 is subject to a strong inhibitory signal from 
PI3K. They also confirm that the concurrent engagement of TLRs and C5a receptors may have 
different effects on different inflammatory mediators. 
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A further study by the Ward group was the first to demonstrate the possible contribution of 
the second C5a receptor, C5L2, to the TLR-C5a receptor interaction [Gao 2005]. The 
investigators found that whereas mAb blockade of C5aR abolished the previously reported 
synergy between LPS and C5a in the induction of IL-6 release by rat neutrophils, the synergistic 
enhancement was greatly potentiated by blockade of C5L2. These findings suggested that the 
C5a receptors played antagonistic roles in the TLR-C5a receptor interaction, with C5L2 exerting 
a constitutive inhibition of C5aR’s capacity to synergise with TLR ligands in inducing IL-6 
release from neutrophils. 
1.5.3 Findings from murine knock-out and gene silencing studies 
The use of experimental models involving mice with targeted deletions or silencing of either 
(or both) of the two receptors for C5a has yielded much information about the differing roles 
of C5aR and C5L2 in the TLR-C5a receptor interaction. 
As discussed in section 1.3.4.2 above, a study by Feinstein and colleagues identified an 
apparent anti-inflammatory effect of C5L2 on LPS-mediated inflammation in rat astrocytes 
[Gavrilyuk 2005]. Blockade of C5L2 synthesis induced an increase in LPS-induced NOS mRNA 
and nitrite levels in the absence of exogenously administered C5a. Transfection of C6 glioma 
cells (which do not express C5L2) with C5L2 resulted in a significant reduction (>70%) of NF-κB 
activation in response to LPS treatment compared with cells not expressing C5L2. These 
findings are intriguing, because they suggest a role for C5L2 in modulating TLR-induced 
inflammatory responses in the absence of exogenously administered C5a. A potential 
explanation for this is of course artefactual generation of C5a in the culture conditions, but the 
data are also compatible with the possibility of a regulatory effect of C5L2 on TLR signal 
transduction, although it is unclear how such an effect might be exerted.  
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The Yeh group’s 2007 study using an independently generated C5L2-deficient mouse model2 
found a complex effect of C5L2 on the TLR-C5a receptor interaction [Chen 2007]. The group 
found that co-stimulation of wild-type neutrophils with LPS+C5a resulted in inhibition of LPS-
induced TNF-α, and enhancement of IL-6 release. This apparent capacity of C5a to modulate 
the TLR response (either upwards or downwards) was lost in C5L2-deficient mice, suggesting 
that C5L2 was critically involved in whatever contribution C5a made to response to the 
combined TLR+C5a receptor stimulus. In contrast with previous reports and with the effect on 
TNF-α and IL-6 release in neutrophils, co-stimulation with LPS and C5a in macrophages was 
found to inhibit the LPS-induced release of both cytokines; again this effect was lost in C5L2-
deficient cells.  
The involvement of the PI3K/Akt, ERK1/2, p38 and JNK1/2 MAPK pathways was also 
investigated: consistent with the findings of the Ward group, Chen et al. found that C5a 
stimulation induced phosphorylation of Akt, ERK1/2 and p38 in neutrophils and macrophages, 
while LPS did not, but the addition of LPS to C5a tended to enhance the C5a-mediated 
phosphorylation of kinases. In both conditions, the C5a-induced phosphorylation was 
attenuated or lost in C5L2-deficient mice, suggesting again that the contribution of C5a to the 
signalling pathways implicated in the TLR-C5a receptor interaction was mediated by C5L2. 
Interestingly, in a model of lethal endotoxic peritonitis (which would inevitably also have 
induced substantial complement activation), the survival of the C5L2-deficient mice was 
markedly worse than that of WT littermates, perhaps suggesting that the overall effect of C5L2 
(at least in this experimental model) was anti-inflammatory.  
                                                          
2
 Two independently-generated C5L2-deficient mouse models are reported in the literature: the first 
was generated by the Gerard group and reported in 2005 [Gerard 2005]. This model was subsequently 
used in all of the other studies that report the use of a C5L2-deficient murine model, except that cited 
here which was generated by the Yeh group [Chen 2007]. 
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A further study by the Ward group using Gerard’s C5L2-deficient mice [Gerard 2005] produced 
findings both consistent and contrasting with the two previous reports, and also appeared to 
implicate C5L2 in the regulation of TLR signal transduction in the absence of concurrent C5a 
stimulus [Rittirsch 2008]. Consistently with the group’s previous reports, deletion of C5aR had 
an anti-inflammatory effect on CLP sepsis, resulting in substantial decreases in the plasma 
levels of IL-1β, IL-6, MIP-1α and MIP-2. C5aR deletion had no effect on TNF-α levels. Deletion 
of C5L2 had a more complex effect: IL-1β, MIP-1α and MIP-2 levels were reduced and TNF-α 
unaffected, but IL-6 was markedly up-regulated. Blockade or deletion of either receptor 
tended to improve survival; in high-grade (100% lethality) CLP sepsis, blockade or deletion of 
both receptors was necessary to induce a protective effect. Thus, it would appear that the 
contribution of C5aR to the net inflammatory response to polymicrobial sepsis was to 
potentiate TLR-induced release of IL-1β, IL-6, MIP-1α and MIP-2, whereas C5L2 potentiated IL-
1β, MIP-1α and MIP-2 but inhibited IL-6 release; the net effect on survival suggested a pro-
inflammatory role for C5L2 in the context of murine CLP sepsis. 
As discussed in section 1.3.4.2 above, another important finding of this study was that C5L2 
appeared to regulate the release of the nuclear protein HMGB1. Peritoneal macrophages 
secreted HMGB1 in response to LPS (strongly), C5a (less strongly) and LPS+C5a (~the sum of 
each alone). C5aR deletion had no effect on the level of HMGB1 released by cells in response 
to any of the stimuli, indicating that the C5a-induced HMGB1 secretion was not mediated by 
C5aR. Intriguingly, however, the deletion of C5L2 greatly reduced HMGB1 release in response 
not only to C5a and C5a+LPS, but also to LPS alone. These findings are reminiscent of those of 
the Feinstein group [Gavrilyuk 2005], who also reported a regulatory effect of C5L2 on LPS-
induced inflammatory responses, again without the addition of exogenous C5a. 
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A study by Song and co-workers [Zhang 2007] indirectly demonstrated a far-reaching 
interaction between complement and TLR activation by utilising a murine model of peritonitis 
in mice deficient in a key inhibitor of complement activation. The investigators demonstrated 
that mice with genetic deletion of the glycosylphosphoinositol-linked cell surface complement 
inhibitory protein, decay-accelerating factor (DAF, CD55) were hypersensitive to a sub-lethal 
intra-peritoneal LPS challenge, exhibiting worse symptoms of endotoxaemia and elevated 
plasma levels of IL-6, TNF-α and IL-1β compared with wild-type littermates. Since DAF 
accelerates the proteolytic breakdown of both C3 and C5 convertases, it was hypothesized 
that the DAF-deficient mice were exhibiting an exaggerated inflammatory phenotype as a 
consequence of enhanced LPS-induced complement activation. Accordingly, the plasma levels 
of activated C3 in the DAF-deficient mice were significantly higher than in wild-type mice, and 
the differences between DAF-deficient and DAF-sufficient mice were abolished in DAF/C3 
double-knockout mice. 
It was not possible, however, to attribute the greatly enhanced pro-inflammatory response in 
the DAF-deficient mice solely to the effects of increased complement activation in that 
population. The administration to wild-type mice of cobra venom factor (CVF), which causes 
massive complement activation, resulted in only a modest increase in plasma levels of IL-6; 
CVF administered in conjunction with LPS, however, resulted in a ~40-fold increase in plasma 
IL-6 levels compared with that induced by LPS alone, in effect reproducing the effect of DAF 
insufficiency. The effect could be partially blocked by concurrent administration of an 
antagonist to C3a (or C3a deficiency) and completely abolished by a C5a antagonist or by C5 
deficiency, indicating that the TLR-C5a receptor interaction was primarily responsible for the 
enhancement in LPS-induced inflammatory cytokine release seen in the DAF-deficient mice. 
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Once again, the increased cytokine release seen in DAF-deficient mice was associated with 
increased activation of MAPK and NF-κB pathways. Splenocytes from DAF-deficient mice 
showed greater and more rapid phosphorylation of IκB after LPS injection, and lower levels of 
IκB overall. DAF-deficient RAW264.7 cells transfected with an NF-κB luciferase reporter 
showed a greater activation of NF-κB when stimulated with C5a+LPS than LPS or C5a alone, 
with a corresponding pattern of TNF-α release. Lysates of splenocytes from DAF-deficient mice 
showed increased ERK1/2 and JNK1/2 phosphorylation 30 minutes after in vivo LPS challenge 
compared with wild-type mice. Since the Ward and Gerard groups had previously reported 
that LPS alone did not induce MAPK phosphorylation in this time frame, but that LPS 
potentiated C5a-induced kinase phosphorylation, it is tempting to speculate that this effect 
was attributable to LPS potentiation of C5a in this model also; however, this hypothesis was 
not tested (for example by examining the effects of LPS + anti-C5a in the DAF-deficient mice). 
DAF knockout was found to potentiate not only TLR4 but TLR2 and TLR9 as well. 
Intraperitoneal injection of zymosan, a TLR2/6 ligand also known to be capable of activating 
complement, induced an enhancement of plasma levels of IL-6 in DAF-deficient mice 
compared with wild type littermates. Again, the normal phenotype was restored by a DAF/C3 
or DAF/C5aR double knockout. Similar findings resulted from intra-peritoneal challenge with 
the TLR9 ligand CpG DNA, indicating that TLR2 and 9 activation were similarly susceptible to 
modulation by the C5a receptor. Hence the effects of DAF deficiency were unlikely to be a 
result of an effect of DAF on the TLR4-LPS interaction (DAF has been reported to be capable of 
directly interacting with LPS [El-Samalouti 1999, Heine 2003]).  
While the investigators undeniably demonstrated a far-reaching effect of the TLR-C5a receptor 
interaction, the indirect means by which they did so (via increased complement activation in 
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DAF-deficient cells) makes it difficult to formulate a clear theory as to the mechanism by which 
TLR and C5a receptor signal transduction might have affected cytokine release in their model.  
1.5.4 The TLR-C5a receptor interaction and release of immunomodulatory 
cytokines 
1.5.4.1 IL-12 
IL-12 is a heterodimeric pro-inflammatory and immunomodulatory cytokine released by 
monocytes and macrophages in response to TLR ligands. It is comprised of p40 and p35 
subunits, which are separate gene products; a heterodimer of p40 and p35 (IL-12p70) and a 
homodimer of p40 are released by cells. IL12 is known to drive polarisation of CD4+ cells 
towards a TH1 phenotype through its ability to induce proliferation and IFNγ secretion in T and 
NK cells. Its excess has been implicated in autoimmune diseases, and its deficiency in 
susceptibility to bacterial and viral infections; supplementing IL-12 has been investigated as a 
therapeutic strategy in such infections [Trinchieri 2003].  
Werfel and colleagues [Wittmann 1999] found that IFNγ-primed human monocytes that were 
pre-exposed to C5a before addition of LPS manifested a C5a dose-dependent loss of 
intracellular staining for IL-12p40 and p70 compared with cells stimulated with LPS alone. This 
suggested that C5a receptor activation had an inhibitory effect upon LPS-induced secretion of 
IL-12-family cytokines. Similar results were reported by a number of groups, using a range of in 
vitro and in vivo experimental models [Braun 2000, La Sala 2005, Hawlisch 2005, Zhang 2007, 
Okazaki 2010, Wang 2010 and Liang 2010]. The inhibitory effect of C5a on TLR-induced IL-12 
secretion was shown to be mediated by the PI3K/Akt, ERK1/2 and JNK1/2 pathways. It was 
also found to be dependent on autocrine secretion of IL-10, suggesting that the apparent 
inhibitory effect of C5a in TLR-induced inflammatory responses might in fact have been due to 
an enhancing effect of C5a receptor activation upon TLR-induced IL-10 release. 
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1.5.4.2 IL-17 
Another study by the Song group in 2009 [Fang 2009] showed that the TLR-C5a synergy in the 
induction of IL-6 release also extended to the release of TGF-β, and created in plasma a 
cytokine milieu that favoured differentiation of naive CD4+ T cells towards an auto-
immunogenic TH17 profile. Incubation of naïve CD4
+ T cells activated by plate-bound anti-
CD3/CD28 with serum from wild-type mice subjected to intraperitoneal challenge with LPS, 
CVF and/or C5a showed that the combination of LPS and CVF or LPS and C5a (but neither 
agent alone) induced a TH17 polarisation comparable with that seen when activated T-cells 
were incubated with IL-6 and TGF-β (the positive control for TH17 polarisation). The absence of 
IL-6 (due to antibody blockade in the secondary culture or genetic deletion in the mice given 
the in vivo challenge) resulted instead in an IFNγ-producing TH1 phenotype, indicating that the 
TLR-C5a receptor synergy in the production of IL-6 was critical in determining this outcome.  
There are accumulating reports in the literature that IL-17 isoforms (IL-17A and F) can be 
produced by cells of the innate immune system as well as by TH17-polarised CD4
+ T cells. 
Substantial levels of IL-17A were released in the genetic absence of αβ T cells after CLP [Flierl 
2008] and in a model of endotoxic shock, plasma IL-17A levels were not reduced by the 
genetic absence of αβ or γδ T-cells, or CD4+ cells, whereas depletion of F4/80+ macrophages 
did reduce IL-17A levels [Bosmann 2011]. The Ward group recently demonstrated that the 
release of the IL-17F isoform by peritoneal macrophages in response to LPS (but not TLR2, 3, 5 
or 9 ligands) was subject to a synergistic enhancement by C5a in a manner that was 
dependent on MyD88, C5aR (but not C5L2) and PI3K/Akt.  
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1.5.5 The TLR-C5a receptor interaction and the lymphocytes of the innate 
immune system 
The capacity of the TLR-C5a receptor interaction to modulate responses of innate immune 
lymphocytes was investigated by the Köhl and Mattner groups [Fusakio 2011] using a C57/BL6 
mouse model of E. coli sepsis. Deficiency of C5aR but not C5L2 had a significant effect in 
reducing mortality. NK and NK T cells are able to rapidly secrete large amounts of IFNγ and 
TNF-α in response to microbial infections without prior sensitisation or clonal proliferation, 
and have been identified as key contributors to the harmful systemic inflammatory response 
in sepsis [Chiche 2011]. The investigators assessed the effects of either C5aR deficiency or 
genetic deletion of NK and NKT cells on the response to E. coli peritonitis. Deletion of C5aR 
(but not C5L2) or depletion of NK/NK T cells resulted in a substantial reduction in mortality and 
in serum levels of TNF-α and IFNγ. In an elegant series of ex vivo experiments, the 
investigators tested the capacity of splenocytes harvested from mice 24 h after induction of E. 
coli peritonitis to secrete TNF-α and IFNγ in response to ligands for TLR 1, 2, 4, 5, 6 and 9. Cells 
from C5aR-deficient mice showed a significantly reduced capacity to secrete TNF-α and IFNγ 
compared with wild-type littermates, suggesting that in vivo C5a-C5aR activation led to 
enhanced TLR-mediated cytokine release.  
Next, the investigators harvested naïve splenocytes from wild-type, NK/NKT-deficient, C5L2-
deficient and C5aR-deficient mice and stimulated them with TLR ligands alone or TLR 
ligands+C5a. The results are complex and intriguing: in wild-type cells, TLR 1/2, 2/6 and 9 
ligands synergised with C5a in inducing IFNγ and TLR1/2, 2/6 and 5 with C5a in inducing TNF-α. 
TLR4 ligation+C5a failed to show statistically significant synergy in inducing either cytokine, 
and TLR5 activation failed to induce a significant IFNγ response either with or without C5a. 
These findings suggest that different TLR ligand/C5a combinations may preferentially induce 
different cytokines. The overall population of splenocytes would have contained a range of cell 
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types, including neutrophils, monocyte/macrophages, DCs, NK and NK T cells and of course B- 
and T-lymphocytes, and it is possible that the differential effects of different TLR ligand/C5a 
combinations on cytokine release simply reflect the presence of different cell types which 
predominantly express different TLRs and also have different capacities for secreting TNF-α 
and IFNγ. The investigators did not identify specific subpopulations for individual study but the 
involvement of NK/NK T cells in the TNF-α/IFNγ response was strongly implicated by data from 
NK/NKT-deficient animals, which showed a consistent reduction in the cytokine response to all 
TLR ligands both with and without C5a. Furthermore, the capacity of TLR ligands to synergise 
with C5a seen in wild-type splenocytes was in some cases lost in the NK/NKT-deficient 
animals, whilst the capacity to respond to TLR ligand alone was preserved (albeit with reduced 
sensitivity), suggesting that the NK/NK T cell population was at least partly responsible for the 
enhanced cytokine release observed in the wild-type animals. 
Additional work by this group using an ex vivo co-culture model of bone-marrow-derived  
dendritic cells (BMDCs) with NK or NK T cells suggested that the TLR-C5a receptor interaction 
has an effect on the capacity of splenic DCs to drive NK/NKT secretion of TNF-α and IFNγ. 
Monocultures of BMDCs or NK cells from septic animals did not secrete detectable IFNγ in 
response to TLR ligands, whereas IFNγ release from BMDC+NK co-cultures was both 
substantial, and markedly attenuated by C5aR deficiency in the BMDCs. A similar BMDC C5aR-
dependent effect was shown on NK T cell TNF-α release in response to ligands for TLR1/2, 2/6 
and 5 (but not 4) in a corresponding co-culture model. TLR ligand-induced TNF-α and IFNγ 
secretion were found to be due not to direct stimulation of TLRs on NK/NKT cells, but to C5aR-
dependent release of IL-12 and IL-18 in response to TLR ligation on co-cultured DCs. Hence the 
authors concluded that the elevated systemic levels of IFNγ and TNF-α, which are an 
important component of the ‘cytokine storm’ seen early in sepsis, may be a powerful but 
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indirect effect of the TLR-C5aR crosstalk in DCs, which then triggers massive pro-inflammatory 
cytokine release from NK and NK T cells.  
A further level of complexity was suggested by Salmon et al. [Qing 2012], who demonstrated 
that TLR-C5a receptor synergistic enhancement of NK cell activation was not only indirectly 
mediated by DCs, but also that DC-mediated priming of NK cells was itself an indirect 
phenomenon, being the consequence of a TLR-C5aR mediated synergistic enhancement of 
TGF-β release from immature Gr1+ myeloid cells (pre-monocyte/neutrophils). Thus, it appears 
that the synergistic enhancement of inflammatory cytokines attributed to the TLR-C5a 
receptor interaction in in vivo models of sepsis is a complicated phenomenon involving 
interactions between a number of different cell types, and that NK and NKT lymphocytes may 
play a key role in the acute inflammatory response to infection. 
1.5.6 Summary 
The previously reported findings discussed here indicate a complex relationship between TLR 
and C5a receptor activation, with far-reaching effects. It appears that concurrent TLR and C5a 
receptor activation may dramatically amplify the release of a range of inflammatory mediators 
(particularly IL-6 and a number of chemokines), in many cases by several orders of magnitude 
over the responses that would be elicited by either stimulus alone. Thus, it is plausible that the 
TLR-C5a receptor interaction may play a key role in the efficient clearance of infections, but 
also in the excessive cytokine and chemokine response to infection that characterises the 
pathophysiology of sepsis.  
On the other hand, the TLR-C5a receptor interaction may markedly inhibit the release of 
certain mediators compared with that induced by a TLR stimulus alone. The effect of 
concurrent C5a and TLR ligand activation on the release of TNF-α in particular appears to vary 
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in different cell types: neutrophils have been consistently reported to release less TNF-α if 
stimulated with LPS+C5a than with LPS alone, while resident tissue macrophages and epithelial 
cells typically showed an enhancement in TNF-α release in response to co-stimulation. The net 
effect of TLR+C5a receptor co-stimulation on systemic TNF-α release seems to be positive, 
since plasma levels were typically found to be inhibited in models of sepsis in which C5a 
signalling was interrupted by genetic deletions or antibody blockade of C5a. 
An inhibitory effect of C5a on TLR-mediated IL-12 secretion was consistently found in both in 
vivo and in vitro models, and in a number of different cell types. However, in spite of some 
inconsistencies between reported studies, it is likely that this apparent inhibitory effect is 
secondary to changes in IL-10 secretion. Thus it might be more accurate to view the effect of 
the TLR-C5a receptor interaction on IL-12 release as the result of an enhancement of TLR- or 
C5a-induced IL-10 secretion, rather than as an inhibitory effect on IL-12 release per se. 
Investigators have consistently found that the MAP kinases ERK1/2 and p38 and the PI3K/Akt 
pathway appear to be involved in mediating the effect of the C5a receptor-TLR interaction on 
cytokine release. A number of studies have demonstrated that C5a induces kinase 
phosphorylation, and that this is enhanced by concurrent TLR activation. This might indicate 
that TLR-mediated potentiation of the C5a-induced activation of these pathways is a key 
component of the TLR-C5a receptor interaction that results in modulation of cytokine release. 
The findings of the Ward group [Wrann 2008] in murine neutrophils are particularly striking in 
this respect, as they suggest that the PI3K/Akt pathway may be disproportionately and 
preferentially engaged when both TLRs and C5a receptors are activated in comparison with its 
level of engagement in response to either stimulus alone. 
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1.6 Hypothesis, Aims and Objectives  
The capacity of TLR ligands + C5a to synergise and modulate pro-inflammatory and 
immunomodulatory cytokine production is well-established. This led to the conclusion that 
crosstalk between C5a receptors and TLRs occurs, which strengthens the innate host defense 
during infection. Most studies, however, have focused on the immunoregulatory effect of C5a 
on TLR-driven inflammation, neglecting potential effects of TLR activation on complement-
mediated inflammation. In the present study, it was hypothesised that a genuine bi-directional 
signalling crosstalk between TLRs and C5a receptors exists by which not only may C5a receptor 
activation modulate TLR-mediated responses, but also TLR activation may modulate the extent 
and/or quality of cellular responses to C5a. This may guarantee a prompt, strong and efficient 
response to the microbial challenge and rapid clearance of infection. Thus the aim of the 
project was to evaluate the impact of TLR activation on C5a-driven cytokine and chemokine 
production in vitro and ex vivo. 
Objectives 
This study sought to: 
1. Use an in vitro experimental model system to test the capacity of TLR activation to 
synergistically enhance inflammatory responses induced by C5a. 
2. Conduct a detailed characterisation of the nature and extent of the putative 
modulatory effect of TLRs on C5aR-mediated pro-inflammatory responses. 
3. Develop a suitable in vivo model to corroborate these findings. 
4. Investigate the mechanism by which TLR activation may modulate C5a-induced 
cellular responses in vitro and in vivo. 
5. Identify the key signal transduction intermediates involved in the effects of TLRs on 
C5a receptors. 
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Chapter 2: RESULTS 
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2.1 Modulation of cell sensitivity to C5a by TLR activation 
2.1.1 Synergistic enhancement of pro-inflammatory cytokine release by 
co-stimulation via TLR and C5a receptors 
In order to confirm the previously reported TLR-C5a receptor-mediated synergistic 
enhancement of pro-inflammatory cytokine release, human PBMC were stimulated with the 
TLR4 ligand LPS, recombinant human C5a or a combination of both ligands concurrently, and 
the levels of the prototypical neutrophil chemoattractant IL-8 (CXCL-8) released by the cells in 
each condition were estimated (ELISA) in the culture supernatants. Figure 19A shows that 
concurrent stimulation of PBMC with LPS+C5a resulted in a marked enhancement of IL-8 
release compared with the estimated additive effect of each ligand alone. The synergistic 
effect of LPS+C5a was observed over a range of C5a concentrations tested, and resulted in IL-8 
levels several-fold higher than those resulting from stimulation with the indicated 
concentrations of C5a alone (Figure 19B). The viability of cryopreserved PBMC after 
resuscitation and at the end of the culture period was ≥99% and >95%, respectively, as 
assessed by the trypan blue exclusion test. 
112 
 
Figure 19. Effect of co-stimulation of PBMC with LPS and C5a. Human PBMC 
(1.5 x 105/well) were stimulated for 14 h with LPS (500 pg/mL), C5a (20 nM
or as indicated) or LPS + C5a concurrently. (A) Overall IL-8 levels in culture 
supernantants. (B) –fold increase in IL-8 release over a range of stimulating 
concentrations of C5a. –fold increase was calculated as the ratio of IL-8 
release induced by LPS+C5a to that induced by C5a alone, after subtraction 
of the relevant background. Results shown are mean (±SD) values of three 
independent experiments from a single donor representative of four. (*** p 
< 0.005).
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2.1.2 Effect of TLR activation on cell sensitivity to C5a 
In order to investigate the possibility that TLR activation modulates C5a-induced cytokine 
release, thus contributing to the synergistic effect observed and described previously, PBMC 
were first exposed to a typical TLR4 ligand (LPS), then washed thoroughly, and stimulated with 
C5a before estimation of cytokine levels in the cell culture supernatants (activation model 
illustrated in Figure 39A and discussed in section 5.2.2 below). Figure 20A shows that the 
levels of IL-8 released by C5a-stimulated cells that had been pre-exposed to LPS were 
significantly higher than those released by cells not pre-exposed to the TLR ligand. Thus, pre-
exposing cells to LPS before C5a stimulation reproduced the LPS+C5a synergistic effect on IL-8 
release observed upon co-stimulation (Figure 19A), indicating cell hypersensitivity to C5a 
following cell ‘priming’ by TLR activation. Notably, when the reverse cell treatment sequence 
was followed (pre-exposure to C5a followed by stimulation with LPS), the level of IL-8 released 
was only additive (Figure 20B). Indeed, it was not possible in this model to induce 
hypersensitivity of PBMC to LPS by pre-exposing them to C5a, as judged by the release of IL-8.  
The possibility that the observed enhanced IL-8 release from cells pre-exposed to LPS was due 
to the presence of residual LPS during the C5a stimulation phase, carried over from the TLR 
activation phase, was evaluated – although the levels of IL-8 at the end of the culture in the 
supernatants of cells pre-exposed to LPS and not activated with C5a were extremely low 
(Figure 20A). PBMC were pre-exposed (or not) to a deliberately high concentration of LPS (10 
ng/ml), then washed thoroughly, and cultured for 14h (no stimulation) in the presence and 
absence of polymyxin B – a cationic polypeptide that inactivates LPS by forming complexes 
with bacterial lipopolysaccharides [Jacobs and Morrison 1975, Morrison and Jacobs 1976]. 
Figure 20C shows that the levels of IL-8 released at the end of the culture following cell pre-
exposure to LPS was unaffected by the presence of polymyxin B, suggesting that residual LPS  
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Figure 20. Effect of cell activation by TLR on PBMC sensitivity to C5a. Human 
PBMC (1.5 x 106/ml) were (A) activated (14h) with LPS (100 pg/ml) before 
stimulation (14h) with C5a (20 nM),  (B) activated with C5a (20 nM) before 
stimulation with LPS (10 ng/ml), or (C) activated with LPS (10 ng/ml) before washing 
and culture (14h) in the absence or presence of polymyxin B (PMB, 10 μg/ml), 
before estimation of IL-8 levels in the  supernantants by ELISA. Inset in (C) shows a 
control experiment, the effect of PMB (10 μg/ml) on LPS (10 ng/ml, 14h)-induced 
IL-8 release by PBMC. Results are means (±SD) of triplicate cultures of one 
experiment from a single donor representative of more than 20 (A) and two (C and 
D). (*p<0.05, **p<0.01, LPS-pre-exposed cells vs. cells not pre-exposed; NS, not 
significant, PMB vs. no PMB) 
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was not present following pre-exposure and washing, even when a relatively high priming 
concentration of LPS was used. 
2.1.3 Hypersensitivity to C5a after activation of PBMC via different TLRs 
and other receptors 
In order to test whether or not the capacity of TLR activation to enhance cell sensitivity to C5a 
was limited to TLR4, PBMC were pre-exposed to ligands for a range of other TLRs (Figure 21A) 
and for non-TLR receptors (Figure 21B) before C5a activation, including: Pam3Cys-Ser-Lys4 
(TLR1/2), Zymosan (TLR2/6), poly I:C (TLR3), bacterial flagellin (TLR5), the antiviral compound 
imiquimod (TLR7/8), IL-1β (which utilises the MyD88-dependent signal transduction pathway, 
like TLR4), TNF-α and IL-6. In addition, the effect of non-receptor-mediated cell stimulation by 
phorbol 12-myristate 13-acetate (PMA) + ionomycin was also tested (Figure 21B). As seen in 
Figure 21A, cells pre-exposed to previously defined optimal concentrations of ligands for all 
TLRs tested except TLR3 showed variable degrees of hypersensitivity to C5a. Notably, and in 
contrast to the effects of ligands for other TLRs, pre-exposure to the TLR3 ligand poly I:C 
induced a marked reduction in cell sensitivity to C5a. Of the other stimuli tested, only IL-1β-
induced cell stimulation resulted in hypersensitivity to C5a (Figure 21B). 
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Figure 21. Effect of pre-exposure to a range of TLR and non-TLR ligands on PBMC 
sensitivity to C5a. (A) PBMC were pre-exposed or not (14h) to LPS (100 pg/ml), 
Pam3Cys (100 ng/ml), Zymosan (1 μg/ml), Flagellin (5 μg/ml), Imiquimod (3 μg/ml) or 
poly I:C (80 μg/ml), before washing and stimulation with C5a at the indicated 
concentrations. Mean (±SD) C5a-induced IL-8 concentrations were estimated by 
subtracting the background levels of IL-8 present in cultures not activated with C5a 
and pre-exposed or not to TLR ligands from the corresponding C5a-activated 
samples (IL-8 background levels (ng/ml): No ligand/No C5a, 1.67±0.7; LPS, 2.3±1.2; 
Pam3Cys, 1.5±0.6; Zymosan, 1.3±0.9; Flagellin, 6.9±2.5; Imiquimod, 5.3±1.1; poly I:C 
1.8±0.4). (*p<0.05, **p<0.01, *** p < 0.01 pre-exposed cells vs. not  pre-exposed). 
(B) Human PBMC (1.5 x 106/ml) were pre-exposed or not  (14h) to LPS (10 ng/ml), IL-
1β (5 ng/ml), TNF-α (10 ng/ml), IL-6 (10 ng/ml) or PMA/Ionomycin (50/500 ng/ml) 
before stimulation (14h) with C5a (20 nM). Mean (±SD) –fold increase in IL-8 release 
(primed cells compared with unprimed) is shown.  All results are from one 
experiment conducted in triplicate, representative of at least four for each ligand.
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2.1.4 Effect of TLR ligand and C5a concentration on hypersensitivity to C5a 
In order to investigate how sensitive human PBMC are to TLR-mediated modulation of 
responses to C5a, cells were pre-exposed to a wide range of LPS concentrations before 
washing and exposure to C5a. As Figure 22A shows, even LPS concentrations as low as 10 
pg/ml, a concentration well below those found systemically in sepsis patients (~100 pg/ml to 
~700 pg/ml) [Opal 1999], were able to induce a substantial enhancement (2-fold) of C5a-
induced IL-8 release.  
The response of cells to a wide range of C5a concentrations following TLR-mediated priming 
was also tested and compared with that of cells not primed. Notably, it was found that the C5a 
dose-response of cells pre-exposed and not pre-exposed to TLR ligands differed. Indeed, the 
C5a dose-response profile of PBMC that were stimulated with increasing concentrations of 
C5a without prior exposure to LPS exhibited a typical, saturable, dose-response relationship 
between the C5a concentrations and IL-8 release. However, when PBMC were pre-exposed to 
LPS before C5a stimulation, the C5a dose-response profile showed a peak of IL-8 release at 
relatively low stimulating concentrations of C5a (this concentration varied depending on the 
blood donor) followed by lower IL-8 levels that reached values lower than the plateau level 
seen in maximally-stimulated unprimed cells (Figure 22B). Cell viability in these experiments 
was assessed at the end of the culture period by trypan blue exclusion test and was found to 
be >95% in all conditions, with no significant differences between cells stimulated at higher 
and lower concentrations of C5a. 
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Figure 22. Effect of LPS and C5a concentration on TLR-induced 
hypersensitivity to C5a. (A) Human PBMC (1.5 x 105/well) were pre-
exposed or not (14h) to LPS at the indicated concentrations before 
washing and stimulation (14h) with C5a (20 nM). Mean (±SD) –fold 
increase in C5a-induced IL-8 release is shown. (B) PBMC were pre-
exposed or not (14h) to LPS (10 ng/ml) before stimulation (14h) with C5a 
at the indicated concentrations. Mean (±SD) C5a-induced IL-8 release is 
shown. Results in (A) and (B) are from one experiment, representative of 
three. (*p<0.05, **p<0.01, pre-exposed cells vs. not pre-exposed). 
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2.1.5 Effect of TLR activation on C5a-induced pro-inflammatory cytokine 
gene transcription 
It was next tested whether the positive modulatory effect of TLR activation on C5a-induced 
inflammatory responses affected gene transcription or only the release of the pro-
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inflammatory mediator. To this end, PBMC primed with LPS and subsequently activated with 
C5a were lysed at the end of the culture and mRNA levels for IL-8 as well as for IL-6 were 
analysed by RT-qPCR. Both IL-8 and IL-6 transcripts were found to be up-regulated in cells pre-
exposed to LPS and stimulated with C5a compared with cells only pre-exposed to LPS or only 
stimulated with C5a (Figure 23A), indicating that TLR-induced cell hypersensitivity to C5a not 
only affects the release but also the transcription of pro-inflammatory mediators. 
Furthermore, the effect of TLR activation was not restricted to IL-8, as transcription of another 
potent pro-inflammatory cytokine, IL-6, was similarly affected. Consistent with this latter 
finding, the C5a-induced release of IL-6 protein was found to be enhanced following PBMC 
pre-exposure to LPS (Figure 23B).  
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Figure 23. Effect of  cell pre-exposure to LPS on C5a-induced expression of IL-8 and IL-
6. (A) Human PBMC (1 x 106/condition) were pre-exposed or not (14h) to LPS (100 
ng/ml) before washing and stimulation (14h) with C5a (20 nM). Cells were lysed and 
relative levels of mRNA for IL-8 and IL-6 estimated by RT-qPCR. (B) IL-6 levels in the 
culture supernatant corresponding to the experiment in (A). Mean (±SD) levels of IL-8 
and IL-6 mRNA and IL-6 protein are shown from one experiment representative of 
three. (*p<0.05, *** p< 0.01 LPS pre-exposed cells vs. not  pre-exposed).
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To further study the effect of TLR activation on C5a-induced gene transcription, the effect of 
cell pre-exposure to LPS on the C5a-induced activation and nuclear translocation of the 
transcription factor NF-κB p65 (RelA) – a key regulator of immunoregulatory gene 
transcription – was investigated. Figure 24 shows that, similarly to the positive effect on IL-8 
and IL-6 production and release, pre-exposure to LPS resulted in levels of NF-κB in nuclear 
extracts of C5a-stimulated PBMC that were markedly higher than in cells not pre-exposed to 
LPS, suggesting that TLR modulation of cell sensitivity to C5a might affect a wide range of 
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inflammatory mediators. Addition of the NF-κB inhibitor pyrrolidine dithiocarbamate (PDTC) 
[Németh 2003] during the C5a stimulation phase abolished the enhancing effect of LPS on 
C5a-induced IL-8 release (Figure 24B). However, since NF-κB inhibition also abolished cytokine 
release induced by C5a alone, this strategy was not investigated further. 
Figure  24. NF-κB activation and LPS-induced hypersensitivity to C5a. (A) Mean 
(±SD) NF-κB concentrations in nuclear extracts of PBMC (1.5 x 105/well) pre-
exposed (14h) or not to LPS (10 ng/ml) before stimulation (14h) with 10 nM C5a. 
(B) Mean (± SD) IL-8 release from PBMC (1.5 x 105/well) upon stimulation with 
C5a in the presence and absence of the NF-κB inhibitor PDTC, after pre-
exposure (14h) or not to LPS (10 ng/ml). Results are from one experiment, 
representative of three. (* p<0.05).
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2.1.6 Modulation of blood cell sensitivity to C5a by TLR activation 
In order to evaluate the in vivo relevance of the positive modulatory effect of TLR activation on 
cell sensitivity to C5a, a minimally perturbed experimental model was used in which 
anticoagulated human whole blood was pre-exposed to LPS or whole heat-killed E. coli. 
Following washing, the blood cells were re-suspended in heat-inactivated autologous plasma 
and stimulated with varying concentrations of C5a. Pre-exposure of whole blood to LPS or 
whole bacteria resulted in a substantially higher sensitivity of blood cells to C5a stimulation 
(Figure 25A), suggesting that TLR modulation of C5a sensitivity in peripheral blood 
immunocompetent cells might occur during infections in vivo. 
The modulatory effect of TLR activation on blood cell sensitivity to C5a was investigated 
further in blood samples from a cohort of 15 healthy donors that were pre-exposed to a 
defined dose of LPS and stimulated with increasing concentrations of C5a (Figure 25B). 
Notably, the hypersensitivity to C5a of different donors varied widely, some donors exhibiting 
up to 60-fold increase in C5a-induced IL-8 release as a consequence of LPS pre-exposure, 
whereas others showed minimal or no augmentation. This indicated a marked intersubject 
variability in the capacity of TLR activation in different donors to amplify sensitivity to C5a. 
Furthermore, the shape of the C5a dose-response curve was variable, most donors showing a 
similar bell-shaped curve to that seen in PBMC (Figure 22B), with a peak hyperresponsiveness 
at relatively low stimulating concentrations of C5a and falling abruptly as the C5a 
concentration increased, while others – those showing a low capacity to augment C5a 
sensitivity in response to LPS priming – exhibited a sigmoid-like dose-response curve in which 
C5a hypersensitivity approached a plateau as the stimulating concentration of C5a increased 
(Figure 25B) . 
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Figure 25. Sensitivity to C5a of human whole blood pre-exposed to 
LPS or E. coli. (A) Mean (±SD) C5a-induced levels of IL-8 in blood cell 
culture supernatants following pre-exposure (14h) of heparinised whole 
blood (100 µl/well) to LPS (500 pg/ml) or whole heat-killed E. coli (1x108
cfu/ml). (B) -fold increase in C5a-induced IL-8 secretion from 
heparinised whole blood from 15 healthy donors as a result of pre-
exposure (14h) to LPS (500 pg/ml). Each line represents a single donor. 
Values in (A) are mean (±SD) of 3 independent experiments from a 
single donor representative of three, and in (B) are mean –fold increase 
of 3 experiments from each donor. (*p<0.05, ** p< 0.01, pre-exposed 
cells vs. not pre-exposed. )
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2.1.7 Effect of TLR activation on blood cell sensitivity to C5a in TLR4 
signalling-deficient mice 
In order to confirm that microbial-induced hypersensitivity to C5a strictly depended upon TLR 
activation, a murine model of LPS-induced peritonitis was designed to mimic the in vitro model 
of cell priming and stimulation (illustrated in Figure 39A, and discussed in section 5.2.2 below). 
Wild-type (WT) mice (C3H/HeN) and mice deficient in TLR4 signal transduction (C3H/HeJ) were 
inoculated with LPS or mock-inoculated (PBS only) by i.p. injection. After 1 h, the animals were 
sacrificed, blood was drawn, and following washing, the blood cells were re-suspended in 
culture medium and stimulated ex vivo with increasing concentrations of recombinant mouse 
C5a or mock-stimulated (medium alone). Following stimulation, the blood cell sensitivity to 
C5a of WT and TLR4-signalling deficient mice was compared by testing the cell culture 
supernatants for pro-inflammatory chemokine levels (Figure 26). 
The effect of pre-exposure to LPS on cell sensitivity to C5a observed in vitro in human PBMC 
and whole blood was reproduced in blood cells from WT mice. Indeed, blood cells from 
C3H/HeN animals pre-exposed to LPS in vivo responded to C5a with a greatly increased 
secretion of the prototypical neutrophil chemoattractant, keratinocyte-derived chemokine 
(KC, a murine functional counterpart of IL-8), and monocyte chemoattractant protein 1 
(MCP1), compared with mock-injected animals. However, while blood cells from the TLR4 
signalling-deficient mice (C3H/HeJ) retained the capacity to respond to C5a, they showed no 
capacity for augmentation of the chemokine response to C5a as a result of in vivo LPS pre-
exposure. 
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2.2 Study of the mechanism underlying TLR-induced cell 
hypersensitivity to C5a 
The findings presented above indicated that prior TLR activation was capable of positively 
modulating inflammatory responses of isolated PBMC and whole blood to C5a in a manner 
similar to that previously reported for concurrent activation through both TLR and C5a 
receptors. This positive modulation, which appeared to be TLR-, MyD88- and NFκB-dependent, 
raised the question of its exact underlying mechanism. This was investigated next. 
2.2.1 Duration of pre-exposure to a TLR ligand and cell hypersensitivity to 
C5a 
In order to evaluate the impact that the duration of the pre-exposure phase had on TLR-
induced cell hypersensitivity to C5a, PBMC were pre-exposed to LPS for different times 
between 30 min and 14h before washing and activation with C5a as described above. As 
shown in Figure 27, even a brief pre-exposure (30 min) to a low concentration of LPS (100 
pg/ml) was sufficient to induce maximal hypersensitivity to C5a, suggesting that the 
mechanism underlying the TLR modulatory effect is relatively rapid. 
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Figure 27. Effect of duration of cell pre-exposure to LPS on hypersensitivity to C5a. -
Fold increase in C5a-induced levels of IL-8 released by PBMC (1.5 x 105/well) as a result of 
pre-exposure to LPS (100 pg/ml) for the indicated times (starting from 30 min), and 
subsequently activated (14h) with C5a (10 nM). Values shown are mean (±SD) of one 
experiment representative of 3. (*p<0.05, *** p< 0.005, LPS-treated cells vs. untreated. 
 
2.2.2 TLR activation and cell-surface expression of C5aR 
TLR-induced up-regulation of the cell-surface receptor for C5a (C5aR) might be a mechanism 
by which TLR activation resulted in increased sensitivity to C5a. In order to investigate this 
possibility, PBMC and whole blood were pre-exposed or not to LPS for 30 min before washing 
and stimulation with C5a for different intervals up to 12h. At each time point, C5aR expression 
on gated monocytes (PBMC) and neutrophils (whole blood) was estimated by flow cytometry 
(Figure 28A and B; representative examples of the fluorescence histograms are shown in the 
Appendix, Figure 46). C5aR expression on both monocytes and neutrophils was found not to 
be up-regulated after 30 min pre-exposure to LPS; in fact LPS pre-exposure resulted in >50% 
decrease in both monocyte and neutrophil C5aR expression, which was sustained over the 
following 12h in the absence of further stimulation with C5a. Stimulation of LPS-primed cells 
with C5a induced a further decrease in C5aR expression, followed by a partial recovery over 
time in monocytes but not neutrophils. This effect of C5a stimulation was also seen in 
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unprimed cells, and likely reflects ligand-dependent internalisation and recycling of C5aR back 
to the cell surface, as previously reported [Scola 2009]. Estimation of IL-8 levels in the culture 
supernatants confirmed TLR-induced hypersensitivity to C5a in PBMC from the same donors, 
subjected to the same experimental conditions (Figure 28A, inset). 
mRNA extracted from samples of PBMC taken at the end of the experiment shown in Figure 
28A was analysed by RT-qPCR for C5aR expression. Consistent with the LPS-induced down-
modulation of C5aR cell-surface expression described above, LPS-primed cells were found to 
express lower levels of mRNA for C5aR than unprimed cells, irrespective of C5a stimulation 
(Figure 28C). Together, these findings indicated that TLR-induced hypersensitivity to C5a was 
not due to C5aR up-regulation, and indeed occurred in spite of a marked TLR-induced down-
regulation of C5aR expression.  
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2.2.3 TLR activation and C5a-induced Ca2+ mobilisation 
C5aR G protein-dependent signal transduction is known to involve cytoplasmic Ca2+ 
mobilisation [Johswich 2006]. Therefore, in order to assess the possible involvement of Ca2+-
dependent signalling in the LPS-induced hypersensitivity to C5a, C5a-induced intracellular Ca2+ 
flux was estimated in PBMC pre-exposed or not to LPS for 3 min, 30 min and 14 h. As shown in 
Figure 29, pre-exposure of PBMC to LPS for any of the indicated periods of time did not induce 
any change in the kinetics (amplitude or duration) of C5a-induced Ca2+ mobilisation. This 
suggested that TLR-induced modulation of cell sensitivity to C5a either operates by affecting a 
G protein-dependent signal transduction pathway separate from Ca2+ signalling or a G protein-
independent pathway used by C5aR.  
 
131 
 
 3 min No LPS/ + C5a 
+ LPS / + C5a 
+LPS
30 min
0.0
0.5
1.0
1.5
2.0
2.5
0 50 100 150 200
N
o
rm
a
li
s
e
d
[C
a
 2
+
] i
14 h 
0 50 100 150 200
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
0 50 100 150 200
Time (s)
0.0
0.5
1.0
1.5
2.0
2.5
3.0
Figure 29. Effect of TLR activation on C5a-induced Ca2+ flux.
C5a (10 nM)-induced changes in monocyte cell fluorescence over 180 s 
as a measure of intracellular Ca2+ mobilisation, detected by flow 
cytometry following exposure of PBMC (1 x 106 per condition) to LPS 
(100 pg/ml) or culture medium alone (No LPS) for the indicated times 
and staining with the Ca2+-chelating fluorescent dye, Fluo-3-AM. 
Background fluorescence was determined before addition of C5a (time 
0) in cells pre-exposed or not to LPS.  Results are expressed as 
normalised [Ca2+]i, the ratio between the mean fluorescence intensity at 
time t after C5a addition and that observed at time 0. One experiment 
representative of four is shown; representative examples of 
fluorescence histograms used to generate the data are shown in Figure 
47 (Appendix).
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2.2.4 TLR activation and C5a-induced HMGB1 mobilisation 
Seven transmembrane receptors, like those for C5a, also signal through a G-protein-
independent pathway that involves the activity of β-arrestins, multifunctional adaptor proteins 
that mediate signalling and also control receptor desensitization and trafficking [Bamberg 
2010 and Lefkowitz 2004]. Notably, C5aR signalling through the β-arrestin pathway was 
reported to be negatively modulated by the second C5a receptor, C5L2, a G protein-uncoupled 
receptor [Bamberg 2010]. Thus, in order to evaluate the possibility that a C5a-triggered G-
protein-independent signalling event was the target of TLR modulation, it was tested whether 
TLR-induced hypersensitivity to C5a involved an effect on C5L2. As discussed in section 1.4 
above, C5L2 (but not C5aR) has been reported to mediate the cytoplasmic mobilisation and 
secretion of the nuclear protein HMGB1 in response to stimulation with C5a via a G protein-
independent signal transduction pathway [Rittirsch 2008]. Therefore, the effect of TLR 
activation on C5L2 activity was investigated by estimation of C5a-induced HMGB1 
mobilisation. To this end, PBMC were pre-exposed (or not) to LPS and activated with C5a as 
described above. Cytoplasmic cell extracts were then tested by Western blotting for HMGB1 
levels. Figure 30A shows that cell stimulation by C5a resulted in cytoplasmic mobilisation of 
HMGB1. However, when cells were pre-exposed to LPS before C5a stimulation, C5a-induced 
HMGB1 mobilisation was reduced, suggesting that TLR activation negatively affected C5L2 
activity. This finding was in contrast to the positive effect of TLR activation on C5a-induced IL-8 
secretion previously demonstrated (section 2.1.) and confirmed here, as the C5a-induced IL-8 
levels in the PBMC culture supernatants from this experiment were substantially higher in LPS-
primed compared with unprimed cells (Figure 30B).  
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Figure 30. Effect of TLR activation on C5a-induced HMGB1 mobilisation.
(A) Western blot analysis and densitometric scanning of HMGB1 levels in 
cytoplasmic cell extracts of PBMC (0.5 x 106 per condition) pre-exposed 
(14h) or not to LPS (100 pg/ml) and subsequently stimulated (or not) with 
C5a (10 nM). (B) Mean (±SD) IL-8 levels in cell culture supernatants of the 
experiment shown in (A). Results are of one experiment representative of 
five. (**p<0.01).
N
o 
L
PS
 / 
N
o 
C
5a
25 kDa
N
o 
L
PS
 / 
+ 
 C
5a
+ 
 L
PS
 / 
N
o 
C
5a
+ 
 L
PS
 / 
+ 
C
5a
HMGB1
A
H
M
G
B
1
(D
e
n
si
to
m
et
ry
 u
n
it
s)
0
50
100
150
200
IL
-8
 (
n
g
/m
l)
0
5
10
15
20
25
**
No LPS/+C5a
No LPS/ No C5a
No LPS/ + C5a
+ LPS/ No C5a
+ LPS/ + C5a
+LPS/+C5a
B
 
 
134 
 
Consistent findings were observed when WT and TLR4 signalling-deficient mice were 
challenged with LPS in vivo. Their blood cells were subsequently stimulated with C5a ex vivo 
and the culture supernatants analysed by Western blot for HMGB1 (Figure 31A). Blood cells 
from WT mice responded to C5a stimulation with release of HMGB1 into the culture 
supernatant (Figure 31A, WT, No LPS/+C5a). WT mice first inoculated with LPS before ex vivo 
cell stimulation with C5a showed greatly reduced levels of HMGB1 released (Fig 31A, WT, 
+LPS/+C5a). Notably, this LPS-induced inhibition of C5a-induced HMGB1 release was not 
observed in the TLR4 signalling-deficient mice (Figure 31A, C3H/HeJ mice, +LPS/+C5a 
compared with No LPS/+C5a). The negative effect on (WT) mouse blood cell HMGB1 release, 
like that observed in human PBMC, contrasted with the positive (inverse) effect on chemokine 
release by these cells (Figure 31B), and further supported the concept that TLR activation 
negatively affects C5L2 activity. Given that C5L2 has been reported to act as a negative 
regulator of C5aR, these findings raised the possibility that TLR-induced inhibition of C5L2 
might be implicated in the enhancement of C5a-induced cytokine release. 
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Figure 31. Effect of TLR activation in vivo on C5a-induced release of HMGB1 
by mouse blood cells ex vivo. (A) Western blot and densitometric analysis of 
C5a (60 nM)-induced HMGB1 levels in culture supernatants of whole blood 
(100 μl/well) from wild-type (C3H/HeN) and TLR4 signalling-deficient (C3H/HeJ) 
mice (n= 5/condition) challenged (1h) i.p. with LPS (50 μg/mouse) or PBS (No 
LPS). Pooled supernatant from 5 animals was used in each experimental 
condition. (B) Mean (±SEM) chemokine levels  in supernatants  corresponding 
to the experiment described in (A), reproduced from Figure 26. (*p<0.05, 
**p<0.01, ***p<0.005 LPS-treated mice vs. untreated. Chemokine
concentrations shown are after background subtraction).
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2.2.5 TLR and C5a effect on C5L2 activity and expression 
If the second C5a receptor, C5L2, were the target of TLR modulation, it might be expected that 
inhibition or blockade of C5L2 would reproduce the contrasting effects of TLR activation on 
both HMGB1 (negative) and IL-8 (positive) described above. To test this possibility, PBMC were 
stimulated with C5a in the presence and absence of a C5L2-specific mAb previously shown to 
be able to prevent C5L2 ligation by C5a [Bamberg 2010]. The cytoplasmic cell extracts and 
culture supernatants were tested for HMGB1 and IL-8 levels, respectively. As shown in Figure 
32, PBMC stimulated with C5a alone showed a strong cytoplasmic HMGB1 band (Figure 32A) 
and a very modest increase in IL-8 release (Figure 32B). However, PBMC stimulated with C5a in 
the presence of the C5L2 blocking Ab showed a marked reduction in C5a-induced HMGB1 
levels (Figure 32A), but a substantial increase in IL-8 release (Figure 32B). Since the presence of 
even trace amounts of a heat-stable TLR ligand such as LPS can induce a similar effect on IL-8 
to that shown here by using the anti-C5L2 mAb, in control experiments the antibody was 
denatured by boiling for 30 min before addition to the culture. The denatured antibody lost 
the capacity both to inhibit C5a-induced HMGB1 release and to enhance IL-8 secretion (Figure 
32, A and B), confirming its genuine effect. Thus, the effect of C5L2 blockade was similar to 
that of cell pre-exposure to a TLR ligand, suggesting that the positive effect of TLR activation 
on C5a-induced responses may involve inhibition of C5L2.  
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In order to further test whether TLR-induced hyperresponsiveness to C5a involved inhibition 
of C5L2, the effect of cell pre-exposure to LPS on C5L2 protein expression was next examined 
(Figure 33). PBMC were stimulated with C5a after pre-exposure to LPS. At the end of the 
culture period, the cells were lysed and the expression levels of C5L2 in the cell lysates were 
estimated by Western blot. Pre-exposure to LPS did not result in any change in the expression 
of C5L2 at the end of the culture period in cells that were not subsequently stimulated with 
C5a (Figure 33, left panel, +LPS/No C5a). However, whilst stimulation of cells with C5a without 
prior exposure to LPS resulted in a slight increase in C5L2 expression (Figure 33, left panel, No 
LPS/+C5a), cells stimulated with C5a after LPS priming (Figure 33, left panel, +LPS/+C5a) 
showed a strong LPS dose-dependent reduction in C5L2 expression. This finding indicated that 
TLR activation negatively modulates C5L2 activity, at least in part, by reducing C5L2 
expression. It is noteworthy, however, that this inhibitory effect of LPS occurred only upon 
subsequent C5a stimulation.  
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Figure 33. Effect of TLR activation on C5L2 expression. Western blot and densitometric
analyses of C5L2 levels in cell lysates of PBMC (0.5 x 106) pre-exposed (14h) or not to 
the indicated concentrations of LPS and subsequently activated (14h) with C5a (10 nM). 
Data shown are from one experiment representative of four.
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2.2.6 TLR activation and sensitivity to C5a in C5L2-deficient mice 
In order to test further the involvement of C5L2 in the positive effect of TLR activation on cell 
sensitivity to C5a, a comparative analysis of the effect of in vivo pre-exposure to LPS on C5a-
induced cytokine secretion by blood cells from WT and C5L2-deficient mice was conducted 
following challenge (i.p.) of mice for 1h with LPS (Figure 34). The C5a-induced release of KC 
was extremely low in both WT and C5L2-deficient mice that had not been challenged with LPS. 
Notably, pre-exposure to LPS resulted in a significant increase in cell sensitivity to C5a in WT 
but not in C5L2-deficient mice at all C5a concentrations tested. This finding further confirmed 
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the involvement of C5L2 in the modulatory effect of TLRs on C5a-mediated pro-inflammatory 
responses.  
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Figure 34. Ex vivo sensitivity to C5a of C5L2-deficient and wild-type 
mice. Mean (±SEM) C5a-induced levels of KC in blood cell (100 µl/well) 
culture supernatants following in vivo i.p. challenge (1h) of C5L2-deficient 
and WT mice (n=5 mice/condition) with LPS (50 μg/mouse) or PBS (no 
LPS). Chemokine concentrations shown are after background subtraction, 
as indicated in Figure 21. Values are expressed as the mean (±SEM) (n= 5 
mice/condition. (*p<0.05, *** p< 0.005, LPS-treated vs. untreated.) 
 
2.3 The effect of LPS and C5a on the transcription of genes 
involved in MAPK and NF-κB activation 
It appeared that TLR activation induced cell hypersensitivity to C5a by inhibiting the C5a-
induced expression of C5L2, which itself can exert a negative regulatory effect on C5aR-
mediated pro-inflammatory responses. However, it was not clear by what mechanism TLR 
activation was able to affect C5L2 expression. Addressing this question has the added difficulty 
that it is also not clear how C5aR activity positively affects C5L2 expression, nor how C5L2 is 
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able to modulate C5aR-mediated signals. In an attempt to further investigate the mechanism 
underlying the effect of TLR activation on C5L2, a gene expression profiling strategy was used 
to identify candidate proteins for further investigation. Since TLR- and C5a receptor (C5aR and 
C5L2)-induced cytokine expression is known to involve activation of both MAPK and NF-κB 
signalling pathways (discussed in section 1.5), the mRNA expression levels of a panel of 176 
genes known to be involved in MAPK and NF-κB signalling (see detailed list in Tables 10A and 
B, Appendix) were screened by RT-qPCR.  
The relative expression levels of mRNAs in PBMC were quantified in each of the three 
experimental conditions used in this study to evaluate the effect of TLRs on C5aR-mediated 
responses (cells not pre-exposed to LPS and subsequently stimulated with C5a, cells pre-
exposed to LPS and not stimulated with C5a, and cells pre-exposed to LPS and stimulated with 
C5a) by comparison with control cells (not pre-exposed and not stimulated with C5a). Genes 
that showed a less than 2-fold negative or positive change relative to control cells (i.e. relative 
expression from 0.51 to 1.99) were considered to be unaffected. Genes whose transcription 
was found affected by any of the three experimental conditions are listed in Tables 5A – G 
below. Positive changes (relative expression ≥ 2.00) in gene transcription are shown in green 
and negative changes (relative expression ≤ 0.50) in red.  
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Table 5A. Genes encoding pattern recognition receptors* 
Gene 
Symbol**  
Description No LPS 
+C5a 
+LPS      
No C5a 
+LPS       
+C5a 
NOD1 Nucleotide-binding 
oligomerization domain 
containing 1 
0.53 0.32 0.11 
TLR1 Toll-like receptor 1 1.06 0.45 0.52 
TLR2 Toll-like receptor 2 0.41 3.49 0.69 
TLR4 Toll-like receptor 4 0.75 0.18 0.24 
*Expression levels in each experimental condition relative to the control condition No LPS/No C5a are shown. Red font indicates a 
greater than two-fold reduction, and green font a greater than two-fold increase in mRNA expression relative to unstimulated 
cells. 
**HUGO Database Gene Nomenclature. 
 
 
 
Table 5B. Genes encoding TLR signal transduction intermediates* 
Gene 
Symbol** 
Description No LPS 
+C5a 
+LPS      
No C5a 
+LPS      
+C5a 
IRAK1 Interleukin-1 receptor-associated 
kinase 1 
15.17 12.50 1.67 
IRAK2 Interleukin-1 receptor-associated 
kinase 2 
7.64 1.07 5.47 
TBK1 TANK-binding kinase 1 2.58 1.02 2.06 
TICAM1 Toll-like receptor adaptor molecule 1 
(TRIF) 
8.22 0.77 5.86 
TICAM2 Toll-like receptor adaptor molecule 2 
(TRAM) 
1.42 0.17 0.19 
TRAF3 TNF receptor-associated factor 3 0.93 0.53 0.28 
TRAF6 TNF receptor-associated factor 6 0.51 0.34 0.06 
*Expression levels in each experimental condition relative to the control condition No LPS/No C5a are shown. Red font indicates a 
greater than two-fold reduction, and green font a greater than two-fold increase in mRNA expression relative to unstimulated 
cells. 
**HUGO Database Gene Nomenclature. 
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Table 5C. Genes encoding MAPK signal transduction intermediates* 
Gene 
Symbol** 
Description No LPS 
+C5a 
 +LPS      
No C5a 
+LPS   
+C5a 
ARRB1 Beta-arrestin 1 12.84 0.44 0.71 
MAP3K1 Mitogen-activated protein kinase 
kinase  kinase 1, MEKK1 
0.39 0.17 0.44 
MAPK10 Mitogen-activated protein kinase 10 
(JNK3) 
0.48 0.30 1.34 
MAPK11 Mitogen-activated protein kinase 11 
(p38β) 
0.93 2.01 1.97 
MAPK12 Mitogen-activated protein kinase 12 
(p38γ) 
0.55 0.47 0.42 
MOS V-mos Moloney murine sarcoma 
viral oncogene homolog 
1.10 1.15 2.14 
PAK1 P21 protein (Cdc42/Rac)-activated 
kinase 1 
0.69 0.59 0.45 
RAF1 V-raf-1 murine leukemia viral 
oncogene homolog 1 
4.38 2.07 3.04 
RHOA Ras homolog gene family, member A 1.18 0.50 1.16 
*Expression levels in each experimental condition relative to the control condition No LPS/No C5a are shown. Red font indicates a 
greater than two-fold reduction, and green font a greater than two-fold increase in mRNA expression relative to unstimulated 
cells. 
**HUGO Database Gene Nomenclature. 
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Table 5D. Genes encoding NF-κB pathway signal transduction intermediates* 
Gene 
Symbol** 
Description No LPS 
+C5a 
+LPS     
No C5a 
+LPS    
+C5a 
IKBKB Inhibitor of kappa light 
polypeptide gene enhancer in 
B-cells, kinase beta (IκB kinase 
β) 
0.67 0.56 0.30 
IKBKE Inhibitor of kappa light 
polypeptide gene enhancer in 
B-cells, kinase epsilon (IκB 
kinase ε) 
1.72 0.21 0.94 
IKBKG Inhibitor of kappa light 
polypeptide gene enhancer in 
B-cells, kinase gamma (IκB 
kinase γ) 
0.69 0.59 0.25 
NFKB2 Nuclear factor of kappa light 
polypeptide gene enhancer in 
B-cells 2 (NF-κB p52/p100) 
1.22 0.47 0.45 
NFKBIA Nuclear factor of kappa light 
polypeptide gene enhancer in 
B-cells inhibitor, alpha (IκBα) 
1.09 0.65 0.45 
NFKBIB Nuclear factor of kappa light 
polypeptide gene enhancer in 
B-cells inhibitor, beta (IκBβ) 
0.57 0.55 0.12 
NFKBIE Nuclear factor of kappa light 
polypeptide gene enhancer in 
B-cells inhibitor, epsilon (IκBε) 
2.19 0.71 1.18 
REL V-rel reticuloendotheliosis viral 
oncogene homolog (C-Rel) 
0.30 0.98 0.84 
RELA V-rel reticuloendotheliosis viral 
oncogene homolog A (Rel-A, 
NF-κB p65) 
1.02 0.39 0.28 
*Expression levels in each experimental condition relative to the control condition No LPS/No C5a are shown. Red font indicates a 
greater than two-fold reduction, and green font a greater than two-fold increase in mRNA expression relative to unstimulated 
cells. 
**HUGO Database Gene Nomenclature. 
145 
 
 
Table 5E. Genes encoding transcription factors* 
Gene 
Symbol** 
Description No LPS 
+C5a 
+LPS      
No C5a 
+LPS     
+C5a 
ATF1 Activating transcription factor 1 0.79 1.18 0.37 
STAT1 Signal transducer and activator of 
transcription 1, 91kDa 
1.62 0.81 0.47 
ELK1 ELK1, member of ETS oncogene 
family 
0.25 1.02 0.73 
IRF1 Interferon regulatory factor 1 0.56 0.59 0.20 
JUN Jun proto-oncogene, c-Jun 3.29 1.75 0.93 
FOS FBJ murine osteosarcoma viral 
oncogene homolog, c-Fos 
0.79 0.40 0.36 
MEF2C Myocyte enhancer factor 2C 1.14 1.21 3.69 
*Expression levels in each experimental condition relative to the control condition No LPS/No C5a are shown. Red font indicates a 
greater than two-fold reduction, and green font a greater than two-fold increase in mRNA expression relative to unstimulated 
cells. 
**HUGO Database Gene Nomenclature. 
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Table 5F. Genes encoding cytokines* 
Gene 
Symbol** 
Description No LPS 
+C5a 
+LPS        
No C5a 
+LPS    
+C5a 
CCL2 Chemokine (C-C motif) ligand 2 6.46 5.52 14.74 
CSF1 Colony stimulating factor 1 
(macrophage) 
0.26 0.73 0.28 
CSF2 Colony stimulating factor 2 
(granulocyte-macrophage) 
2.44 5.17 4.27 
CSF3 Colony stimulating factor 3 
(granulocyte) 
1.28 0.32 3.58 
IFNG Interferon, gamma 0.18 0.18 0.53 
IL10 Interleukin 10 2.77 2.09 4.27 
IL1A Interleukin 1, alpha 1.07 35.91 118.20 
IL1B Interleukin 1, beta 3.22 61.61 64.30 
IL8 Interleukin 8 2.61 7.41 8.54 
LTA Lymphotoxin alpha (TNF 
superfamily, member 1) 
0.81 0.58 3.67 
TNF Tumor necrosis factor alpha 1.69 0.61 0.37 
TNFSF14 Tumor necrosis factor (ligand) 
superfamily, member 14 
0.36 1.68 1.86 
*Expression levels in each experimental condition relative to the control condition No LPS/No C5a are shown. Red font indicates a 
greater than two-fold reduction, and green font a greater than two-fold increase in mRNA expression relative to unstimulated 
cells. 
**HUGO Database Gene Nomenclature. 
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Table 5G. Genes encoding proteins related to control of cell cycle and apoptosis* 
Gene 
Symbol** 
Description No LPS   
+C5a 
+LPS      
No C5a 
+LPS 
+C5a 
CCNA1 Cyclin A1 1.01 1.89 3.03 
RIPK1 Receptor (TNFRSF)-interacting 
serine-threonine kinase 1 
0.23 0.39 0.72 
TNFRSF1A Tumor necrosis factor receptor 
superfamily, member 1A 
0.75 0.41 0.50 
BIRC2 Baculoviral IAP repeat containing 
2 
1.24 0.15 0.43 
BIRC3 Baculoviral IAP repeat containing 
3 
1.12 0.81 0.51 
CARD11 Caspase recruitment domain 
family, member 11 
0.34 0.34 0.23 
CFLAR CASP8 and FADD-like apoptosis 
regulator 
0.72 0.87 0.33 
CASP8 Caspase 8, apoptosis-related 
cysteine peptidase 
0.92 0.75 0.35 
BCL3 B-Cell Lymphoma Protein 3 0.93 0.33 0.25 
BCL2L1 B-Cell Lymphoma 2-like 1 0.98 0.62 0.24 
BCL2A1 BCL2-related protein A1 4.02 3.08 4.79 
LTBR Lymphotoxin beta receptor (TNFR 
superfamily, member 3) 
0.76 0.48 0.13 
CD40 CD40 molecule, TNF receptor 
superfamily member 5 
1.67 0.11 0.11 
TNFSF10 Tumor necrosis factor (ligand) 
superfamily, member 10 
0.65 0.56 0.14 
TNFRSF10A Tumor necrosis factor receptor 
superfamily, member 10a 
1.35 0.10 0.11 
TNFRSF10B Tumor necrosis factor receptor 
superfamily, member 10b 
0.76 0.78 0.16 
TNFAIP3 Tumor necrosis factor, alpha-
induced protein 3 
1.90 1.10 0.77 
FADD Fas (TNFRSF6)-associated via 
death domain 
1.07 7.80 1.23 
FASLG Fas ligand (TNF (ligand) 
superfamily, member 6) 
0.53 0.81 0.10 
*Expression levels in each experimental condition relative to the control condition No LPS/No C5a are shown. Red font indicates a 
greater than two-fold reduction, and green font a greater than two-fold increase in mRNA expression relative to unstimulated 
cells. 
**HUGO Database Gene Nomenclature. 
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Through the use of a gene array screening strategy it was possible to identify many gene 
transcripts that were affected by the different experimental conditions used. Many of them 
code for key signal transduction intermediates involved in inflammatory responses and thus 
would be worthy candidates for further study. However, given the impossibility of 
investigating all of them, β-arrestin 1 (Table 5C) was initially singled out for further 
examination for the following reasons: 1) β-arrestins are known to be involved in G-protein-
independent GPCR signal transduction, and C5aR, like other GPCRs, is capable of signalling 
through a G-protein-independent pathway that involves β-arrestins [Bamberg 2010, Lefkowitz 
2004, Rajagopal 2010]; 2) this pathway was reported to be negatively modulated by C5L2 
[Bamberg 2010]; 3) the finding that TLRs exert positive modulation of cell sensitivity to C5a 
without affecting Ca2+ mobilisation (section 2.2.3) suggested that a G protein-independent 
signalling pathway was involved in the TLR effect; 4) β-arrestin 1 has been shown to couple to 
C5L2 in a C5a-dependent manner with a resulting inhibition of ERK-1 phosphorylation 
[Bamberg 2010]; 5) ERK1/2 phosphorylation is known to be critical in the transduction of 
C5aR-mediated pro-inflammatory signals (see section 1.3.4.1 d. above) Thus, it appears that β-
arrestin 1 is involved not only in G-protein-independent C5aR signalling – which may result in 
up-modulation of C5L2 – but also in the C5L2-dependent constitutive negative regulation of 
C5aR-mediated pro-inflammatory signals [Bamberg 2010]. These findings raised the possibility 
that TLR-mediated inhibition of C5L2 expression activity may involve a negative effect on β-
arrestin 1. 
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2.4 A Role for β-arrestin 1 in the TLR-C5a receptor crosstalk 
 
In order to investigate a possible role for β-arrestin 1 in the TLR-C5L2-C5aR interaction, PBMC 
were primed or not with LPS and subsequently activated (or not) with C5a. After 4h of C5a 
activation, the cells were lysed and β-arrestin 1 mRNA expression estimated by RT-qPCR 
analysis using home-made primers, in order to confirm the findings by the gene arrays 
method. C5a enhanced, and cell pre-exposure to LPS inhibited β-arrestin 1 mRNA expression 
(Figure 35A); the effect of LPS was predominant, resulting in complete abolition of the C5a 
effect. These results were qualitatively similar to those previously observed (Table 5C). 
Changes in β-arrestin 1 protein expression correlated with those in mRNA (Figure 35B). 
Western blot analysis of PBMC lysates following 14h stimulation with C5a showed an increase 
in β-arrestin 1, whereas cell pre-exposure to LPS before C5a stimulation reduced β-arrestin 1 
to levels below those observed in unstimulated cells. As was observed at mRNA level, the 
effect of LPS was predominant, abolishing the C5a-induced enhancement of β-arrestin 1 
protein expression. 
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Figure 35. Effect of TLR activation on β-arrestin 1 expression in PBMC. (A) Mean 
(±SD) –fold change in β-arrestin 1 mRNA expression in PBMC pre-exposed  (14h) or 
not to LPS (500 pg/ml) before being stimulated (4h) or not with C5a (1nM). (B)
Western blot and densitometric analysis of β arrestin-1 expression in PBMC (0.5 x 
106) pre-exposed or not (14h) to LPS (500 pg/ml) and subsequently activated (14h) 
with C5a (1 nM). Data shown are from one experiment representative of three.
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2.5 The physiological relevance of TLR-induced hypersensitivity 
to C5a. 
The TLR-based cell priming model for testing cell sensitivity to C5a may not accurately reflect 
the sequence of events during infections in vivo. Rather, it was developed in order to address a 
specific question, namely that of whether an effect of TLR activation on C5aR-mediated 
inflammatory responses might contribute to the synergistic enhancement of cytokine release 
observed when cells were concurrently stimulated with both ligands, in which context the 
pathophysiological relevance of the model was not a primary concern. However, the fact that 
priming cells with a TLR ligand followed by C5a stimulation reproduced the effects of 
concurrently stimulating cells with both ligands tended to validate the experimental model 
used here. 
In an attempt to investigate further the possible in vivo relevance of TLR-induced 
hypersensitivity to C5a in human subjects undergoing clinically significant infections, the in 
vivo/ex vivo model of TLR-mediated cell priming applied to mice in this study was extended to 
a cohort of patients with severe sepsis or septic shock (n=19) who presented to the intensive 
care unit (ICU) within 36 hours of the presumed onset of the infective insult (Table 8, section 
5.2 below). It was anticipated that circulating leucocytes from these patients would have been 
exposed to a range of TLR ligands as a consequence of their infections, and thus would have 
been ‘primed’ for increased responsiveness to C5a. Anticoagulated blood was taken from 
patients on admission, and blood cells were washed and re-suspended in complete medium. 
The blood cells were then stimulated overnight with a range of concentrations of C5a before 
testing for IL-8 in the culture supernatants. Since it was not possible to test the ex vivo 
‘unprimed’ cytokine response to C5a (the response of cells to C5a without preceding TLR 
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activation) in a pre-morbid sample from the same patients, the IL-8 response to C5a in blood 
taken from a cohort of healthy control donors (n=15) was used for comparison. 
As can be seen in Figure 36A, and contrary to expectations, blood cells from the sepsis donors 
showed a uniformly reduced sensitivity to C5a compared with healthy controls. Furthermore, 
and also contrary to expectations, the basal IL-8 secretion by blood cells from sepsis patients 
not stimulated with C5a was no higher than that of blood from healthy control donors. Since it 
was inconceivable that the blood cells of patients with documented severe sepsis had not 
been exposed to TLR ligands during the course of their infection, the possibility was 
considered that the ability of the patients’ leucocytes to mount a cytokine response was 
impaired. Indeed, sepsis-induced immunosuppression is a well-recognised phenomenon, and 
is characterised by lymphocyte apoptosis, neutrophil anergy, and by failure of monocytes to 
mount an appropriate cytokine response to inflammatory stimuli [Lendemans 2003, Opal 
2010]. Therefore, in order to address this issue, the sensitivity of whole blood from the 19 
sepsis patients shown in Figure 36A and healthy controls (n=15) to a range of TLR ligands and 
whole heat-killed bacteria was also tested. As shown in Figure 36B, the IL-8 response to TLR 
ligands and bacteria was also reduced in blood from sepsis patients compared with that of 
healthy control donors, indicating a global impairment of cytokine responses, which is 
characteristic of sepsis-induced immunosuppression.  
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Figure 36. Ex vivo sensitivity to C5a and TLR ligands of whole blood from sepsis 
patients. (A) Mean (±SD) C5a-induced levels of IL-8 in blood cell (100 µl/well) 
culture supernatants from sepsis patients (n=19) and healthy control subjects 
(n=15) following ex vivo stimulation with C5a at the indicated concentrations. (B) 
Mean (±SD) IL-8 levels in culture supernatants in response to ex vivo stimulation 
of blood cells from the sepsis patients and controls described in (A) with TLR 
ligands LPS (1 ng/ml), Pam3Cys (10 ng/ml) and whole heat-killed E. coli (2 x 10
4
cfu/ml) or L. monocytogenes (4 x 105 cfu/ml). (*p<0.05, *p<0.01 *** p< 0.005, 
healthy controls  vs. sepsis patients.)
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2.6 Intersubject variation in TLR-induced hypersensitivity to C5a 
and C5a receptor expression. 
It is possible that the varying capacity of individuals to augment their cytokine response to C5a 
as a result of cell pre-exposure to TLR ligands (Figures 22B and 25B) is related to the activity of 
C5L2. The intersubject variability in LPS-induced hypersensitivity shown here might reflect 
variations in the constitutive expression level of C5L2 and the extent to which LPS pre-
exposure (indirectly) induces its down-regulation. A preliminary flow cytometric analysis of 
monocyte C5a receptor expression in two of the human donors shown in Figure 25B is 
consistent with this hypothesis (Figure 37). Blood cells from Donor A showed a comparatively 
strong response to LPS pre-exposure, showing up to ~10-fold enhancement in C5a-induced IL-
8 secretion, whereas Donor B showed a much more limited response to LPS pre-exposure, 
suggesting a high C5L2 activity (Figure 37A). Both C5aR and C5L2 were expressed at higher 
levels in Donor B (the ‘TLR low responder’) than in Donor A (the ‘high responder’; Figure 37B 
and C). However, while the low responder exhibited higher absolute levels of C5L2 than the 
high responder, the ratio of C5L2 to C5aR was lower (0.41) in the low responder than in the 
high responder (0.63).  
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Figure 37. Intersubject variations in TLR-induced hypersensitivity to C5a and 
monocyte C5aR and C5L2 expression and activity. (A) Mean (±SD) -fold increase in 
C5a-induced IL-8 levels in cell culture supernatants as a consequence of LPS (500 
pg/ml) pre-exposure (14h) of whole blood (100 μl/well) from individuals with high 
(Donor A) and low (Donor B) capacity for LPS-induced hypersensitivity to the indicated 
concentrations of C5a. (B) and (C) C5aR and C5L2 expression estimated by flow 
cytometry on gated monocytes in unstimulated blood from the two donors shown in 
(A). Mean (±SD) –fold increases in IL-8 from 3 independent experiments are shown in 
(A), and (B) shows receptor expression (MFI) of C5aR and C5L2 from one experiment 
representative of three. (*p<0.05, **p<0.01, **p<0.005 Donor A vs. Donor B. MFI,  
mean fluorescence intensity).
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Chapter 3: DISCUSSION 
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3.1 A genuine bi-directional signalling crosstalk 
A mutually regulated and concerted activity of TLRs and the complement system would 
strengthen the efficiency of innate host defence against microbial pathogens. In support of 
this possibility, synergistic effects between TLRs and C5aR, and regulation of TLR-mediated 
pro-inflammatory and immunoregulatory responses by complement receptors have been 
reported, suggesting crosstalk between TLRs and complement receptors. However, the 
possibility of a modulatory effect exerted by TLRs on complement receptor-mediated pro-
inflammatory responses, which would indicate a genuine bi-directional crosstalk, has not been 
directly investigated. The present study aimed at determining whether such a crosstalk exists 
by examining the capacity of TLR activation to influence inflammatory responses to the 
complement anaphylatoxin C5a, and demonstrated that activation of TLRs is capable of 
positively modulating inflammatory responses of mononuclear cells and whole blood to C5a, 
by a mechanism involving TLR-induced inhibition of the expression and activity of the second 
C5a receptor, C5L2 (Figure 38).  
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Figure 38. Proposed model of TLR-C5L2-C5aR crosstalk. 
It appears that a complex interaction between C5aR, C5L2 and TLR activation exists. 
Microbial-induced complement activation results in generation of C5a, which binds to 
both C5aR and C5L2 (a). C5aR ligation activates signal transduction cascades including 
ERK1/2, resulting in synthesis and release of inflammatory mediators and positive 
modulation of C5L2 expression and activity (b). Binding of C5a to C5L2 recruits β-arrestin 1 
to C5L2, resulting in inhibition of C5aR-mediated ERK1/2 signalling, attenuating the direct 
C5a-induced release of inflammatory mediators (c). Concurrent (or preceding) TLR 
activation results in indirect (C5a-dependent) down-regulation of C5L2 expression (d) and 
direct (C5a-independent) down-regulation of β-arrestin 1 expression (e). This attenuates 
the C5L2/β-arrestin-1 inhibitory signal on C5aR, resulting in synergistic enhancement of 
C5a-mediated release of inflammatory mediators, in spite of a direct TLR-induced down-
regulation of cell surface C5aR expression (f).  The TLR-mediated positive effects on pro-
inflammatory production may be amplified by a similarly positive effect of C5aR activation 
on TLR signalling (g), as previously reported (discussed in section 1.5).
TLR C5aR
C5L2
TLR Ligand C5a
C5a
Microbial challenge
β-arrestin1
ERK1/2a
a
b
b
c
d
e
g
f
b
 
159 
 
The previously-reported capacity of TLRs and C5aR, when simultaneously activated, to 
synergistically enhance pro-inflammatory cytokine release by immunocompetent cells was 
reproduced here in an in vitro PBMC stimulation model system (Figure 19). Importantly, an 
enhancing effect on pro-inflammatory cytokine release (and gene transcription) was similarly 
observed when TLR activation was induced by cell pre-exposure in vitro (Figures 20-25) or in 
vivo (Figure 26) to a number of TLR ligands before C5a stimulation. Of note, the inverse 
sequence of cell stimulation (first via C5aR and then via TLR, Figure 20B) was unable to induce 
a greater-than-additive effect on IL-8 cytokine release. This indicates that, in the model system 
described in the present study at least, the TLR/C5aR synergy in cytokine release is mainly due 
to a modulatory effect of TLR activation on C5a receptor sensitivity rather than vice versa. This 
is in contrast with previous reports claiming a modulatory effect of C5aR activation on TLR-
induced inflammatory responses (discussed in section 1.5 above), but is not inconsistent with 
published data. Since TLR ligands (especially LPS, the ligand most commonly used in studies of 
TLR ligand-C5a synergy) are typically more potent stimuli of cytokine release than C5a, it has 
generally been assumed in previous reports that the synergistic enhancement of the cytokine 
response observed as a result of co-stimulation with both ligands was a consequence of a 
modulating effect of C5aR on a dominant TLR-mediated signal (see Section 1.5 above and 
related references). However, it has not been customary to test this hypothesis rigorously, for 
example by using a pre-exposure/exposure model system such as that described in the 
present study. The only published study which employed such a model [Laudes 2002] found a 
similar cell response to that reported here: vascular endothelial cells pre-exposed to LPS 
before activation with C5a responded with a synergistic enhancement of chemokine release, 
whereas the effect was less than additive if C5a was used as the priming agent. This previous 
observation however was not investigated further. 
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A potential confounding factor in the experimental model described in the present study was 
the possibility that the TLR-mediated enhancing effect on cell sensitivity to C5a observed here 
resulted from residual TLR ligands present during the C5a stimulation phase and carried over 
from the TLR activation phase. This is unlikely for the following reasons: 1) the levels of IL-8 at 
the end of the culture in the supernatants of cells pre-exposed to TLR ligands and not 
activated with C5a were extremely low (Figures 20A and 21A, see Figure legend); 2) polymyxin 
B added to the culture medium following cell pre-exposure to LPS and washing did not affect 
the levels of IL-8 released by the cells at the end of the cultures (Figure 20C), thus indicating 
the absence of residual LPS during the C5a activation phase. Of note, a 20- to 100-fold higher 
priming concentration of LPS than that typically used for the in vitro pre-exposure assays was 
deliberately used for this control experiment (10 ng/ml compared with 100-500 pg/ml) to 
maximise the possibility of residual traces of LPS being present after washing; 3) a TLR 
modulatory effect on cell sensitivity to C5a of similar intensity was observed over a wide range 
of LPS priming concentrations (0.1-1000 ng/ml, Figure 22A), which was inconsistent with the 
presence of residual LPS during C5a activation; 4) cells pre-exposed to LPS and then cultured in 
the absence of C5a did not show activation of NF-κB – a key regulator of cytokine/chemokine 
gene transcription that is activated by LPS – at the end of the culture (Figure 24), suggesting 
that there was no ongoing LPS stimulation of the primed cells during the C5a activation phase. 
3.2 A potent but self-limiting mechanism for amplifying host 
defence 
The high degree of leucocyte sensitivity to LPS pre-exposure is striking. Pre-exposure to 
concentrations of LPS as low as 10 pg/ml was able to double their sensitivity to C5a (Figure 
22A). The median plasma levels of LPS reported during sepsis in humans are ~ 500 pg/ml [Opal 
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1999], a level much higher than that necessary to induce hypersensitivity of PBMC to C5a in 
this model system. Thus, TLR modulation of cell sensitivity to C5a appears to be an extremely 
sensitive mechanism that might operate during the course of mild as well as severe infections. 
It is plausible that the effects of TLR activation in enhancing sensitivity to C5a might contribute 
substantially to the excessive and dysregulated release of inflammatory cytokines that is the 
critical feature of the pathogenesis of inflammatory tissue injury and organ failure in septic 
shock. The TLR-mediated priming effect demonstrated in mononuclear cells was reproduced in 
the more physiological whole blood model (Figure 25) and in the in vivo (pre-exposure)/ex vivo 
(stimulation) mouse model systems (Figure 26), adding further support to the physiological 
relevance of microbial modulation of cell responses to C5a and confirming the crucial role that 
TLR activation plays in this phenomenon. 
The capacity of LPS to enhance C5a-induced cytokine release was typically greatest at 
relatively low stimulating concentrations of C5a (Figures 22B and 25B) such as might occur in 
infected tissues at an early stage of infections. However, the synergistic enhancement of 
cytokine release tended to be self-limiting at higher concentrations of C5a – such as those 
reported systemically in severe sepsis and septic shock [Ward 2010a and 2010b] – in the 
donors that showed the greatest capacity for synergistic enhancement of cytokine responses 
(Figure 25B). It is possible that at higher C5a concentrations, such as those that might be 
generated in vivo during an acute infection, a more pronounced activation and ligand-induced 
down-regulation of C5aR may lead to C5L2 becoming proportionally more engaged. This may 
result in a stronger negative modulatory effect on C5aR responses that would counteract and 
limit the TLR enhancing effect. Thus, an individual’s capacity to clear infection efficiently and 
successfully resolve inflammation might be determined, at least in part, by the extent of the 
TLR’s enhancing effect relative to C5L2’s capacity to counteract this positive effect. 
162 
 
3.3 A MyD88-dependent pathway 
It appears that the capacity of inflammatory stimuli to induce hypersensitivity to C5a may be 
dependent on TIR domain-mediated, MyD88-dependent, signal transduction. Cell activation 
via TLRs and the IL-1β receptor, which was able to modulate C5a sensitivity (Figure 21B), 
requires TIR domain activation, whereas the other pro-inflammatory stimuli tested do not. 
Indeed, activation of a diverse array of pro-inflammatory pathways, the Jak/Stat (IL-6), 
FADD/TRAF2/RIP (TNF-α) and PKC/Ca2+ (PMA/ionomycin) pathways – all of which are able to 
induce inflammatory cytokine secretion in PBMC by a TIR domain-independent pathway – had 
no effect on subsequent sensitivity to C5a. The contrasting inhibitory effect of TLR3 activation 
on pro-inflammatory cytokine release is intriguing in light of the fact that, whereas the other 
TLRs and IL1βR all signal through the MyD88 signal adaptor, TLR3 does not. The precise nature 
of the different functional effect of TLR3 on C5aR sensitivity remains a subject of future 
investigation, as it may provide further insight into the mechanism underlying the effect of 
TLRs on C5a receptor-mediated responses.  
3.4 Intersubject variability in the capacity of TLR activation to 
induce hypersensitivity to C5a 
The degree of intersubject variation in the capacity of whole blood cells to respond to LPS 
priming by up-regulating their responsiveness to C5a is also striking (Figure 25B). Whilst many 
donors exhibited a marked capacity for LPS-induced hypersensitivity to C5a, others showed 
little or no LPS-induced augmentation in C5a sensitivity. The shape of the C5a dose-response 
curve was also subject to variation. Donors that exhibited a high degree of LPS-induced 
hypersensitivity to C5a tended to show maximal enhancement at low stimulating 
concentrations of C5a, followed by a decrease at higher concentrations. Other donors, who 
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showed overall lesser capacity for LPS-induced hypersensitivity to C5a, tended to exhibit a 
sigmoid-type response curve that reached a plateau at higher stimulating concentrations. 
These variations are intriguing; if reproduced in the context of in vivo infections, they might 
reflect a predisposition in different individuals towards a particular kind of chemokine 
response to a given infectious challenge. The subjects that showed greater LPS-induced 
hypersensitivity to relatively low C5a concentrations might represent a population capable of 
mounting a greatly enhanced chemokine response to low stimulating concentrations of TLR 
ligands released by pathogens, such as might occur in the early stages of infection when 
microbial numbers are relatively low. This might be beneficial to the host by amplifying the 
pro-inflammatory cytokine response to minor infections, preventing the pathogen from 
gaining a foothold. However, when faced with massive complement activation, such as might 
occur in disseminated infections or when the bacterial inoculum is massive (for example in 
gross faecal contamination of the peritoneum after a bowel perforation), attenuation of the 
inflammatory response might be protective against the cytokine-induced systemic 
inflammatory tissue injury that characterises the syndrome of septic shock. 
The preliminary data shown in Figure 37 raise the possibility that the capacity of a particular 
individual to respond to TLR activation by increased sensitivity to C5a may depend upon the 
ratio of monocyte C5L2 to C5aR expression. It is possible that in the ‘low responder’ (who 
exhibited a lower C5L2:C5aR ratio), a proportionally weaker inhibitory signal from C5L2 
(relative to the strength of the C5aR-mediated signal) was responsible for attenuating the 
C5aR-mediated pro-inflammatory responses in the absence of preceding TLR activation. This 
might result in TLR activation having less capacity to enhance C5a sensitivity by inhibiting C5L2 
expression (i.e. there was less inhibition to remove). These findings, however, need to be 
corroborated in a larger study.  
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3.5 TLR-induced downregulation of C5L2 expression and activity 
The study of the mechanism underlying the positive modulatory effect of TLR activation on cell 
sensitivity to C5a identified the second C5a receptor, C5L2, as a target for regulation by TLRs 
that appears to be critically involved in the TLRs’ modulatory effects. Thus, TLR activation 
appears to increase cell sensitivity to C5a, at least in part, by reducing the inhibitory effect 
exerted by C5L2 on C5aR activity. As suggested by some studies [Gavrilyuk 2005, Gao 2005, 
and Gerard 2005] and confirmed by this work, the negative modulation of C5aR by C5L2 
appears to be profound. This conclusion is supported by the finding reported here that TLR 
activation is capable of increasing C5aR sensitivity in spite of inducing a substantial down-
regulation of C5aR cell-surface expression in both monocytes and neutrophils. The observed 
concomitant down-regulation of cell-surface C5aR might thus be a compensatory mechanism 
to prevent excessive release of inflammatory mediators in cells exposed to microbial 
components. 
The relationship between TLR activation and C5L2 down-regulation appears to be complex, 
since pre-exposure of cells to LPS without subsequent C5a activation induced no change in 
cytoplasmic or secreted HMGB1 (Figures 30A and 31A, WT mice), and had no effect on cellular 
C5L2 expression (Figure 33). However, when LPS priming was followed by C5a stimulation, a 
marked down-regulation of HMGB1 (Figures 30A and 31A, WT mice) and a profound LPS dose-
dependent inhibition of C5L2 expression occurred (Figure 33). Thus, it appears that TLR 
activation exerts a negative effect on C5L2 expression only upon C5a-induced C5aR activation, 
which itself has a positive effect on C5L2 expression. The observed TLR-induced down-
regulation of cell-surface C5aR might thus at least contribute to the negative effect of TLRs on 
C5L2 expression. 
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The effect on pro-inflammatory cytokine release of C5L2 deficiency in mice was also 
somewhat more complex than expected. Although the mice did lose their capacity to up-
regulate C5a sensitivity after LPS pre-exposure, confirming the crucial role of C5L2 in LPS-
induced hypersensitivity to C5a, it was surprising to observe that blood cells from C5L2-
deficient mice were no more sensitive to C5a than the WT (Figure 34). These findings were 
unexpected, as it was speculated that the absence of the putative negative regulator of C5aR, 
C5L2, should result in increased cell sensitivity to C5a. It is possible that an additional, 
compensatory, negative regulatory mechanism controlling responses to C5a operates only in 
the complete absence of C5L2 (C5L2KO mice). This would be compatible with the increased 
sensitivity to C5a resulting from C5L2 receptor inhibition by TLR activation or Ab blockade 
observed in this study, as such a compensatory negative regulatory mechanism would not be 
operational due to the presence of C5L2. In contrast to C5L2, the putative second regulatory 
mechanism would not be susceptible to negative regulation by TLRs, as the blood cells from 
C5L2KO mice pre-treated with LPS did not show increased KC production (Figure 34, C5L2KO, + 
LPS). 
3.6 The role of β-arrestin 1 in LPS-induced hypersensitivity to C5a 
The findings described in sections 2.3 and 2.4 above indicated that LPS has the capacity to 
down-regulate transcription and expression of β-arrestin 1, a signal intermediate involved in 
C5aR and C5L2 activities. The effects of C5a stimulation and LPS priming alone on β-arrestin 1 
expression in PBMC deserve brief comment. C5a stimulation up-regulated β-arrestin 1 at both 
mRNA and protein levels, whereas cell exposure to LPS, with or without subsequent C5a 
stimulation, resulted in inhibition of β-arrestin 1 expression. The C5a-induced enhancement of 
β-arrestin 1 expression is consistent with an increased requirement for β-arrestin 1 in the 
normal process of ligand-dependent receptor deactivation, internalisation and recycling 
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[Shukla 2011]. However, if, as Gerard and colleagues proposed [Bamberg 2010], β-arrestin 1 
mediates the inhibitory effect of C5L2 on C5aR-mediated inflammatory responses, C5a-
induced C5aR-mediated enhancement of β-arrestin 1 might equally reflect the increased 
engagement of the C5L2/β-arrestin 1 inhibitory mechanism for controlling C5aR-dependent 
inflammatory signalling.  
If this were the case, LPS-induced inhibition of β-arrestin 1 expression might be an important 
mechanism by which TLR activation down-regulates the inhibitory effect of C5L2 on C5aR-
mediated pro-inflammatory responses. Alternatively, given that cell pre-exposure to LPS 
induced down-regulation of both C5aR (directly, Figure 28) and C5L2 (indirectly, Figure 33), it 
is possible that LPS-induced down-regulation of β-arrestin 1 is a reactive change, reflecting a 
reduced requirement for β-arrestin 1 by both receptors, either in the process of ligand-
induced receptor deactivation (in the case of C5aR) or the inhibition of C5aR-mediated pro-
inflammatory signalling (in the case of C5L2). Furthermore, since β-arrestins are involved in 
regulation of other 7 transmembrane region receptors as well as C5aR and C5L2, a role for 
LPS-induced inhibition of β-arrestin 1 in the regulation of other GPCRs (chemokine receptors, 
for example) cannot be excluded. 
3.7. Gene Array screening of signal transduction intermediates 
The gene microarray strategy that was employed to screen for potential mediators of the 
observed TLR-induced hypersensitivity to C5a has several limitations. RT-qPCR provides 
quantitative information about mRNA expression, but this may not directly reflect protein 
levels, especially when expression of the gene product is also subject to regulation at a 
translational or posttranslational level (as is the case with inflammatory cytokines).  
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Furthermore, findings may be very difficult to interpret; for example, in this study, mRNA for 
NF-κB p65, a critical inducer of cytokine gene expression, underwent a three-fold down-
regulation as a result of stimulation with C5a after LPS priming. However, this change did not 
directly reflect its involvement in the LPS effect on C5a-induced cytokine responses, since it 
was previously shown that NF-κB p65 activation and nuclear translocation were dramatically 
enhanced by C5a after cell pre-exposure to LPS (Section 2.1.5 and Figure 24). A plausible 
explanation for the reduced abundance of mRNA transcripts for p65 in light of the data from 
Figure 24 is that the reduction in p65 transcription might be a compensatory effect to limit and 
control pro-inflammatory responses induced by large-scale NF-κB activation. However, in the 
absence of comparable data on expression level and activation status of many of the proteins 
whose transcription was either induced or inhibited by LPS or C5a, the gene array data may be 
difficult to interpret.  
As a result of these concerns, the pathway-focussed qPCR arrays were employed only as a 
screening strategy to identify proteins as candidates for further study, especially where large 
changes in gene expression were detected. No more detailed inferences were drawn from any 
of the data. 
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4.1 The physiological relevance of TLR-induced hypersensitivity 
to C5a 
As noted above, ex vivo testing of the sensitivity to C5a of blood cells from sepsis patients 
failed to reproduce the TLR-induced hypersensitivity to C5a observed in vitro; in fact, the 
capacity of blood from sepsis patients to produce a cytokine response to a range of 
inflammatory stimuli was globally impaired. This is perhaps not entirely surprising; in order to 
meet the diagnostic criteria for severe sepsis or septic shock, patients must display evidence of 
infection, a systemic inflammatory response to that infection, and failure of at least one organ 
system (for example, renal failure). Since a severe inflammatory tissue injury had already 
taken place (as indicated by the presence of organ failure, Table 8, section 5.2 below), it is 
plausible that at the time blood was sampled from these patients, a compensatory anti-
inflammatory response was dominant, resulting in sepsis-induced immunosuppression. Hence, 
it appears that by the time the patients were admitted to the ICU, the window of opportunity 
for examining mechanisms regulating the initial excessive cytokine response had already 
passed. In light of this, the low cytokine response of sepsis patients to C5a reported above is 
not inexplicable. 
However it is plausible that the TLR-C5a receptor crosstalk might nevertheless play an 
important role in determining the amplitude of the cytokine response to infection in vivo, but 
at an earlier point in the disease process; perhaps during the initial encounter between 
monocytes/neutrophils and microorganisms and at the time when the cytokine response that 
leads to systemic inflammation and organ failure is triggered. A different experimental model 
will be necessary to test this hypothesis further in humans. Possible models might include 
testing the ex vivo sensitivity to C5a of blood drawn from patients at an earlier stage of 
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infections; however, this approach would have a number of practical difficulties, including the 
difficulty of identifying and recruiting patients with such infections, the impossibility of 
standardising the infective challenge and of taking a control sample in order to assess each 
subject’s ‘unprimed’ sensitivity to C5a. However, one possible ex vivo model overcomes most 
of these difficulties. The induction of low-level endotoxaemia by intravenous injection of 
purified LPS in human subjects is an established experimental model [Michie 1988]. Blood 
drawn before and immediately (30 min) after LPS inoculation will be stimulated with C5a in 
order to assess the effect of in vivo endotoxaemia on ex vivo sensitivity to C5a. The extent of 
endotoxaemia-induced enhancement of C5a sensitivity (if demonstrated) will be correlated 
with the relative monocyte expression levels of C5aR and C5L2 in samples taken at baseline 
and 30 min after induction of endotoxaemia. This will provide a necessary test of the in vivo 
relevance of the phenomenon identified in this study, and provide further valuable data 
regarding the relationship between C5aR/C5L2 expression and LPS-induced hypersensitivity to 
C5a. 
It will also be interesting to test the sensitivity to C5a of blood cells of mice relatively late after 
being challenged in vivo, to test whether this model reproduces the sepsis-induced 
immunosuppression observed in humans. Reproducing sepsis-induced immunosuppression in 
an animal model would support the conclusion that the hyporesponsiveness observed in the 
sepsis patients was indeed due to the timing of the experiments. Furthermore, it would pave 
the way for evaluating novel strategies to rescue the pro-inflammatory response of these 
patients. 
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4.2 C5aR and C5L2 expression and TLR-induced hypersensitivity 
to C5a 
It was found that the capacity of PBMC and whole blood cells to respond to TLR-mediated 
activation with enhanced sensitivity to C5a varied greatly between different donors (section 
2.1.6 and Figure 25). These findings are interesting for a number of reasons.  
As mentioned above, the inflammatory cytokine response to infection is something of a ‘two 
edged sword’. It is vital that the presence of pathogenic microbes in a normally sterile tissue 
induces a rapid and robust local inflammatory response in order to contain, kill and clear the 
infective organisms before they establish a foothold. However, it is equally important that 
there be mechanisms that restrict the inflammatory response to the immediate vicinity of the 
infection in order to prevent systemic inflammation and injury to healthy tissues. It is often 
observed anecdotally that human subjects seem to vary in their susceptibility to an excessive, 
systemic inflammatory response to a given infective insult. An apparently similar microbial 
challenge (for example, a perforated bowel leading to faecal contamination of the 
peritoneum) might in one subject cause peritonitis that resolves promptly after surgical 
intervention, while in another it may result in septic shock and a prolonged period of multi-
organ failure. It is of course impossible to test the veracity of this observation by experiment, 
since a ‘standardised infectious challenge’ does not exist, and many other confounding factors 
such as age and co-morbidity might also influence the outcome. However, it is plausible that 
intersubject variations in the mechanisms that regulate the magnitude of the pro-
inflammatory cytokine response to infection might contribute to the different outcomes. 
It is also plausible that intersubject variations in such a regulatory mechanism might be 
conserved as representing a survival advantage in different circumstances. An individual who 
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is prone to a more robust inflammatory response to infection might be better able to clear 
pathogens at an early stage of colonisation and thus prevent an infection from gaining a 
foothold, but be more susceptible to a fatal systemic inflammatory response if an infection 
becomes established. On the other hand, an individual prone to a less robust cytokine 
response might be more susceptible to infections but less likely to develop fatal sepsis. Either 
characteristic might represent a survival advantage depending on the prevalence of different 
infectious hazards in the environment. For example, an environment in which a particularly 
virulent pathogen was endemic might favour individuals prone to a more robust cytokine 
response, since infection might prove rapidly lethal if allowed to gain a foothold. Thus the 
characteristic might persist in the population in a similar way to the persistence of terminal 
complement pathway deficiencies in regions with a high prevalence of Neisserial infections 
[Walport 2001a] or sickle cell trait in areas where malaria is endemic [Rosenthal 2011]. 
As noted in section 2.6 above, it is possible that the varying capacity of individuals to augment 
their cytokine response to C5a as a result of cell pre-exposure to TLR ligands (Figures 22B, 25B 
and 37) is related to the relative expression levels of C5aR and C5L2 in monocytes. These 
findings, however, need to be corroborated in a larger study, and work is on-going to expand 
this study in a larger population of healthy donors to test the hypothesis that the absolute 
expression level of C5L2 or the ratio of C5L2 to C5aR expression might be associated with a 
differing capacity for TLR-induced hypersensitivity to C5a. If substantiated in a larger 
population, this would provide a valuable insight both into the mechanisms of C5a-induced 
cytokine induction and the pathophysiology of the cytokine response to infections. 
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4.3 The effect of C5L2 gene silencing on C5a sensitivity 
As discussed in Section 3.5 above, it was surprising to find that genetic deletion of C5L2 did not 
have any (amplifying) effect on the ex vivo sensitivity of mouse blood cells to C5a in the 
absence of preceding TLR activation; this might be explained by the existence of an alternative 
regulatory pathway operative in the complete absence of C5L2. In order to provide further 
support for the proposed role of C5L2 in regulating C5aR-induced cytokine induction, a siRNA 
knockdown strategy may be used to assess the effect of C5L2 gene silencing upon C5a 
sensitivity. An in vitro model will be established in order to test the capacity of C5L2 gene 
silencing to reproduce the effects of C5L2 blockade.  
4.4 The role of β-arrestin 1 in TLR-induced hypersensitivity to 
C5a. 
β-arrestin 1 has been implicated in the inhibitory effect of C5L2 upon C5aR-induced pro-
inflammatory responses, and its expression – like that of C5L2 – was found in this study to be 
down-regulated by cell pre-exposure to LPS. Therefore, it was concluded that TLR activation 
may also target β-arrestin 1 for negative modulation as part of the mechanism underlying 
TLR’s positive effect on C5aR sensitivity (Section 2.4). The Gerard group [Bamberg 2010] found 
that the inhibitory effect of C5L2 on neutrophil responses to C5a was mediated by an 
inhibition of ERK1/2 phosphorylation, and inhibition of ERK1/2 has also been shown to be 
associated with reduction in C5a-induced responses [Hawlisch 2005, La Sala 2005 and 
Bamberg 2010]. In this study, the mRNA expression upon C5a stimulation of several key 
components of the MAPK pathway was found to be affected by cell pre-exposure to LPS 
(Section 2.3, Table 5C). Therefore, the pathway linking β-arrestin 1 and ERK1/2 deserves to be 
investigated in greater detail. Specific inhibitors and siRNA gene silencing of β-arrestin 1 may 
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be employed in order to investigate its role in this context. The expression levels of proteins 
whose mRNA expression was affected may be assessed by Western blot, and the 
phosphorylation (activation) states of key signalling intermediates may be studied using 
protein phosphorylation arrays. Specific inhibitors of key intermediates may also be employed 
to test their roles in TLR-induced C5a hypersensitivity.  
4.5 The problem of autocrine effects of C5a 
As noted in sections 1.3.4.2d and 1.5.3 above, gene silencing studies have raised the possibility 
of a modulatory effect of C5a receptors on TLR-mediated inflammatory responses in the 
absence of exogenous C5a [Gavrilyuk 2005, Rittirsch 2007, Zhang 2007 and Fusakio 2011]. 
Although artefactual generation of C5a from C5 in serum-supplemented culture media cannot 
be excluded as a possible explanation for this observation, it is unlikely in the culture 
conditions described in these studies. However, an autocrine/paracrine effect of C5a 
generated from C5 secreted and activated by the phagocytic cells themselves cannot be ruled 
out, since synthesis and secretion of complement proteins by a range of extrahepatic cell 
types is well-documented (see Table 6 below), as is the ability of phagocytic cells to activate C5 
[Huber-Lang 2002]. If this were the case, it is possible that effects (on signal transduction and 
cytokine secretion) that were attributed to TLR activation alone were in fact due to the 
combination of TLR and C5a receptor activation. Although the extent of the contribution of the 
constitutively generated C5a cannot be estimated, (and indeed may be minimal compared 
with that of TLR activation) a careful consideration of the experimental designs of the studies 
cited in section 1.5 makes it difficult to exclude this possibility.  
In order to design an experimental system in which the possibility of an effect of endogenous 
C5a on TLR-mediated inflammatory responses could be confidently excluded, it would be 
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necessary to prevent C5 secretion and/or activation, or to ensure that any endogenously 
generated C5a was prevented from interacting with either of its receptors. The latter 
possibility seems more likely to be successful (though by no means certain) and might be  
Table 6. Extrahepatic synthesis of complement components 
 
BMDC, Bone-marrow-derived dendritic cell; HUVEC, human vascular endothelial cell; MDC monocyte-derived 
dendritic cell, NKC, Natural killer cell. [adapted from Li 2007]. 
 
Type of Cell/Tissue Complement Protein Detected 
Myeloid/Lymphoid cells 
 
 
Monocyte C1q, C2-9, B, D, I, P 
Macrophage C1-9 
Neutrophil C3 
BMDC C3 
MDC C1q, C3, C5, C9, I, H, B, D, P 
NKC C4 
T Cell C3 
Organ/Tissue/Cell 
 
 
HUVEC C3, C5-9, H 
Intestinal Epithelial cell C3, C4, B 
Pancreatic Duct Epithelial Cell C3, C4, B 
Fibroblast C2, C3, C5-9,  
Keratinocyte C3, B, H 
Pneumocyte C3-9, B, H, I 
Mesothelial Cell C3, C4 
Muscle Cell C3-5 
Chondrocyte C1r, C1s, C2-4 
Adipocyte C1qrs, C2-9 
Astrocyte C1-9, B, D, H, I 
Microglia C1q, C2-4 
Neuroblastoma C1q, C3-9, B, H 
Oligodendrocyte 
 
C1qrs, C2-9 
Renal Biopsy C1q, C2-4, B, D, H, P 
Glomerular endothelial cell C3 
Glomerular epithelial cell C1r, s, C2-4, B 
Mesangial Cell C3, C4 
Renal tubule epithelial Cell C2-4, H, B 
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achieved by the use of an excess of a neutralising antibody to C5a in experiments designed to 
test the effects of TLR activation alone. This avenue of investigation will be pursued in future 
work. 
177 
 
 
 
 
 
 
 
Chapter 5: MATERIALS AND METHODS 
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5.1 Antibodies and reagents 
Antibodies and immunoreagents used and their sources are listed in Table 7 below. 
Recombinant human C5a (expressed in E. coli) was kindly provided by Dr P.N. Monk, Sheffield 
University, U.K (used in the experiments shown in Figures 20-30, 32-33, and 37-38). Purified 
natural human C5a was from CompTech (Tyler, TX, USA) and was used in the experiments 
shown in Figure 35 and Table 5. Preliminary experiments indicated that both sources of human 
C5a were free from detectable LPS contamination (representative experiment shown in Figure 
40, Appendix). The relative potencies of recombinant and purified C5a were assessed and 
found to be similar (Figure 41, Appendix). Recombinant mouse C5a (Figures 31 and 34) was 
from Hycult Biotech (Plymouth Meeting, PA, USA).  
RPMI-1640, L-glutamine and Fluo3-AM were supplied by Invitrogen Ltd (Paisley, U.K.). Low-
endotoxin foetal calf serum (FCS) was from Hyclone (Logan, UT, USA; < 0.06 EU/ml endotoxin); 
Ficoll-Histopaque-1077, bovine serum albumin, sodium dodecyl sulphate (SDS), leupeptin, 
pepstatin A, molecular biology grade chloroform, ethanol and isopropanol, red blood cell lysis 
buffer, Nonidet P-40 (NP-40), polymyxin B, ammonium persulphate, sodium azide, DL-
dithiothreitol (DTT), TRIS-hydrochloride, glycerol, phorbol myristate acetate (PMA) and 
ionomycin were from Sigma-Aldrich UK (Dorset, U.K.). Ultra-pure LPS (Escherichia coli O111:B4 
strain), heat-killed Listeria monocytogenes and Escherichia coli, polyinosinic-polycytidylic acid 
(poly I:C), zymosan, flagellin, IL-1β, IL-6 and TNFα were from Invivogen (San Diego, CA, U.S.A.). 
The synthetic bacterial lipopeptide Pam3-Cys-Ser-(Lys)4 HCl (Pam3Cys) was from EMC 
microcollections GmbH (Tübingen, Germany). Bicinchoninc Acid (BCA) protein quantification 
assay was from Bio-Rad (Hercules, CA, USA). Glycine, p-formaldehyde, bromophenol blue and 
phenylmethylsulfonyl fluoride (PMSF) were from Fisher Scientific UK (Loughborough, UK). All 
other chemicals were reagent grade. 
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Table 7. Antibodies and immunoreagents used 
Antibody Clone/Code Isotype Source 
Human CD3 HIT3a-PE   Mouse 
IgG2a 
eBioscience, San Diego, 
CA, USA 
Human CD3 B-B11 IgG1 Diaclone, Besancon, 
France 
Human CD14 MY4 (and MY4-
FITC) 
Mouse 
IgG2b 
Coulter, Luton, UK 
Human CD19 B-C3 -PE Mouse 
IgG 1 
Diaclone, Besancon, 
France 
Human C5aR S5/1 (and S5/1-
FITC) 
Mouse 
IgG2a 
R&D Systems,  
Minneapolis, MN, USA 
Human C5L2 1D9 M12  
(and 1D9 M12-PE) 
Mouse 
IgG2a 
Biolegend, San Diego, CA, 
USA 
Human/Mouse  
HMGB1 
Ab18256 Rabbit Igs Abcam, Cambridge, UK 
Human β-arrestin 1 SC-74591 Mouse 
IgG1 
Santa Cruz, CA, USA 
Mouse IgG1 MOPC-21 Mouse 
IgG1 
Biolegend, San Diego, CA, 
USA 
Mouse IgG2 UPC-10 Mouse 
IgG2 
Sigma-Aldrich, Dorset, UK 
FITC-conjugated Rabbit  
anti-mouse Igs 
F0313 Rabbit Igs DAKO, Cambridge, UK 
PE-conjugated Rabbit  
anti-mouse  Igs 
R0439 Rabbit Igs DAKO, Cambridge, UK 
HRP-conjugated Rabbit  
anti-Mouse Ig 
A9044 Rabbit Igs Sigma-Aldrich, Dorset, UK 
HRP-conjugated Goat        
anti-Rabbit Ig 
A6154 Goat Igs Sigma-Aldrich, Dorset, UK 
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For RT-qPCR experiments, Tri-reagent was from Ambion (Austin, TX, USA), reverse 
transcription kit (High Capacity cDNA Reverse Transcription) and Sybr green/Rox qPCR 
mastermix (Power Sybr Green) were from Applied Biosystems (Foster City, CA, USA). For the 
pathway-focussed gene arrays, on-column RNA extraction kits (RNeasy Kit), nuclease-free 
water, DNAse, reverse transcription kits (RT2 First Strand cDNA Synthesis Kit), Sybr green/Rox 
qPCR mastermix (RT2 Sybr Green Mastermix) and gene arrays (RT2 profiler PCR Arrays) were 
from Qiagen (Dusseldorf, Germany). 
For Western blotting, Amersham Hybond nitrocellulose membrane was from GE Healthcare 
Life Sciences (Buckinghamshire, UK) and Pierce enhanced chemiluminescence (ECL Plus) 
reagents were from Fisher Scientific UK. 
5.2 Cells and cell activations 
Human whole blood samples were obtained from healthy volunteers and sepsis patients, and 
PBMC from the buffy coat fractions of blood donations provided by the Welsh Blood Service, 
in accordance with local NHS research ethics committee permissions (REC reference 
10/WSE04/21). Patient samples were taken from adults with a diagnosis of severe sepsis or 
septic shock by consensus definitions [Levy 2003] on admission to the intensive care unit if 
within 36h of the presumed onset of the infective illness. Patient characteristics are shown in 
Table 8, below. 
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Table 8. Demographic and clinical characteristics of sepsis patients 
Patient characteristics Focus of Infection†* Causative organism‡ 
Male:Female (total) 7:12 (19) Respiratory tract 6 Gram +ve cocci 
Age (yrs) 57±13 Urinary 4 Streptococcus pneumoniae 2 
Admission APACHE 
II score 
16.4 ±8.2 Biliary tract 3 Enterococcus faecalis 1 
Outcome 
(lived:died) 
14:5 Peritonitis 6 Gram +ve bacilli 
Days on ICU 15.7 
±14.2 
Soft tissue 4 Dermabacter hominis 1 
Duration of organ 
support (days) 
9.4 ±8.5   Gram -ve bacilli   
†On admission  Escherichia coli 6 
*Some patients presented with more than one infection Enterobacter cloacae 1 
‡Some samples were positive for more than one pathogen Pseudomonas aeruginosa 1 
    Klebsiella pneumonia 1 
    Haemophilus influenzae 2 
    No organism isolated 10 
 
5.2.1. Isolation, cryopreservation and resuscitation of peripheral blood 
mononuclear cells 
PBMC were extracted by Ficoll density-gradient centrifugation of buffy coats. The blood was 
diluted 1:1 with room temperature RPMI-1640 medium, overlaid (12 ml) onto 8 ml of room 
temperature Ficoll-Histopaque (Sigma) to a blood: Ficoll final ratio of 3:2, and centrifuged at 
750 x g for 20 min at room temperature. The upper (plasma) and lower (red cells and PMN) 
phases were discarded, and the interphase containing the PBMC was recovered and washed 
three times at room temperature with RPMI-1640 medium (first wash, 370 x g, 12 min; 
second, 190 x g, 10 min; third, 120 x g, 8 min). Monocytes comprised 5-10% and lymphocytes 
90-95% of the PBMC, as assessed by CD3, CD14 and CD19 staining and forward- and side-
scatter profile. Neutrophils accounted for less than 0.1% of the cell preparations. Following 
washing, the PBMC were resuspended in freezing medium (10% DMSO / 20% FCS / 70% RPMI-
1640) at a concentration of ~20 x 106 cells/ml and frozen in 1 ml cryotubes immersed in 
isopropanol. Cells were stored at -70°C for up to 48h and thereafter in liquid nitrogen for up to 
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1 year. Cell aliquots were resuscitated by prompt defrosting at 37 °C, and drop wise dilution 
with RPMI-1640 medium followed by washing (3x) to remove the DMSO. Cell viability was 
always ≥ 99% as estimated by the trypan blue exclusion test. 
5.2.2. Cell activation protocols 
To test the effect of TLR activation on PBMC sensitivity to C5a in vitro, the experimental 
protocol shown in Figure 39A was used. Triplicate aliquots of PBMC (1.5 x 105 cells/well, unless 
stated otherwise) were cultured in phenol red-free RPMI-1640 medium supplemented with 
10% heat-inactivated (56 °C, 30 min) FCS (HyClone) and 2 mM glutamine (complete medium), 
and stimulated (pre-exposed) at 37 °C for 14h or the time indicated with previously-defined 
optimal concentrations of LPS (100 pg/ml), Pam3Cys (100 ng/ml), zymosan (1 μg/ml), flagellin 
(5 μg/ml), imiquimod (3 μg/ml) or polyI:C (80 μg/ml), or medium alone (mock-stimulation). 
The effect of cell pre-exposure to stimuli other than TLR ligands was also tested (Figure 21): IL-
1β (5 ng/ml), TNFα (10 ng/ml), IL-6 (10 ng/ml) or PMA/ionomycin (50/500 ng/ml). Following 
incubation, cells were washed (3x, RPMI-1640 medium, room temperature), resuspended in 
complete medium, and activated for a further 12-14h with the indicated concentrations of C5a 
or mock-activated. In some experiments (Figure 20C), polymyxin B (10 μg/ml) was added 
during the C5a stimulation phase of the culture. Cell culture supernatants were then collected 
and tested for IL-6, IL-8, KC or MCP-1 by ELISA (Duoset, R&D Systems, Minneapolis, MN, USA). 
For C5L2 receptor blocking experiments (Figure 32), PBMC were preincubated (30 min at 37 
°C) with the anti-human C5L2 blocking mAb, clone 1D9-M12 (5 μg/ml), before stimulation with 
C5a (2.5 nM). In control experiments the 1D9-M12 mAb was denatured by boiling for 10 min.  
Whole blood cell sensitivity to C5a before and after pre-exposure to TLR ligands and whole 
bacteria was tested (Figure 25) using the same experimental protocol described above for 
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PBMC and in Figure 39A. Here, triplicate samples of heparinised (10 IU/ml) human whole 
blood (100 μl/well) were  
Figure  39. Experimental models of TLR/C5a receptor activation.
(A) In vitro model. Cells (PBMC or whole blood) were exposed to TLR ligands or 
whole heat-killed bacteria for variable durations before washing and stimulation 
with C5a for 14h. Following incubation, cell culture supernatants were tested for 
cytokine release (ELISA). Cell lysates were prepared and tested for NF-κB
activation (ELISA) or HMGB1, C5L2 and β-arrestin 1 expression (Western blot). 
(B) In vivo / ex vivo model. Mice [C3H/HeN (WT), C3H/HeJ (TLR4 signalling 
deficient), BALB/c or C5L2KO (BALB/c background)] were pre-exposed in vivo to 
LPS by i.p. injection. After 1h, animals were sacrificed, blood drawn and the 
blood cells washed before being stimulated with C5a for 14h. After stimulation, 
culture supernatants were taken for chemokine determinations (ELISA) or 
HMGB1 levels (Western blot). Experimental details are described under 
Materials and Methods, sections 5.2 and 5.8.
Readout
14 h≤14 h
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TLR ligand
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pre-exposed to LPS (500 pg/ml) or heat-killed Escherichia coli (1 x 108 cfu/ml) for 14h. 
Subsequently, samples were centrifuged (300 x g, 5 min, room temperature), the blood cells 
washed (x3, RPMI-1640 medium, room temperature), resuspended in an equivalent volume of 
heat-inactivated (30 min, 56 °C) 100% autologous plasma, and activated for 14h with the 
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indicated concentrations of C5a before cell culture supernatants were collected and tested for 
cytokine levels by ELISA.  
To test the sensitivity of sepsis patients’ whole blood to C5a or TLR activation (Figure 36), 
triplicate samples of heparinised whole blood (100 μl/well) were washed three times in RPMI-
1640 and resuspended in equivalent volumes of complete medium before stimulation for 14h 
with the indicated concentrations of C5a or with LPS (10 ng/ml), Pam3Cys (100 ng/ml), whole 
heat-killed Escherichia coli (2 x 104 cfu/ml) or Listeria monocytogenes (4 x 105 cfu/ml). Sub-
optimal stimulating concentrations were chosen on the basis of dose-response titration 
experiments; a representative experiment is shown in Figure 42 (Appendix). IL-8 
concentrations were estimated in the culture supernatant by ELISA.  
In some experiments the C5a-induced IL-8 concentrations after background subtraction were 
shown. They were estimated by subtracting the background levels of IL-8 present in cultures 
not activated with C5a and pre-exposed or not to TLR ligands from the corresponding C5a-
activated samples (background levels of IL-8 in the experiments described in Figure 21 – 
typical of all experiments – are shown in the figure legend). Fold changes in IL-8 release were 
estimated by comparing the C5a-induced IL-8 release in cells previously stimulated with TLR 
ligands or whole bacteria with that seen in cells not previously stimulated. 
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5.3 Enzyme-linked immunosorbent assay (ELISA) 
Cytokine levels in cell culture supernatants were estimated by ELISA. Duoset ELISA kits 
for IL-6, IL-8, KC or MCP-1 were supplied by R&D systems (Minneapolis, MN, USA) and were 
used according to the manufacturer’s instructions. Briefly, Costar 96-well stripwell plates 
(Corning Costar, Sussex, UK) were coated with a capture antibody to the protein of interest by 
overnight incubation at room temperature. After washing (x3 washing buffer: 0.05% Tween-20 
in PBS), wells were blocked with 1% bovine serum albumin in PBS, followed by washing 
(washing buffer) and incubation with appropriately diluted samples and standards in PBS. 
Following washing, the wells were incubated with a biotinylated detection antibody, washed 
and incubated with streptavidin-HRP solution (The Jackson Laborotory Bar Harbour, MN, USA). 
Following a final wash, wells were incubated with colour development reagent 
(tetramethylbenzidine and hydrogen peroxide 1:1 v/v; TMB, SureBlue™, KPL) and the reaction 
stopped by addition of 1M HCl. Absorbance at 450 nM was measured (Benchmark microplate 
reader, Bio-Rad) and the cytokine concentration in the samples was estimated by 
extrapolating the absorbances of the samples in the standard curve prepared in parallel. All 
antibody concentrations and incubation times were optimised for the particular antibody pair 
for each ELISA. 
5.4 Quantitative RT-PCR (RT-qPCR) 
For RT-qPCR experiments (Figures 23 and 35), triplicate aliquots of PBMC (1 x 106 cells/ 
condition) were cultured in complete medium, stimulated or not with 100 pg/ml LPS, washed, 
and activated or not with C5a (10 nM), as described above. RNA was phenol/chloroform-
extracted and precipitated with isopropanol overnight at -4°C. Precipitates were washed three 
times with 70% ice-cold ethanol and allowed to dry before reconstitution with nuclease-free 
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water. RNA concentration was quantified by spectrophotometry (Nanodrop 
Spectrophotometer, Thermo Scientific, Wilmington, USA) and RNA purity confirmed by A260:280 
(≥2.0) and A260:230 (≥1.8) readings. Reverse transcription was performed on equal masses of 
RNA using random primers in a thermal cycler (MJ PTC-200, MJ Research, St Bruno, Quebec, 
Canada). qPCR was performed on the resulting cDNA using the Power SYBR Green PCR master 
mix (Applied Biosystems) and specific primers (Invitrogen; see Table 9 below). The primers 
were designed to avoid amplification of potential contaminant genomic DNA (one primer of 
each pair was designed to hybridise across two exons). In order to determine the primers’ 
amplification efficiency, each pair of primers was titrated against varying amounts of cDNA. 
Efficiency for all primers was between 75 and 100%. A representative titration experiment is 
shown in Figure 43 (Appendix). PCR was carried out using the ABI 7900HT real-time PCR 
system (Applied Biosystems) with a thermal cycle profile of 10 min at 95oC followed by 40 
cycles of 15s at 95 oC and 45s at 60 oC. The results were analysed by the ΔΔCt method [Livak 
and Schmittgen 2001], using β-glucuronidase as a housekeeping gene. Dissociation curves of 
the amplicons generated by all primer pairs showed a single clear dissociation peak; a 
representative example is shown in Figure 44 (Appendix).  
Table 9. RT-qPCR Primers  
Gene 
Symbol* 
Forward 
(5’ – 3’) 
Reverse 
(5’ – 3’) 
IL6 CAGTTCCTGCAGAAAAAGGC GAATGAGATGAGTTGTCATG 
IL8 GAACTGAGAGTGATTGAGAGTGGA CTCTTCAAAAACTTCTCCACAACC 
C5AR1 GGAGACCAGAACATGAACTC ATCCACAGGGGTGTTGAGGT 
ARRB1 CCTGACCTTTCGCAAGGACC CAAGCCTTCCCCGTGTCTTC 
GUSB TCTGTATTCATTGGAGGTGC AAGGTTTCCCATTGATGAGG 
*HUGO database gene nomenclature. IL6, interleukin-6; IL8, interleukin-8; C5AR1, C5aR/CD88; ARRB1, β-arrestin 1; GUSB, β-
glucuronidase.  
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5.5 NF-κB assays 
PBMC (1 x 107 cells/ condition) were pre-exposed to 100 pg/ml LPS, washed, and activated 
with C5a (10 nM) as described above (section 5.2.2 and Figure 39). In some experiments 
(Figure 24), the NF-κB inhibitor pyrrolidine dithiocarbamate (PDTC, 10 ng/ml) [Németh 2003] 
was added during the C5a stimulation phase. At the end of the culture, nuclear extracts were 
prepared (Nuclear Extract kit, Active Motif, Carlsbad, CA, USA) by lysing the cells with 0.5% NP-
40 in a phosphatase inhibitor buffer (125 mM NaF, 250 mM β-glycerophosphate, 250 mM p-
nitrophenyl phosphate, 25 mM NaVO3) followed by centrifugation (all at 4 °C). The nuclear 
pellet was lysed using the manufacturer’s proprietary lysis buffer containing a cocktail of 
protease inhibitors, and protein concentration was then determined (ProStain Fluorescent 
Protein Quantification, Active Motif). Five micrograms of total protein/sample were used to 
determine NF-κB p65 concentrations (ELISA, TransAM NF-κB p65, Active Motif). 
5.6 In vivo model of TLR activation 
Inbred 8- to 12-week-old C3H/HeN, C3H/HeJ (Harlan laboratories, Carshaltan, UK), BALB/c 
(The Jackson Laboratory, Bar Harbour, MN, USA) and C5L2-deficient mice (on BALB/c 
background, kindly provided by Prof. Jörg Köhl, Institute for Systemic Inflammation Research, 
University of Lübeck, Lübeck, Germany) were maintained under barrier conditions and 
pathogen free. All experimental procedures were carried out under Home Office (U.K.) or the 
Ministerium für Landwirtschaft, Umwelt und Ländliche Räume (Kiel, Germany) project 
licenses. In order to test the effect of TLR activation in vivo on blood cell sensitivity to C5a ex 
vivo, the experimental protocol described in figure 41B was used. Mice (n= 5/condition) were 
i.p. injected with a previously-defined dose of LPS (50 μg/mouse) or phosphate-buffered saline 
(PBS). After 1h, blood was collected by cardiac puncture and samples (100 μl/condition) were 
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washed (x3, RPMI 1640), resuspended in complete medium, and stimulated (14 h) with the 
indicated concentrations of mouse C5a. The cell culture supernatants were tested for KC and 
MCP-1 levels by ELISA (R&D Systems), and for HMBG1 by Western blot. The in vivo phase and 
ex vivo blood cell stimulations of the experiment involving C5L2-deficient mice were 
conducted at Prof. Jörg Köhl’s Laboratory, and the cell culture supernatants were transported 
to our laboratory (Cardiff University, School of Medicine) on dry ice for chemokine and 
HMGB1 determinations. 
5.7 Flow cytometric analysis  
The expression levels of C5aR and C5L2 in monocytes and neutrophils were assessed by flow 
cytometry as previously described [Rey Nores 1999]. Here, PBMC (1 x 106 cells/condition) or 
whole blood (100 μl/condition) were pre-exposed for 30 min to 100 pg/ml (PBMC) or 500 
pg/ml (whole blood) LPS or mock-stimulated (PBS). Following incubation, cell aliquots were 
collected for C5aR receptor expression, and the remaining samples were washed and activated 
or not with C5a (10 nM) for the indicated times, before aliquots were taken and also analysed 
for C5aR expression. In preparation for flow cytometric analysis of monocyte C5aR expression, 
PBMC were washed twice and resuspended in binding buffer (PBS, 0.5% BSA, 0.05% NaN3). Fc 
receptors were blocked by incubating the samples with a 20% normal rabbit serum solution in 
binding buffer (100 μl/ 5 x 105 cells) for 15 min at room temperature. Subsequently, cells were 
incubated with the human C5aR-specific mAb S5/1-FITC or its isotype control (mouse IgG2a, 
UPC-10, Sigma), (1 μg mAb per 1 x 106 cells in 100 μl binding buffer) for 30 min at 4oC, washed 
(2 x 2 ml binding buffer), before being fixed in 2% p-formaldehyde. Neutrophil C5aR 
expression was analysed in aliquots of anticoagulated whole blood. At each time point, 
aliquots of whole blood (100 µl) were incubated with the S5/1-FITC anti C5aR mAb or isotype 
control (UPC-10, 30 min at 4oC) before red cell lysis and fixation. C5L2 expression was analysed 
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on monocytes and neutrophils from whole blood samples incubated (30 min at room 
temperature) with the human C5L2-specific mAb 1D9 M12-PE or its isotype control (mouse 
IgG1, MOP C-21, Sigma) at 1 µg mAb per 1 x 106 cells in 100 μl binding buffer, before red cell 
lysis and subsequent cell fixation. The stained cells were analysed by flow cytometry, 10,000 
events being acquired for each sample using a FACSCalibur cytometer (Becton Dickinson, San 
Jose, CA, USA), equipped with the CellQuest™ Pro software. Data were analysed using the 
FlowJo software package (Treestar, OR, USA). C5aR or C5L2 receptor expression was estimated 
on gated monocytes or neutrophils identified by their CD14+ staining and forward-and side-
scatter profiles; the gating strategy is shown in Figure 45 (Appendix) and was used for the 
experiments shown in Figures 28A and 29. Representative examples of flow cytometric 
estimation of C5aR expression (corresponding to data presented in Figure 28) are also shown 
in Figure 45 (Appendix). 
5.8 Calcium mobilisation assays 
Calcium mobilisation in gated monocytes was analysed by flow cytometry following a 
previously described method [Schepers 2009] with some modifications. PBMC (1 x 106 
cells/condition) were activated or not with LPS ( 100 pg/ml ) for 30 min or 14h before staining 
(30 min, room temperature) with the Ca2+-chelating fluorescent dye Fluo3-AM (10 μM) or first 
stained with Fluo3-AM before a 3-min activation with LPS (no calcium mobilisation was 
detected in response to LPS alone). An aliquot was taken from each sample to measure the 
background fluorescence at time 0. C5a (10 nM) was subsequently added to the remaining 
samples, and fluorescence was first measured 10 s after addition of C5a, and thereafter every 
30 s for a total of 3 min. Results are expressed as normalized [Ca2+]i, as a measure of the fold 
increase in intracytoplasmic Ca2+ concentration at each time point after the addition of C5a, by 
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determining the ratio between the mean fluorescence intensity at time t and that at time 0. A 
representative experiment is shown in Figure 47 (Appendix). 
5.9 Denaturing polyacrylamide gel electrophoresis (SDS-PAGE) 
and Western blotting 
HMGB1, C5L2 and β-arrestin 1 levels in cytoplasmic preparations from PBMC and in culture 
supernatants (20 μl) of mouse blood cells (HMGB1) were evaluated by Western blot analysis 
using a previously described technique [LeBouder 2003]. Cultured PBMC (0.5 x 106 
cells/condition) were pre-exposed (14 h) or not to LPS (100 pg/ml or as indicated), then 
washed and stimulated (14 h) or not with C5a (10 nM). To test the effect of blocking C5L2 on 
HMGB1 levels (section 2.2.5 and Figure 32), the PBMC were stimulated with C5a (2.5 nM) in 
the absence or presence of an anti C5L2 mAb (1D9 M12, 5 µg/ml) or the same mAb denatured 
by boiling, before cell lysis. Cells were lysed (0.5% (v/v) NP-40, 50 mM Tris-HCl, 150 mM NaCl, 
1 μg/ml leupeptin and pepstatin, 1 mM PMSF, pH 7.4 buffer) for 1h on ice, and the protein 
content of the cytoplasmic cell extracts was estimated (BCA assay, Bio-Rad).  
SDS-PAGE was carried out using the Bio-Rad Mini Protean II gel apparatus. Equal amounts of 
cell extracts (5 μg protein /condition) and 25 µl of mouse blood cell culture supernatants were 
diluted with Laemmli [Laemmli 1970] reducing sample buffer (2% SDS, 100 mM DTT, 50 mM 
Tris-HCl, pH 6.8, 10 % glycerol and 0.1% bromophenol blue) and boiled for 4 min prior to SDS-
PAGE (10% acrylamide gels for C5L2 or β-arrestin 1 and 12.5% for HMGB1). Pre-stained 
molecular weight markers (Precision Plus™ Protein Standards, Bio-Rad) were run in parallel. 
Electrophoresis (200 volts) was carried out using SDS containing running buffer (25mM Tris 
base, 192 mM glycine, 0.1% SDS). After electrophoresis, the gels were briefly washed twice 
with PBS before proceeding to Western blotting. 
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The gels were incubated (with shaking) with transfer buffer (48 mM Tris base, 39mM glycine, 
20% (v/v) methanol) at room temperature for a total of 20 min with 3 changes of buffer. Extra 
thick filter paper (Bio-Rad) and the nitrocellulose membrane (GE Healthcare) used for 
electrotransfer were kept in transfer buffer for 20 min before use. Electrotransfer was carried 
out in a semi-dry transfer cell (Transblot SD, Bio-Rad) for 30 min at 13 volts. Following transfer, 
the membranes were blocked for 1 h at room temperature with blocking buffer consisting of 
PBS/0.1% Tween-20 (PBS-T) supplemented with 5% BSA (for C5L2 and β-arrestin 1) or 5% 
skimmed milk (for HMGB1). Membranes were then washed (1 x 15 min and 2 x 5 min at room 
temperature in PBS-T) and incubated with the primary antibody (all at 1 μg/ml) overnight at 
4˚C with gentle rocking. HMGB1 was detected by using a human and mouse HMGB1-specific 
polyclonal Ab (Ab18256); β-arrestin 1 using the mouse anti-human mAb SC-74591; C5L2 using 
the mouse anti-human mAb 1D9-M12. Following incubation and washing (detailed above), the 
membranes were incubated (1 h, room temperature) with the appropriate horseradish 
peroxidase-conjugated secondary antibody in 2% BSA (C5L2 and β-arrestin 1) or milk (HMGB1) 
in PBS-T. Subsequently, the membranes were washed (PBS-T, 1 x 15 min and 4 x 5 min at room 
temperature) before detection by enhanced chemiluminescence (ECL, Pierce). Densitometric 
measurements were performed on scanned films using the ImageJ software package (National 
Institutes of Health, Bethesda, MD, USA). The specificity of all Western blots was confirmed by 
blotting duplicate samples with isotype control antibodies; representative examples are 
shown in Figure 48 (Appendix). 
192 
 
5.10 Pathway-focussed gene arrays 
Pathway-focussed gene arrays were from Qiagen and were used according to the 
manufacturer’s instructions. Briefly, PBMC (1 x 106 cells/ condition) were cultured in complete 
medium, pre-exposed (14 h) or not to 500 pg/ml LPS, washed, and activated or not with C5a (1 
nM, 4 h), as described above. Cells were lysed and RNA extracted on-column (RNEasy kit). RNA 
concentration was quantified and RNA integrity was assessed using the Agilent 2100 
Bioanalyzer; all samples had RNA Integrity Numbers ≥7. Reverse Transcription (RT kit, Qiagen) 
was performed on 500 ng of RNA after on-column DNAse treatment to remove genomic DNA. 
cDNA was diluted according to the manufacturer’s instructions, and PCR was carried out using 
SYBR Green/Rox qPCR mastermix (Qiagen) in the ABI 7900HT real-time PCR system (Applied 
Biosystems). The thermal cycle profile was 10 min at 95 oC followed by 40 cycles of 15s at 95 oC 
and 45s at 55 oC, in 96-well plates pre-coated with primers for a panel of 172 genes associated 
with the pathways of interest (Table 10A and B, Appendix). Results were analyzed by the ΔΔCt 
method [Livak and Schmittgen 2001]. Gene expression changes were normalised to a panel of 
housekeeping genes including β-2-microglobulin, hypoxanthine phosphoribosyltransferase 1, 
ribosomal protein L13a, glyceraldehyde-3-phosphate dehydrogenase and β actin. Internal 
controls for genomic DNA contamination and failure of reverse transcription were negative in 
all samples. 
5.11 Statistical analysis 
Statistical analysis of the data was performed using Microsoft XL 2010. Mean values were 
compared using Student’s t test for paired samples. p values <0.05 were considered 
significant. 
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Table 10A. Pathway-focussed gene arrays: MAPK pathway 
Gene 
Symbol* 
Description Gene 
Symbol* 
Description 
ARAF V-raf murine sarcoma 
3611 viral oncogene 
homolog 
CDK4 Cyclin-dependent kinase 4 
ATF2 Activating transcription 
factor 2 
CDK6 Cyclin-dependent kinase 6 
BRAF V-raf murine sarcoma 
viral oncogene homolog 
B1 
CDKN1A Cyclin-dependent kinase 
inhibitor 1A (p21, Cip1) 
CCNA1 Cyclin A1 CDKN1B Cyclin-dependent kinase 
inhibitor 1B (p27, Kip1) 
CCNA2 Cyclin A2 CDKN1C Cyclin-dependent kinase 
inhibitor 1C (p57, Kip2) 
CCNB1 Cyclin B1 CDKN2A Cyclin-dependent kinase 
inhibitor 2A (melanoma, p16, 
inhibits CDK4) 
CCNB2 Cyclin B2 CDKN2B Cyclin-dependent kinase 
inhibitor 2B (p15, inhibits 
CDK4) 
CCND1 Cyclin D1 CDKN2C Cyclin-dependent kinase 
inhibitor 2C (p18, inhibits 
CDK4) 
CCND2 Cyclin D2 CDKN2D Cyclin-dependent kinase 
inhibitor 2D (p19, inhibits 
CDK4) 
CCND3 Cyclin D3 CHUK Conserved helix-loop-helix 
ubiquitous kinase 
CCNE1 Cyclin E1 COL1A1 Collagen, type I, alpha 1 
CDC42 Cell division cycle 42 (GTP 
binding protein, 25kDa) 
CREB1 CAMP responsive element 
binding protein 1 
CDK2 Cyclin-dependent kinase 
2 
CREBBP CREB binding protein 
*HUGO Database Gene Nomenclature. 
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Table 10A. Pathway-focussed gene arrays: MAPK pathway (continued) 
Gene 
Symbol* 
Description Gene 
Symbol* 
Description 
DLK1 Delta-like 1 homolog 
(Drosophila) 
KRAS V-Ki-ras2 Kirsten rat sarcoma 
viral oncogene homolog 
E2F1 E2F transcription factor 1 KSR1 Kinase suppressor of ras 1 
EGFR Epidermal growth factor 
receptor 
MAP2K1 Mitogen-activated protein 
kinase kinase 1 
EGR1 Early growth response 1 LAMTOR3 Late endosomal/lysosomal 
adaptor, MAPK and MTOR 
activator 3 
ELK1 ELK1, member of ETS 
oncogene family 
MAP2K2 Mitogen-activated protein 
kinase kinase 2 
ETS1 V-ets erythroblastosis 
virus E26 oncogene 
homolog 1 (avian) 
MAP2K3 Mitogen-activated protein 
kinase kinase 3 
ETS2 V-Ets erythroblastosis 
virus E26 oncogene 
homolog 2 (avian) 
MAP2K4 Mitogen-activated protein 
kinase kinase 4 
FOS FBJ murine osteosarcoma 
viral oncogene homolog 
MAP2K5 Mitogen-activated protein 
kinase kinase 5 
GRB2 Growth factor receptor-
bound protein 2 
MAP2K6 Mitogen-activated protein 
kinase kinase 6 
HRAS V-Ha-ras Harvey rat 
sarcoma viral oncogene 
homolog 
MAP2K7 Mitogen-activated protein 
kinase kinase 7 
HSPA5 Heat shock 70kDa protein 
5 (glucose-regulated 
protein, 78kDa) 
MAP3K1 Mitogen-activated protein 
kinase kinase kinase 1 
HSPB1 Heat shock 27kDa protein 
1 
MAP3K2 Mitogen-activated protein 
kinase kinase kinase 2 
JUN Jun proto-oncogene MAP3K3 Mitogen-activated protein 
kinase kinase kinase 3 
*HUGO Database Gene Nomenclature. 
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Table 10A. Pathway-focussed gene arrays: MAPK pathway (continued) 
Gene 
Symbol* 
Description Gene 
Symbol* 
Description 
MAP3K4 Mitogen-activated 
protein kinase kinase 
kinase 4 
MAPK9 Mitogen-activated protein 
kinase 9 
MAP4K1 Mitogen-activated 
protein kinase kinase 
kinase kinase 1 
MAPKAPK2 Mitogen-activated protein 
kinase-activated protein 
kinase 2 
MAPK1 Mitogen-activated 
protein kinase 1 
MAPKAPK3 Mitogen-activated protein 
kinase-activated protein 
kinase 3 
MAPK10 Mitogen-activated 
protein kinase 10 
MAX MYC associated factor X 
MAPK11 Mitogen-activated 
protein kinase 11 
MEF2C Myocyte enhancer factor 2C 
MAPK12 Mitogen-activated 
protein kinase 12 
MKNK1 MAP kinase interacting 
serine/threonine kinase 1 
MAPK13 Mitogen-activated 
protein kinase 13 
MOS V-mos Moloney murine 
sarcoma viral oncogene 
homolog 
MAPK14 Mitogen-activated 
protein kinase 14 
MST1 Macrophage stimulating 1 
(hepatocyte growth factor-
like) 
MAPK3 Mitogen-activated 
protein kinase 3 
MYC V-myc myelocytomatosis viral 
oncogene homolog (avian) 
MAPK6 Mitogen-activated 
protein kinase 6 
NFATC4 Nuclear factor of activated T-
cells, cytoplasmic, calcineurin-
dependent 4 
MAPK7 Mitogen-activated 
protein kinase 7 
NRAS Neuroblastoma RAS viral       
(v-ras) oncogene homolog 
MAPK8 Mitogen-activated 
protein kinase 8 
PAK1 P21 protein (Cdc42/Rac)-
activated kinase 1 
MAPK8IP2 Mitogen-activated 
protein kinase 8 
interacting protein 2 
PRDX6 Peroxiredoxin 6 
*HUGO Database Gene Nomenclature. 
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Table 10A. Pathway-focussed gene arrays: MAPK pathway (continued) 
Gene 
Symbol* 
Description Gene 
Symbol* 
Description 
RAC1 Ras-related C3 botulinum toxin 
substrate 1 (rho family, small 
GTP binding protein Rac1) 
SFN Stratifin 
RAF1 V-raf-1 murine leukemia 
viral oncogene homolog 1 
SMAD4 SMAD family member 4 
RB1 Retinoblastoma 1 TP53 Tumor protein p53 
*HUGO Database Gene Nomenclature. 
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Table 10B. Pathway-focussed gene arrays: NF-κB pathway 
Gene 
Symbol* 
Description Gene 
Symbol* 
Description 
AGT Angiotensinogen (serpin 
peptidase inhibitor, clade 
A, member 8) 
CCL5 Chemokine (C-C motif)    
ligand 5 
AKT1 V-akt murine thymoma 
viral oncogene homolog 1 
CD27 CD27 molecule 
ATF1 Activating transcription 
factor 1 
CD40 CD40 molecule, TNF receptor 
superfamily member 5 
BCL10 B-cell CLL/lymphoma 10 CFLAR CASP8 and FADD-like 
apoptosis regulator 
BCL2A1 BCL2-related protein A1 CHUK Conserved helix-loop-helix 
ubiquitous kinase 
BCL2L1 BCL2-like 1 CSF1 Colony stimulating factor 1 
(macrophage) 
BCL3 B-cell CLL/lymphoma 3 CSF2 Colony stimulating factor 2 
(granulocyte-macrophage) 
BIRC2 Baculoviral IAP repeat 
containing 2 
CSF3 Colony stimulating factor 3 
(granulocyte) 
BIRC3 Baculoviral IAP repeat 
containing 3 
EGFR Epidermal growth factor 
receptor 
CARD11 Caspase recruitment 
domain family, member 
11 
EGR1 Early growth response 1 
CASP1 Caspase 1, apoptosis-related 
cysteine peptidase (interleukin 
1, beta, convertase) 
ELK1 ELK1, member of ETS 
oncogene family 
CASP8 Caspase 8, apoptosis-
related cysteine 
peptidase 
F2R Coagulation factor II 
(thrombin) receptor 
CCL2 Chemokine (C-C motif) 
ligand 2 
FADD Fas (TNFRSF6)-associated via 
death domain 
*HUGO Database Gene Nomenclature. 
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Table 10B. Pathway-focussed gene arrays: NF-κB pathway (continued) 
Gene 
Symbol* 
Description Gene 
Symbol* 
Description 
FASLG Fas ligand (TNF 
superfamily, member 6) 
IL8 Interleukin 8 
FOS FBJ murine osteosarcoma 
viral oncogene homolog 
IRAK1 Interleukin-1 receptor-
associated kinase 1 
HMOX1 Heme oxygenase 
(decycling) 1 
IRAK2 Interleukin-1 receptor-
associated kinase 2 
ICAM1 Intercellular adhesion 
molecule 1 
IRF1 Interferon regulatory factor 1 
IFNA1 Interferon, alpha 1 JUN Jun proto-oncogene 
IFNG Interferon, gamma LTA Lymphotoxin alpha (TNF 
superfamily, member 1) 
IKBKB Inhibitor of kappa light 
polypeptide gene enhancer 
in B-cells, kinase beta 
LTBR Lymphotoxin beta receptor 
(TNFR superfamily, member 3) 
IKBKE Inhibitor of kappa light 
polypeptide gene enhancer 
in B-cells, kinase epsilon 
MALT1 Mucosa associated lymphoid 
tissue lymphoma translocation 
gene 1 
IKBKG Inhibitor of kappa light 
polypeptide gene enhancer 
in B-cells, kinase gamma 
MAP3K1 Mitogen-activated protein 
kinase kinase kinase 1 
IL10 Interleukin 10 MYD88 Myeloid differentiation 
primary response gene (88) 
IL1A Interleukin 1, alpha NFKB1 Nuclear factor of kappa light 
polypeptide gene enhancer in 
B-cells 1 
IL1B Interleukin 1, beta NFKB2 Nuclear factor of kappa light 
polypeptide gene enhancer in 
B-cells 2 (p49/p100) 
IL1R1 Interleukin 1 receptor, 
type I 
NFKBIA Nuclear factor of kappa light 
polypeptide gene enhancer in 
B-cells inhibitor, alpha 
*HUGO Database Gene Nomenclature. 
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Table 10B. Pathway-focussed gene arrays: NF-κB pathway (continued) 
Gene 
Symbol* 
Description Gene 
Symbol* 
Description 
NFKBIB Nuclear factor of kappa light 
polypeptide gene enhancer 
in B-cells inhibitor, beta 
TICAM2 Toll-like receptor adaptor 
molecule 2 
NFKBIE Nuclear factor of kappa light 
polypeptide gene enhancer 
in B-cells inhibitor, epsilon 
TIMP1 TIMP metallopeptidase 
inhibitor 1 
NOD1 Nucleotide-binding 
oligomerization domain 
containing 1 
TLR1 Toll-like receptor 1 
PSIP1 PC4 and SFRS1 interacting 
protein 1 
TLR2 Toll-like receptor 2 
RAF1 V-raf-1 murine leukemia 
viral oncogene homolog 1 
TLR3 Toll-like receptor 3 
REL V-rel 
reticuloendotheliosis viral 
oncogene homolog 
(avian) 
TLR4 Toll-like receptor 4 
RELA V-rel 
reticuloendotheliosis viral 
oncogene homolog A 
(avian) 
TLR6 Toll-like receptor 6 
RELB V-rel 
reticuloendotheliosis viral 
oncogene homolog B 
TLR9 Toll-like receptor 9 
RHOA Ras homolog gene family, 
member A 
TNF Tumor necrosis factor 
RIPK1 Receptor (TNFRSF)-
interacting serine-
threonine kinase 1 
TNFAIP3 Tumor necrosis factor, alpha-
induced protein 3 
STAT1 Signal transducer and 
activator of transcription 
1, 91kDa 
TNFRSF10A Tumor necrosis factor 
receptor superfamily, member 
10a 
TBK1 TANK-binding kinase 1 TNFRSF10B Tumor necrosis factor 
receptor superfamily, member 
10b 
TICAM1 Toll-like receptor adaptor 
molecule 1 
TNFRSF1A Tumor necrosis factor 
receptor superfamily, member 
1A 
*HUGO Database Gene Nomenclature. 
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Table 10B. Pathway-focussed gene arrays: NF-κB pathway (continued) 
Gene 
Symbol* 
Description Gene 
Symbol* 
Description 
TNFSF10 Tumor necrosis factor 
(ligand) superfamily, 
member 10 
TRAF2 TNF receptor-associated factor 
2 
TNFSF14 Tumor necrosis factor 
(ligand) superfamily, 
member 14 
TRAF3 TNF receptor-associated factor 
3 
TRADD TNFRSF1A-associated via 
death domain 
TRAF6 TNF receptor-associated factor 
6 
*HUGO Database Gene Nomenclature. 
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Figure  40. Effect of polymyxin B on sensitivity of PBMC to purified 
natural human C5a. Mean (±SD) IL-8 released by human PBMC (1.5 x 
105/well) stimulated (14 h) with the indicated concentrations of 
purified natural human C5a. Data are shown from one experiment 
representative of three. (NS, not significant)  
 
Figure 41. Relative potencies of recombinant and purified natural
human C5a. Mean (±SD) IL-8 released by human PBMC (1.5 x
105/well) stimulated (14 h) with the indicated concentrations of
recombinant or purified natural human C5a. Data are shown from one
experiment representative of three. (NS, not significant).
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Figure 42. Optimisation of bacterial stimulating concentration. Representative 
example of titration experiments to establish sub-maximal stimulating 
concentrations of heat-killed E. coli. Whole blood (100 μl/well) from a sepsis 
patient (corresponding to one of the patients whose data are shown in Figure 36) 
was washed and re-suspended in complete medium before stimulation (14h) with 
heat-killed E. coli at the indicated concentrations. Mean (±SD) IL-8 concentration in 
culture supernatants is shown. A sub-maximal E. coli concentration of 2 x 104
cfu/ml was selected for the experiment 
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Figure 43. IL-8 primer efficiency titration. CT values against cDNA
concentrations for RT-qPCR conducted on serial dilutions of cDNA
transcripts (100 indicates undiluted) of mRNA extracted from PBMC (1x106
cells) stimulated with LPS (10 ng/ml) for 14 h. Primer efficiency is calculated
as (10(-1/ln(10)x (gradient)) x 100 = 77% for this primer pair.
y = -1.747ln(x) + 33.718
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Figure  44. Dissociation  curve of β-arrestin 1 amplicon. Representative 
dissociation curve of the β-arrestin 1 amplicon (typical of all primer pairs) 
after RT-qPCR performed on cDNA (500 ng) extracted from PBMC (1 x 106  
per condition)  pre-exposed or not to LPS (500 pg/ml, 14 h) and stimulated 
or not with C5a (1 nM, 4h). Data correspond to the experiment shown in 
Figure 35, and genomic DNA controls.
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Figure 45. Flow cytometric gating strategies. Identification of the monocyte population 
in PBMC (A-C) and neutrophil and monocyte populations in aliquots of whole blood after 
red cell lysis, (D-F), on the basis of forward and side-scatter (A and D) and CD14 staining 
profiles (B and E). Projection of cell populations identified as expressing CD14 onto 
scatter cytograms confirms their identification as monocytes (C) and neutrophils (F) 
respectively. One representative example of each of the flow cytometric experiments 
conducted on PBMC (Figures 28A and 29) and whole blood (28B and 37B) is shown.
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Figure 46. Representative examples of fluorescence histograms from experiments
showing C5aR expression (Figure 28). C5aR expression on gated neutrophils from whole
blood samples as shown in Figure 28. Figures shown correspond to the MFI data
presented for C5aR expression in unstimulated neutrophils at time zero compared with
cells pre-exposed to LPS (A) and compared with cells not pre-exposed to LPS and
stimulated with C5a for 6h (B) after background fluorescence subtraction.
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Sample MFI
No Stimulation 467
C5a 10nM 15s 1007
C5a 10nM 30s 1097
C5a 10nM 60s 1092
C5a 10nM 90s 1063
C5a 10nM 120s 1006
C5a 10nM 150s 986
C5a 10nM 180s 967
Figure 47. Calcium signalling assay. Representative example of fluorescence histogram
from calcium signalling experiments shown in Figure 29. PBMC were loaded with Fluo3-
AM and fluorescence was measured by flow cytometry on gated monocytes at baseline
and at the indicated intervals after addition of C5a (10 nM) as described in Figure 29. MFI
at each time point was divided by MFI at time 0 (unstimulated cells) to produce an
estimate of normalised Ca2+ flux [Ca2+]i at each time point.
Fluorescence
R
el
at
iv
e 
ce
ll
 n
u
m
b
er
 
 
 
209 
 
 
200
150
100
75
50
37
25
β-arrestin 1
Primary Antibody
β-arrestin 1 Isotype Ctrl
M
o
le
c
u
la
r 
M
a
s
s
 (
k
D
a
)
150
100
75
50
37
25
M
o
le
c
u
la
r 
M
a
s
s
 (
k
D
a
)
Primary Antibody
None
Isoty pe
Control
C5L2
C5L2
M
o
le
c
u
la
r 
M
a
s
s
 (
k
D
a
)
Figure 48. Control experiments for Western blots. Representative examples of Western blots 
showing the specificity of monoclonal antibodies used to detect (A) β-arrestin 1 and (B) C5L2 in 
cell lysates of PBMC. Equal aliquots of the same cell lysate were run in the same gel and, after 
electrotransfer, the membranes were incubated with the relevant primary antibody or isotype
control (IgG1, clone MOPC-21 for β-arrestin 1 and IgG2a, clone UPC-10 for C5L2)  as shown 
above before washing, incubation with identical secondary antibodies and ECL as described in 
section 5.8. A representative example of a full-length Western blot for β-arrestin 1 (C) is also 
shown (a duplicate experiment of that shown in Figure 35).
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